PHARMACOLOGY – THEORY

This course provides foundational knowledge of various drug classes used in the pharmacotherapy of common diseases. Understanding drug indications, dosage regimens, routes of administration, pharmacokinetics, pharmacodynamics, and contraindications is essential for effective professional practice.

Course Objectives

This course will cover the following key areas:

General Concepts of Pharmacology:
Introduction to pharmacokinetics, pharmacodynamics, and routes of administration.
Pharmacological Classification:
Detailed classification of drugs along with their therapeutic indications.
Dosage Regimen:
Understanding mechanisms of action, appropriate dosage regimens, and contraindications for selected drugs.
Adverse Effects:
Exploration of common adverse effects associated with different drug classes.

Course Outcomes

Upon successful completion of this course, students will be able to:

Describe Basic Concepts:
Explain the fundamental principles of pharmacokinetics and pharmacodynamics.
Classify Drugs:
Identify various drug classes and select appropriate drugs for specific disease conditions.
Advise on Dosage and Administration:
Recommend proper dosage regimens, routes of administration, and highlight contraindications for specific medications.
Identify Adverse Reactions:
Describe common adverse drug reactions and their implications in clinical practice.

General Pharmacology

Introduction

Pharmacology is the branch of medicine and biology concerned with the study of drug action. It encompasses the understanding of how drugs interact with biological systems, their mechanisms of action, therapeutic effects, and the adverse effects they may produce. This field plays a crucial role in the development, regulation, and use of medications, ensuring their safe and effective application in treating diseases.

Scope of Pharmacology

The scope of pharmacology is broad and includes several key areas:

Pharmacokinetics:
This area studies how the body absorbs, distributes, metabolizes, and excretes drugs. Key concepts include:
- Absorption: How drugs enter the bloodstream.
- Distribution: How drugs are transported throughout the body.
- Metabolism: How drugs are chemically altered, primarily in the liver.
- Excretion: How drugs are eliminated from the body, typically through the kidneys.
Pharmacodynamics:
This involves the study of the effects of drugs on the body. It focuses on the mechanisms of action and the relationship between drug concentration and effect. Important concepts include:
- Receptor Interaction: How drugs bind to specific receptors to exert their effects.
- Dose-Response Relationship: The correlation between the dose of a drug and the magnitude of its effect.
Pharmacological Classification:
Drugs are classified into various categories based on their therapeutic effects, mechanisms of action, and chemical structures. Common classifications include:
- Therapeutic Classes: Antihypertensives, antibiotics, analgesics, etc.
- Chemical Classes: Beta-blockers, NSAIDs, etc.
Drug Development and Regulation:
Pharmacology is integral to the process of drug discovery and development, which involves:
- Preclinical Testing: Evaluating drug safety and efficacy in laboratory and animal studies.
- Clinical Trials: Conducting studies in human subjects to assess safety, efficacy, and dosing.
- Regulatory Approval: Ensuring drugs meet safety and efficacy standards set by regulatory agencies (e.g., FDA).
Clinical Pharmacology:
This area focuses on the application of pharmacological principles in clinical settings. It includes:
- Therapeutic Drug Monitoring: Adjusting drug dosages based on individual patient responses.
- Adverse Drug Reactions (ADRs): Identifying and managing unintended effects of medications.
Toxicology:
The study of the harmful effects of drugs and other substances, including their mechanisms, effects, and management of poisoning cases.

Flowchart of Pharmacology

Pharmacodynamics:

Pharmacokinetics

Various Routes of Drug Administration

The route of drug administration significantly influences the onset, intensity, and duration of a drug's action. Here's a breakdown of common routes, their advantages, and disadvantages, along with definitions:

Definitions

Pharmacokinetics: The study of the movement of drugs within the body, including absorption, distribution, metabolism, and excretion.
Bioavailability: The proportion of a drug that enters the systemic circulation and is available to exert its effects.
First-pass metabolism: The metabolic breakdown of a drug by the liver before it reaches the systemic circulation.

person taking a pill

person placing a tablet under their tongue

person placing a tablet between their cheek and gum

rectal suppository

IV drip

intramuscular injection

subcutaneous injection

person applying a cream to their skin

person using a nasal spray

person using an inhaler

flowchart showing the different routes of drug administration

1. Enteral Route

Oral Route: Administration of drugs by mouth.
- Advantages: Most convenient, safest, and economical.
- Disadvantages: Slow onset of action, first-pass metabolism by the liver, can be affected by food and gastric pH.

Sublingual Route: Administration of drugs under the tongue.

Advantages: Rapid absorption, bypasses first-pass metabolism.
Disadvantages: Limited to drugs that can be readily absorbed through the oral mucosa.

Buccal Route:

Definition: Administration of drugs between the cheek and gum.
Advantages: Similar to sublingual, but less prone to swallowing.
Disadvantages: Limited to drugs that can be readily absorbed through the oral mucosa.

Rectal Route:

Definition: Administration of drugs into the rectum.
Advantages: Useful for patients unable to take oral medications, bypasses first-pass metabolism.
Disadvantages: Less convenient, can be irritating to the rectal mucosa.

2. Parenteral Route

Intravenous (IV) Route:
- Definition: Administration of drugs directly into a vein.
- Advantages: Rapid onset of action, precise control of drug delivery.
- Disadvantages: Risk of infection, requires skilled administration, potential for adverse reactions.

Intramuscular (IM) Route:

Definition: Administration of drugs into a muscle.
Advantages: Faster absorption than subcutaneous, suitable for larger volumes.
Disadvantages: Can be painful, risk of tissue damage.

Subcutaneous (SC) Route:

Definition: Administration of drugs into the subcutaneous tissue.
Advantages: Slow, sustained release of drug, less painful than IM.
Disadvantages: Limited to small volumes, can be irritating to the skin.

Intrathecal Route:

Definition: Administration of drugs into the cerebrospinal fluid.
Advantages: Direct delivery to the cerebrospinal fluid, bypasses the blood-brain barrier.
Disadvantages: Requires specialized technique, risk of infection.

3. Topical Route

Skin:
- Definition: Application of drugs to the skin.
- Advantages: Local effect, avoids systemic side effects.
- Disadvantages: Slow absorption, can be irritating to the skin.

Mucous Membranes:

Definition: Application of drugs to mucous membranes, such as the nasal, oral, or vaginal mucosa.
Advantages: Rapid absorption, local effect.
Disadvantages: Can be irritating to the mucous membranes.

4. Inhalation Route

Definition: Administration of drugs by inhalation.
- Advantages: Rapid onset of action, direct delivery to the lungs.
- Disadvantages: Can be irritating to the respiratory tract.

Remember: The choice of drug administration route depends on various factors, including the desired onset of action, the physical and chemical properties of the drug, and the patient's condition.

Drug Absorption

Definition

Drug absorption is the process by which a drug enters the systemic circulation from its site of administration. It involves the transfer of drug molecules across biological membranes.

Types of Drug Absorption

Passive Diffusion:
- Most common mechanism
- Drug molecules move from an area of high concentration to an area of low concentration
- Does not require energy
- Factors affecting passive diffusion:
  - Lipid solubility
  - Molecular weight
  - pH of the environment
Facilitated Diffusion:
- Carrier-mediated process
- Does not require energy
- Drug molecules bind to specific carrier proteins and are transported across the membrane
Active Transport:
- Carrier-mediated process
- Requires energy (ATP)
- Drug molecules are transported against a concentration gradient
Pinocytosis:
- Cell engulfs drug molecules in a vesicle and transports them into the cell

Factors Affecting Drug Absorption

Physicochemical Properties of the Drug:
- Lipid solubility: Lipid-soluble drugs are more readily absorbed across cell membranes.
- Molecular weight: Smaller molecules are more easily absorbed.
- Degree of ionization: Non-ionized drugs are more readily absorbed.
- Particle size: Smaller particles are more easily absorbed.
Route of Administration:
- Oral: Absorption can be affected by factors such as gastric pH, food intake, and intestinal motility.
- Parenteral: Absorption is generally rapid, especially with intravenous administration.
- Topical: Absorption depends on the skin's permeability and the formulation of the drug.
Physiological Factors:
- Blood flow: Increased blood flow to the site of administration enhances absorption.
- pH of the environment: The pH of the environment can affect the ionization of the drug, which in turn affects its absorption.
- Surface area: A larger surface area at the site of administration increases absorption.

Flowchart of Drug Absorption Processes

Opens in a new windowwww.moravek.com

Diagram of Drug Absorption

Bioavailability: A Primer

Bioavailability refers to the proportion of a drug that reaches the systemic circulation and is available to exert its pharmacological effects. In simpler terms, it's a measure of how much of a drug actually gets into your bloodstream to do its job.

Factors Affecting Bioavailability

Several factors can influence a drug's888888 bioavailability:

1. Physicochemical Properties of the Drug

Lipid Solubility: Lipid-soluble drugs are more readily absorbed across cell membranes.
Molecular Weight: Smaller molecules are more easily absorbed.
Degree of Ionization: Non-ionized drugs are more readily absorbed.
Particle Size: Smaller particles are more easily absorbed.

2. Route of Administration

Oral: Absorption can be affected by factors such as gastric pH, food intake, and intestinal motility.
Parenteral: Absorption is generally rapid, especially with intravenous administration.
Topical: Absorption depends on the skin's permeability and the formulation of the drug.

3. Physiological Factors

Blood Flow: Increased blood flow to the site of administration enhances absorption.
pH of the Environment: The pH of the environment can affect the ionization of the drug, which in turn affects its absorption.
Surface Area: A larger surface area at the site of administration increases absorption.

4. First-Pass Metabolism

This occurs when a drug is metabolized by the liver before reaching the systemic circulation.
It can significantly reduce the bioavailability of orally administered drugs.

Impact of Bioavailability on Drug Therapy

Bioavailability is a critical factor in determining the appropriate dosage and dosing interval of a drug. Drugs with low bioavailability may require higher doses to achieve therapeutic effects. Conversely, drugs with high bioavailability may require lower doses to avoid adverse effects.

Understanding the factors that affect bioavailability is essential for optimizing drug therapy and ensuring patient safety and efficacy.

flowchart showing the factors affecting bioavailability

lipidsoluble drug molecule crossing a cell membrane

pill dissolving in the stomach and small intestine

IV injection directly into the bloodstream

Drug Distribution

Drug distribution is the process by which a drug, once absorbed into the bloodstream, is transported throughout the body to its site of action. This distribution is influenced by various factors that determine how efficiently a drug reaches its target tissues.

Factors Affecting Drug Distribution

Physicochemical Properties of the Drug:
- Lipid Solubility: Lipid-soluble drugs can easily cross cell membranes and distribute more widely.
- Molecular Weight: Smaller molecules tend to distribute more readily.
- Protein Binding: Drugs can bind to plasma proteins like albumin, reducing the amount of free drug available for distribution.
- Ionization: Non-ionized drugs are more lipid-soluble and can cross cell membranes more easily.
Physiological Factors:
- Blood Flow: Tissues with high blood flow, such as the heart, liver, and kidneys, receive drugs more quickly.
- Tissue Permeability: The permeability of tissues to drugs can vary. For example, the blood-brain barrier restricts the passage of many drugs into the brain.
- Tissue Volume of Distribution: This is the apparent volume of fluid into which a drug is distributed. It can vary widely depending on the drug and the individual.
Disease States:
- Certain diseases can alter tissue blood flow, protein binding, and tissue permeability, affecting drug distribution.

Key Points to Remember

Blood-Brain Barrier: A highly selective barrier that protects the brain from harmful substances. Only certain drugs can cross this barrier.
Placental Barrier: A barrier that protects the fetus from harmful substances. However, many drugs can cross this barrier.
Tissue-Specific Barriers: Some tissues have specialized barriers that limit drug entry.

Flowchart of Drug Distribution

Biotransformation of Drugs

Biotransformation is the process by which the body chemically alters drugs, often making them more water-soluble and easier to excrete. This process primarily occurs in the liver.

Types of Biotransformation Reactions

Phase I Reactions:
- Introduction of a functional group (e.g., -OH, -NH2, -COOH)
- Catalyzed by enzymes like cytochrome P450
- Examples: oxidation, reduction, hydrolysis
Phase II Reactions:
- Conjugation of a drug or its metabolite with an endogenous substance (e.g., glucuronic acid, sulfate, glycine)
- Increases water solubility, facilitating renal excretion
- Examples: glucuronidation, sulfation, acetylation

Factors Influencing Drug Metabolism

Genetic Factors:
- Genetic polymorphisms in drug-metabolizing enzymes can significantly affect drug metabolism rates.
- Slow metabolizers may experience increased drug levels and adverse effects.
- Rapid metabolizers may require higher doses to achieve therapeutic effects.
Age:
- Infants and the elderly may have reduced drug metabolism capacity due to immature or declining liver function.
Disease States:
- Liver diseases, such as cirrhosis, can impair drug metabolism.
Drug Interactions:
- Some drugs can induce or inhibit drug-metabolizing enzymes, affecting the metabolism of other drugs.
Environmental Factors:
- Exposure to certain chemicals or pollutants can alter drug metabolism.

Key Points to Remember

Biotransformation can significantly alter the pharmacological activity of a drug.
Metabolites may be active, inactive, or even toxic.
Understanding the factors that influence drug metabolism is crucial for optimizing drug therapy.

Flowchart of Drug Metabolism

Pathways for drug metabolism

Drug Excretion

Drug excretion is the process by which the body eliminates drugs and their metabolites. This process is essential for maintaining drug homeostasis and preventing toxicity.

Routes of Drug Excretion

Renal Excretion:
- The kidneys are the primary organs responsible for drug excretion.
- Drugs and their metabolites are filtered from the blood in the glomeruli and reabsorbed or secreted in the renal tubules.
- Factors affecting renal excretion include:
  - Glomerular filtration rate
  - Renal tubular secretion
  - Renal tubular reabsorption
  - Urine pH
Hepatic Excretion:
- The liver plays a significant role in drug excretion by metabolizing drugs into water-soluble metabolites.
- These metabolites are then excreted in the bile and eliminated in the feces.
Pulmonary Excretion:
- Volatile substances, such as alcohol and anesthetic gases, are exhaled through the lungs.
Other Routes:
- Sweat: Some drugs can be excreted through sweat glands.
- Saliva: Saliva can be used to monitor drug levels, especially for therapeutic drug monitoring.
- Breast Milk: Many drugs can be excreted in breast milk, posing a risk to breastfeeding infants.

Flowchart of Drug Excretion Routes

Opens in a new windowwww.diginerve.com

flowchart showing the different routes of drug excretion, including renal, hepatic, pulmonary, and other minor routes

Diagram Illustrating Renal Excretion

Opens in a new windowwww.pharmacy18888888880.com

diagram showing the process of renal drug excretion, including glomerular filtration, tubular reabsorption, and tubular secretion

Factors Affecting Drug Excretion

Renal function: Impaired renal function can lead to drug accumulation and toxicity.
Liver function: Impaired liver function can reduce drug metabolism and excretion.
Age: Infants and the elderly may have reduced renal and hepatic function, affecting drug excretion.
Drug interactions: Some drugs can interfere with the excretion of others.
pH of urine: The pH of urine can influence the reabsorption of certain drugs.

A simplified diagram illustrating processes involved in the urinary excretion of drugs

General Mechanisms of Drug Action

Drugs interact with specific molecular targets within the body to elicit their therapeutic effects. These targets can be:

1. Receptors

Receptor Agonists: Drugs that bind to receptors and activate them, mimicking the action of endogenous ligands.
Receptor Antagonists: Drugs that bind to receptors but do not activate them, blocking the action of endogenous ligands or other agonists.

2. Ion Channels

Ion Channel Blockers: Drugs that block ion channels, preventing the flow of ions across cell membranes.
Ion Channel Openers: Drugs that open ion channels, allowing the flow of ions across cell membranes.

3. Enzymes

Enzyme Inhibitors: Drugs that bind to enzymes and inhibit their activity, reducing the rate of a specific reaction.

4. Carrier Molecules

Carrier Inhibitors: Drugs that block carrier molecules, preventing the transport of substances across cell membranes.

Factors Modifying Drug Action

Several factors can modify the action of a drug:

1. Pharmacokinetic Factors:

Absorption: The rate and extent of drug absorption can affect the onset and intensity of drug action.
Distribution: The distribution of a drug to target tissues can influence its therapeutic effect.
Metabolism: Drug metabolism can alter the drug's activity and clearance.
Excretion: The rate of drug excretion can affect the duration of drug action.

2. Pharmacodynamic Factors:

Receptor Sensitivity: Changes in receptor sensitivity can alter the drug's response.
Tolerance: Repeated drug exposure can lead to decreased drug responsiveness.
Idiosyncratic Reactions: Unpredictable drug reactions that occur in a small percentage of individuals.

3. Physiological Factors:

Age: Age-related changes in physiology can affect drug absorption, distribution, metabolism, and excretion.
Disease State: Underlying diseases can alter drug pharmacokinetics and pharmacodynamics.

4. Environmental Factors:

Diet: Certain foods can interact with drugs, affecting their absorption or metabolism.
Environmental Pollutants: Exposure to environmental pollutants can alter drug metabolism.

Flowchart of Drug Action and Modification

Steps Involved in Neurohumoral Transmission

Neurohumoral transmission is the process by which nerve cells communicate with each other or with target cells. It involves the release of chemical messengers called neurotransmitters. Here are the key steps:

1. Synthesis of Neurotransmitter:

Neurotransmitters are synthesized within the presynaptic neuron.
The specific neurotransmitter produced depends on the type of neuron.

2. Storage of Neurotransmitter:

Neurotransmitters are stored in vesicles within the presynaptic neuron.
These vesicles are clustered near the synapse, ready for release.

3. Release of Neurotransmitter:

When an action potential reaches the presynaptic terminal, it triggers the opening of voltage-gated calcium channels.
Calcium ions enter the presynaptic terminal and stimulate the fusion of synaptic vesicles with the cell membrane.
This process, called exocytosis, releases the neurotransmitter into the synaptic cleft.

4. Binding to Receptors:

Neurotransmitters diffuse across the synaptic cleft and bind to specific receptors on the postsynaptic membrane.
This binding can trigger a variety of responses in the postsynaptic cell, including:
- Opening of ion channels
- Activation of second messenger systems
- Changes in gene expression

5. Termination of Signal:

The neurotransmitter's action is terminated by:
- Reuptake: The neurotransmitter is taken back into the presynaptic neuron for recycling.
- Enzymatic Degradation: The neurotransmitter is broken down by enzymes in the synaptic cleft.
- Diffusion: The neurotransmitter diffuses away from the synapse.

Diagram of Neurohumoral Transmission:

Opens in a new windowwww.pharmacy180.com

neurohumoral transmission, showing the steps from synthesis to termination

Key Points:

Neurohumoral transmission is essential for communication between neurons and target cells.
Disruptions in neurohumoral transmission can lead to various neurological and psychiatric disorders.
Drugs can target different steps in the neurohumoral transmission process to produce their therapeutic effects.

Diagram of Neurohumoral Transmission:

Cholinergic Drugs

Definition

Cholinergic drugs are substances that mimic the effects of acetylcholine, a neurotransmitter in the parasympathetic nervous system. They interact with cholinergic receptors, primarily muscarinic and nicotinic receptors.

Classification

Cholinergic drugs can be classified into two main categories:

Direct-Acting Cholinergic Agonists
- These drugs directly bind to and activate cholinergic receptors.
- Examples: Acetylcholine, Bethanechol, Pilocarpine, Carbachol
Indirect-Acting Cholinergic Agonists
- These drugs inhibit the enzyme acetylcholinesterase, which breaks down acetylcholine.
- This leads to increased acetylcholine levels in the synaptic cleft.
- Examples: Neostigmine, Pyridostigmine, Physostigmine

Pharmacological Actions

The pharmacological actions of cholinergic drugs are diverse and depend on the specific drug and the type of receptor activated. However, some common actions include:

Muscarinic Actions:

Eye: Miosis (pupil constriction), accommodation (focusing on near objects)
Cardiovascular System: Decreased heart rate, vasodilation
Gastrointestinal Tract: Increased motility, increased secretions
Urinary Tract: Increased bladder tone, increased urine output
Respiratory Tract: Bronchoconstriction, increased secretions

Nicotinic Actions:

Neuromuscular Junction: Muscle contraction
Autonomic Ganglia: Stimulation of both sympathetic and parasympathetic ganglia

Dose, Indications, and Contraindications

The specific dose, indications, and contraindications of cholinergic drugs vary depending on the individual drug and the clinical condition being treated. However, some general considerations include:

Dose: The dose of a cholinergic drug is typically determined by the patient's age, weight, and clinical condition. It is important to start with a low dose and gradually increase it as needed to minimize side effects.

Indications: Cholinergic drugs are used to treat a variety of conditions, including:

Glaucoma: To reduce intraocular pressure
Myasthenia gravis: To improve muscle strength
Urinary retention: To stimulate bladder contraction
Alzheimer's disease: To improve cognitive function (in some cases)

Contraindications: Cholinergic drugs are contraindicated in patients with:

Asthma: Due to the risk of bronchoconstriction
Peptic ulcer disease: Due to the risk of increased gastric acid secretion
Hyperthyroidism: Due to the risk of thyroid storm
Bradycardia: Due to the risk of further slowing of the heart rate

Preparations

1. Bethanechol: 10–40 mg oral, 2.5–5 mg s.c.

UROTONIN, BETHACOL 25 mg tab.

2. Pilocarpine: 0.5–4% topically in eye.

PILOCAR 1%, 2%, 4% eye drops; CARPINE 0.5% eye drops; PILODROPS 2% eye drops.

3. Physostigmine: 0.5–1.0 mg oral/i.m., 0.25–0.5% topically in eye.

BI-MIOTIC 0.25% eye drops with 2% pilocarpine nitrate.

4. Neostigmine: 15–30 mg oral, 0.5–2.5 mg s.c./i.m.

PROSTIGMIN, MYOSTIGMIN, TILSTIGMIN 15 mg tab, 0.5 mg/ml in 1 ml and 5 ml inj.

5. Pyridostigmine: 60–180 mg oral.

DISTINON, MYESTIN 60 mg tab.

6. Rivastigmine: Initially 1.5 mg BD, increase every 2 weeks by 1.5 mg/day upto 6 mg BD.

EXELON, RIVAMER 1.5, 3, 4.5, 6.0 mg caps.

7. Donepezil: 5 mg at bed time once daily (max 10 mg/day).

DONECEPT, DOPEZIL, DORENT 5, 10 mg tabs.

8. Galantamine: 4 mg BD (max 12 mg BD).

GALAMER 4, 8, 12 mg tabs.

NOTE- From Pharmacological Classification with dose and preparation of KD Tripathi

Anti-Cholinergic Drugs

Definition

Anti-cholinergic drugs are substances that block the action of acetylcholine, a neurotransmitter in the parasympathetic nervous system. They primarily act by competitively inhibiting the binding of acetylcholine to muscarinic receptors.

Classification

Anti-cholinergic drugs can be classified based on their chemical structure and specific actions:

Synthetic Anticholinergics:
- Tertiary Amines:
  - Atropine: Derived from the deadly nightshade plant, atropine is a prototypical anticholinergic drug. It has a wide range of actions, including blocking muscarinic receptors in the eye, heart, lungs, gastrointestinal tract, and urinary bladder.
- Quaternary Ammonium Compounds:
  - Ipratropium bromide: A selective muscarinic receptor antagonist used primarily for bronchodilation in chronic obstructive pulmonary disease (COPD).
Natural Anticholinergics:
- Belladonna Alkaloids: These alkaloids, derived from plants like Atropa belladonna and Datura stramonium, have anticholinergic properties. They include atropine, scopolamine, and hyoscyamine.

Pharmacological Actions

The pharmacological actions of anticholinergic drugs are primarily due to their ability to block muscarinic receptors. These actions include:

Eye: Mydriasis (pupil dilation), cycloplegia (paralysis of accommodation)
Cardiovascular System: Increased heart rate, decreased salivation
Gastrointestinal Tract: Decreased motility, decreased secretions
Urinary Tract: Decreased bladder tone, urinary retention
Respiratory Tract: Decreased bronchial secretions, bronchodilation
Central Nervous System: Anticholinergic side effects like dry mouth, blurred vision, confusion, and delirium

Dose, Indications, and Contraindications

The specific dose, indications, and contraindications of anticholinergic drugs vary depending on the individual drug and the clinical condition being treated. However, some general considerations include:

Dose: The dose of an anticholinergic drug is typically determined by the patient's age, weight, and clinical condition. It is important to start with a low dose and gradually increase it as needed to minimize side effects.

Indications: Anticholinergic drugs are used to treat a variety of conditions, including:

Gastrointestinal disorders: Irritable bowel syndrome, peptic ulcer disease
Respiratory disorders: Asthma, chronic obstructive pulmonary disease (COPD)
Urinary incontinence: Overactive bladder
Parkinson's disease: To reduce tremor and rigidity
Motion sickness: To prevent nausea and vomiting
Pre-anesthetic medication: To decrease secretions and reduce vagal tone

Contraindications: Anticholinergic drugs are contraindicated in patients with:

Glaucoma: Due to the risk of increased intraocular pressure
Prostatic hypertrophy: Due to the risk of urinary retention
Myasthenia gravis: Due to the risk of worsening muscle weakness
Cardiovascular disease: In some cases, due to the risk of tachycardia and arrhythmias

Preparations

1. Atropine: 0.6–2.0 mg i.m./i.v. (Child 10 µg/kg), 1–2% topically in eye.

ATROPINE SULPHATE 0.6 mg/ml inj, 1% eye drop/oint, ATROSULPH 1% eye drop, 5% eye oint.

2. Hyoscine hydrobromide: 0.3–0.5 mg oral/i.m. (Child 10 µg/kg).

3. Hyoscine butyl bromide: 20–40 mg oral/i.m./s.c./i.v.

BUSCOPAN 10 mg tab, 20 mg/ml amp.

4. Atropine methonitrate: 2.5–10 mg oral/i.m.

MYDRINDON 1 mg (adult), 0.1 mg (child) tab; in SPASMOLYSIN 0.32 mg tab.

5. Propantheline: 15–30 mg oral. PROBANTHINE 15 mg tab.

6. Oxyphenonium: 5–10 mg (Child 3–5 mg) oral. ANTRENYL 5, 10 mg tab.

7. Clidinium: 2.5–5 mg oral.

In SPASRIL, ARWIN 2.5 mg tab with chlordiazepoxide 5 mg. NORMAXIN, CIBIS 2.5 mg with dicyclomine

10 mg and chlordiazepoxide 5 mg tab.

8. Pipenzolate methyl bromide: 5–10 mg (Child 2–3 mg) oral.

In PIPEN 5 mg tab. 4 mg/ml drops with dimethyl polysiloxane.

9. Isopropamide: 5 mg oral. In STELABID, GASTABID 5 mg tab. with trifluoperazine.

10. Dicyclomine: 20 mg oral.

CYCLOSPAS-D 20 mg with dimethicone 40 mg tab; CYCLOPAM INJ. 10 mg/ml in 2 ml, 10 ml, 30 ml amp/vial,

also 20 mg tab with paracetamol 500 mg; in COLIMEX, COLIRID 20 mg with paracetamol 500 mg tab, 10 mg/

ml drops with dimethicone.

11. Valethamate: 8 mg i.m., 10 mg oral, repeated as required.

VALAMATE 8 mg in 1 ml inj, EPIDOSIN 10 mg tab, 8 mg inj.

12. Glycopyrrolate: 0.1–0.3 mg i.m./i.v., 1–2 mg oral.

GLYCO-P 0.2 mg/ml amp., 1 mg in 5 ml vial, PYROLATE 0.2 mg/ml, 1 ml amp, 10 ml vial.

13. Ipratropium bromide: 40–80 µg by inhalation/nasal spray.

IPRAVENT 20 µg/puff metered dose inhaler, 2 puffs 3–4 times daily; 250 µg/ml respirator soln., 0.4–2 ml nebulized in conjunction with a β2

agonist 2–4 times daily.

Also used to control rhinorrhoea in perennial rhinitis and common cold; IPRANASE–AQ 0.084% nasal spray

(42 µg per actuation), 1–2 sprays in each nostril 3–4 times a day.

14. Tiotropium bromide: 18 µg by inhalation. TIOVA 18 µg rotacaps, 1 rotacap by inhalation OD.

15. Oxybutynin: 5 mg BD/TDS oral; children above 5 yr 2.5 mg BD.

OXYBUTIN, CYSTRAN, OXYSPAS 2.5 mg and 5 mg tabs.

16. Flavoxate: 200 mg TDS. URISPAS, FLAVATE, FLAVOSPAS 200 mg tab.

17. Tolterodine: 1–2 mg BD or 2–4 mg OD of sustained release tab. oral; ROLITEN, TOLTER 1, 2 mg tabs, TORQ

2, 4 mg SR tab.

18. Homatropine: 1–2% topically in eye. HOMATROPINE EYE, HOMIDE 1%, 2% eye drops.

19. Cyclopentolate: 0.5–1.0% topically in eye.

CYCLOMID EYE, 0.5%, 1.0%, CYCLOGYL, CYCLOPENT 1% eye drops.

20. Tropicamide: 0.5–1.0% topically in eye. OPTIMIDE, TROPICAMET, TROMIDE 1% eye drops; TROPAC-P,

TROPICAMET PLUS 0.8% + phenylephrine 5% eye drops.

21. Trihexyphenidyl (benzhexol): 2–10 mg/day; PACITANE, PARBENZ 2 mg tab.

22. Procyclidine: 5–20 mg/day; KEMADRIN 2.5, 5 mg tab.

23. Biperiden: 2–10 mg/day oral, i.m. or i.v.: DYSKINON 2 mg tab., 5 mg/ml inj.

Adrenergic Drugs

Definition: Adrenergic drugs are a class of medications that mimic or interfere with the functioning of the sympathetic nervous system. They influence the release or activity of the hormones norepinephrine and epinephrine, often referred to as the "fight-or-flight" response.

Classification:

Adrenergic drugs can be classified based on their primary mechanism of action:

Direct-Acting Adrenergic Agonists:
- These drugs directly bind to and activate adrenergic receptors.
- Examples: Epinephrine, Norepinephrine, Dopamine, Isoproterenol
Indirect-Acting Adrenergic Agonists:
- These drugs increase the release of norepinephrine from nerve terminals.
- Examples: Amphetamines, Tyramine
Mixed-Acting Adrenergic Agonists:
- These drugs combine direct and indirect actions.
- Examples: Ephedrine
Adrenergic Receptor Antagonists:
- These drugs block the effects of norepinephrine and epinephrine by binding to adrenergic receptors.
- Examples: Alpha-blockers (prazosin, terazosin), Beta-blockers (propranolol, atenolol)

Pharmacological Actions: Adrenergic drugs can have a wide range of effects on the body, including:

Cardiovascular system: Increased heart rate, increased blood pressure, increased cardiac output
Respiratory system: Bronchodilation
Central nervous system: Increased alertness, decreased fatigue
Gastrointestinal system: Decreased motility, decreased secretions

Dose, Indications, and Contraindications: The specific dose, indications, and contraindications of adrenergic drugs vary depending on the individual drug and the clinical condition being treated. It's crucial to consult a healthcare professional for specific dosing and usage instructions.

General Indications:

Cardiovascular disorders: Heart failure, shock, hypotension
Respiratory disorders: Asthma, chronic obstructive pulmonary disease (COPD)
Allergic reactions: Anaphylaxis
Hypotension: Low blood pressure

Contraindications:

Hypertension: High blood pressure
Hyperthyroidism: Overactive thyroid gland
Angina: Chest pain
Arrhythmias: Irregular heart rhythms

Note: Adrenergic drugs can have significant side effects, including increased heart rate, anxiety, tremors, and insomnia. It's important to use them under medical supervision and to be aware of potential risks.

Adrenergic Receptors and their Locations

Preparations

1. Adrenaline (Epinephrine): 0.2–0.5 mg s.c./i.m.;

ADRENALINE 1 mg/ml inj; ADRENA 4 mg (of adrenaline bitartrate=2 mg adrenaline base) per ml inj.

2. Noradrenaline (Norepinephrine, Levarterenol): 2–4 µg/min i.v. infusion;

ADRENOR, NORAD, NORDRIN 2 mg (base)/2 ml amp.

3. Isoprenaline (Isoproterenol): 20 mg s.l., 1–2 mg i.m., 5–10 µg/min i.v. infusion;

NEOEPININE 20 mg sublingual tab, ISOPRIN, ISOSOL 4 mg/2 ml inj.

4. Dopamine: 0.2–1.0 mg/min i.v. infusion; DOPAMINE, INTROPIN, DOPACARD 200 mg/5 ml amp.

5. Dobutamine: 2.5–10 µg/kg/min i.v. infusion;

CARDIJECT 50 mg/4 ml and 250 mg/20 ml inj, DOBUTREX, DOBUSTAT 250 mg inj.

6. Ephedrine: 15–60 mg oral, 15–30 mg i.m./i.v.; 0.5–0.75% topically in nose. EPHEDRINE HCL 15, 30 mg tabs,

SUFIDRIN 50 mg in 1 ml inj, ENDRINE 0.75% nasal drops.

7. Phenylephrine: 5–10 mg oral, 2–5 mg i.m., 0.1–0.5 mg slow i.v. inj, 30–60 µg/min i.v. infusion, 0.25% topically

in nose, 5–10% topically in eye; in DECOLD PLUS 5 mg with paracetamol 400 mg + chlorpheniramine 2 mg +

caffeine 15 mg tab; SINAREST 10 mg with chlorpheniramine 2 mg, paracetamol 500 mg, caffeine 30 mg tab;

FRENIN 10 mg in 1 ml inj, in FENOX 0.25% with naphazoline 0.025% nasal drops, DROSYN 10% eye drops, in

DROSYN-T, TROPAC-P 5% with tropicamide 0.8% eye drops.

8. Methoxamine: 10–20 mg i.m., 3–5 mg slow i.v. inj; VASOXINE 20 mg/ml inj.

9. Mephentermine: 10–20 mg oral/i.m., also by i.v. infusion.

MEPHENTINE 10 mg tab, 15 mg in 1 ml amp, 30 mg/ml in 10 ml vial.

10. Amphetamine: 5–15 mg oral.

11. Dexamphetamine: 5–10 mg (children 2.5–5 mg) oral.

12. Methamphetamine: 5–10 mg oral.

Adrenergic Drugs 9

13. Sibutramine: Start with 10 mg OD, increase to 15 mg OD if needed.

14. Xylometazoline: 0.05%–0.1% topically in nose;

OTRIVIN 0.05% (pediatric), 0.1% (adult) nasal drops and nasal spray.

15. Oxymetazoline: 0.025–0.05% topically in nose;

NASIVION, SINAREST 0.025% (pediatric), 0.05% (adult) nasal drops.

16. Naphazoline: 0.1% topically in nose; PRIVINE 0.1% nasal drops.

17. Pseudoephedrine: 30–60 mg oral TDS; SUDAFED 60 mg tab, 30 mg/5 ml syrup; in SINAREST 60 mg with chlorpheniramine 2 mg + caffeine 30 mg + paracetamol 500 mg tab; in CHESTON

30 mg with chlorpheniramine 2 mg + bromhexine 4 mg per tab and per 5 ml syr; in ACTICOLD

60 mg with chlorpheniramine 4 mg + paracetamol 500 mg tab; in CODYLEX 60 mg with chlorpheniramine 4 mg

+ ibuprofen 400 mg tab.

Anti-Adrenergic Drugs

Definition:

Anti-adrenergic drugs are medications that block the effects of the sympathetic nervous system by interfering with the actions of norepinephrine and epinephrine. They are used to treat a variety of conditions, including hypertension, anxiety, and cardiac arrhythmias.

Classification:

Anti-adrenergic drugs can be classified based on the specific adrenergic receptors they block:

Alpha-Adrenergic Blockers:
- These drugs block alpha-adrenergic receptors, leading to vasodilation and decreased blood pressure.
- Examples: Prazosin, Terazosin, Doxazosin
Beta-Adrenergic Blockers:
- These drugs block beta-adrenergic receptors, leading to decreased heart rate, reduced blood pressure, and decreased myocardial contractility.
- Examples: Propranolol, Atenolol, Metoprolol

Pharmacological Actions:

Alpha-Blockers:
- Vasodilation, especially in the peripheral vessels
- Decreased blood pressure
- Improved urinary flow in benign prostatic hyperplasia
Beta-Blockers:
- Decreased heart rate
- Decreased cardiac output
- Decreased blood pressure
- Reduced myocardial oxygen demand
- Decreased renin release

Dose, Indications, and Contraindications:

The specific dose, indications, and contraindications of anti-adrenergic drugs vary depending on the individual drug and the clinical condition being treated. It's crucial to consult a healthcare professional for specific dosing and usage instructions.

General Indications:

Hypertension: To lower blood pressure
Angina: To reduce chest pain
Cardiac arrhythmias: To regulate heart rhythm
Heart failure: To improve heart function
Anxiety disorders: To reduce anxiety symptoms

Contraindications:

Bradycardia: Slow heart rate
Heart failure (some beta-blockers)
Severe asthma or COPD
Peripheral vascular disease
Diabetes (certain beta-blockers can mask hypoglycemic symptoms)

Note: Anti-adrenergic drugs can have significant side effects, including fatigue, dizziness, bradycardia, and hypotension. It's important to use them under medical supervision and to be aware of potential risks.

Preparations

1. Phenoxybenzamine: 20–60 mg/day oral, 1 mg/kg slow i.v. infusion over 1 hour;

FENOXENE 10 mg cap, 50 mg/ml inj, BIOPHENOX 50 mg/ml inj.

2. Ergotamine: For migraine 1–3 mg oral/sublingual, repeat as required (max 6 mg in a day); rarely 0.25–0.5 mg

i.m. or s.c.; ERGOTAMINE, GYNERGEN, INGAGEN 1 mg tab, 0.5 mg/ml and 1 mg/ml inj.

3. Dihydroergotamine: For migraine 2–6 mg oral (max 10 mg/day), 0.5–1 mg i.m., s.c. repeat hourly (max

3 mg); DIHYDERGOT, DHE 1 mg tab, MIGRANIL 1 mg/ml inj.

4. Dihydroergotoxine (codergocrine): For dementia 1–1.5 mg oral or sublingual, 0.15–0.6 mg i.m.,

HYDERGINE 1.5 mg tab, CERELOID 1 mg tab.

5. Phentolamine: 5 mg i.v. repeated as required; REGITINE, FENTANOR 10 mg/ml inj.

6. Prazosin: Start with 0.5–1 mg at bedtime; usual dose 1–4 mg BD or TDS; PRAZOPRES 0.5, 1.0 and 2.0 mg tabs.

MINIPRESS XL: PRAZOSIN GITS 2.5 mg and 5 mg tablets; 1 tab OD.

7. Terazosin: Usual maintenance dose 2–10 mg OD; HYTRIN, TERALFA, OLYSTER 1, 2, 5 mg tab.

8. Doxazosin: 1 mg OD initially, increase upto 8 mg BD;

DOXACARD, DURACARD, DOXAPRESS 1, 2, 4 mg tabs.

9. Alfuzosin: 2.5 BD-QID or 10 mg OD as modified release tab. ALFUSIN, ALFOO 10 mg ER tab.

10. Tamsulosin: URIMAX, DYNAPRES 0.2, 0.4 mg MR cap; CONTIFLO-OD 0.4 mg cap; 1 cap (max 2) in the

morning with meals.

11. Yohimbine: 2 mg oral; YOHIMBINE 2 mg tab.

Preparations

1. Propranolol: Oral—10 mg BD to 160 mg QID (average 40–160 mg/day). Start with a low dose and gradually

increase according to need; i.v.—2 to 5 mg injected over 10 min with constant monitoring. It is not injected s.c.

or i.m. because of irritant property. INDERAL, CIPLAR 10, 40, 80 mg tab, 1 mg/ml inj., BETABLOC 10, 40 mg tab.

2. Sotalol: 80 mg BD–160 mg TDS oral; SOTAGARD 40, 80 mg tabs.

3. Pindolol: 5–15 mg BD; PINADOL 5 mg tab, VISKEN 10, 15 mg tab.

4. Metoprolol: 25 mg BD–100 mg QID oral, 5–15 mg slow i.v. inj;

BETALOC 25, 50, 100 mg tab, 5 mg/ml inj., LOPRESOR, METOLAR 50, 100 mg tab.

5. S(–) Metoprolol: 12.5 mg BD–50 mg QID; METPURE–XL 12.5, 25, 50 mg ER tabs.

6. Atenolol: 25 mg OD–50 mg BD; BETACARD, ATEN, TENORMIN 25, 50, 100 mg tabs.

7. S(–) Atenolol: 12.5–50 mg OD; ATPURE, ADBETA 12.5, 25, 50 mg tabs.

8. Acebutolol: 200 mg BD–400 mg TDS oral; 20–40 mg slow i.v. injection; SECTRAL 200, 400 mg tabs, 10 mg/2 ml amp.

9. Bisoprolol: 2.5–10 mg OD; CONCOR, CORBIS 5 mg tab.

10. Esmolol: 0.5 mg/kg i.v. injection followed by 0.05–0.2 mg/kg/min i.v. infusion;

MINIBLOCK 100 mg/10 ml, 250 mg/10 ml inj.

11. Celiprolol: 100 mg OD–300 mg BD; CELIPRES 100, 200 mg tab.

12. Nebivolol: 5 mg OD (start with 2.5 mg OD in elderly); NODON 5 mg tab, NEBICARD 2.5, 5 mg tabs.

13. Labetalol: Start with 50 mg BD, increase to 100–200 mg TDS oral. In hypertensive emergencies 20–40 mg slow

i.v. injection every 10 min till desired response is obtained.

NORMADATE 50, 100, 200 mg tab; LABESOL, LABETA 50 mg tab, 20 mg/4 ml inj.

14. Carvedilol: for CHF: Start with 3.125 mg BD for 2 weeks, if well tolerated, gradually increase to max. of 25 mg BD.

for hypertension/angina: 6.25 mg BD initially, titrate to max. of 25 mg BD.

CARVIL, CARLOC, CARVAS 3.125, 6.25, 12.5, 25 mg tabs; ORICAR 12.5, 25 mg tabs.

Preparations

1. Timolol: Start with 0.25% eye drops BD, change to 0.5% drops in case of inadequate response. 0.5% OD as gel

forming solution. GLUCOMOL, OCUPRES, IOTIM, LOPRES 0.25% and 0.5% eye drops. TIMOLAST 0.5% gel

forming eye drops (long acting).

Timolol 0.5% + Latanoprost 0.005%: LAPROST PLUS, LATOCHEK-T eye drops.

2. Betaxolol: 0.5% topically in eye BD; OPTIPRES, IOBET, OCUBETA 0.5% eye drops.

3. Levobunolol: 0.5% topically in eye OD; BETAGAN 0.5% ophthalmic solution.

4. Dipivefrine: 0.1% topically in eye BD; PROPINE 0.1% eye drops.

5. Apraclonidine: 0.5–1.0% topically in eye; ALFADROPS-DS 1% eye drops.

6. Brimonidine: 0.2% topically in eye TDS;

ALPHAGAN-P, BRIMODIN-P 0.15% eye drops, IOBRIM 0.2% eye drops.

7. Latanoprost: 0.005% topically in eye OD in evening;

LACOMA, XALATAN, LATOPROST, 9 PM 50 µg/ml eye drops; LACOMA-T, LAPROST-PLUS, LATOCHEK-T

with timolol 0.5% eye drops (store in cold place).

8. Travoprost: 0.004% topically in eye OD in evening; TRAVATAN 0.004% eye drops (refrigeration of the eye

drops not required); TRAVACOM 0.004% with timolol 0.5% eye drops.

9. Bimatoprost: 0.03% as eye drops OD in evening; LUMIGAN, CAREPROST 0.03% eye drops; the eye drop need not

be stored in refrigerator; CAREPROST-PLUS, GANFORT with timolol 0.5% eye drop.

10. Pilocarpine: 0.5%–4% topically in eye; CARPINE, PILOCAR 0.5%, 1%, 2%, 4% eye drops.

11. Dorzolamide: 2% topically in eye BD–TDS; DORTAS, DORZOX 2% eye drops.

Neuromuscular Blocking Agents

Definition:

Neuromuscular blocking agents (NMBA) are drugs that interfere with neuromuscular transmission, leading to muscle paralysis. They are primarily used in anesthesia to facilitate surgery and in intensive care to facilitate mechanical ventilation.

Classification:

NMBA can be classified based on their mechanism of action:

Non-Depolarizing Muscle Relaxants:
- These drugs competitively bind to the nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and initiating muscle contraction.
- Examples: Pancuronium, Vecuronium, Rocuronium
Depolarizing Muscle Relaxants:
- These drugs bind to the nicotinic acetylcholine receptors, initially causing depolarization and muscle contraction. However, prolonged exposure leads to a persistent depolarization block, resulting in muscle paralysis.
- Example: Succinylcholine

Pharmacological Actions:

Non-Depolarizing Muscle Relaxants:
- Muscle relaxation
- Facilitation of intubation and mechanical ventilation
Depolarizing Muscle Relaxants:
- Initial muscle fasciculations (twitching)
- Prolonged muscle paralysis

Dose, Indications, and Contraindications:

The specific dose, indications, and contraindications of NMBA vary depending on the individual drug and the clinical condition being treated. It's crucial to consult a healthcare professional for specific dosing and usage instructions.

General Indications:

Anesthesia: To facilitate surgery and intubation
Intensive care: To facilitate mechanical ventilation
Diagnostic procedures: To facilitate muscle relaxation during certain procedures

Contraindications:

Myasthenia gravis: A neuromuscular disorder
Hyperkalemia: Elevated potassium levels in the blood
Severe electrolyte disturbances

Note: NMBA do not have any analgesic or sedative properties. They only cause muscle paralysis. Therefore, they must always be used in conjunction with general anesthesia or sedation to prevent awareness during surgery.

Neuromuscular Junction and the Mechanism of Action of NMBA

Drugs Used in Myasthenia Gravis

Myasthenia gravis is an autoimmune disorder that affects the neuromuscular junction. It causes muscle weakness and fatigue. Treatment often involves a combination of medications and sometimes surgical intervention.

Here are the primary drug classes used to manage myasthenia gravis:

1. Acetylcholinesterase Inhibitors

Mechanism of Action: These drugs inhibit the enzyme acetylcholinesterase, which breaks down acetylcholine. This leads to increased acetylcholine levels at the neuromuscular junction, improving muscle strength.
Examples: Pyridostigmine, Neostigmine

2. Immunosuppressants

Mechanism of Action: These drugs suppress the immune system, reducing the production of antibodies that attack the acetylcholine receptors.
Examples: Prednisone (corticosteroid), Azathioprine, Mycophenolate mofetil, Cyclosporine

3. Immunoglobulins

Mechanism of Action: Intravenous immunoglobulin (IVIG) therapy involves administering high doses of antibodies. These antibodies can suppress the immune system and reduce the production of autoantibodies.

4. Plasmapheresis

Mechanism of Action: This procedure involves removing harmful antibodies from the blood plasma and replacing them with fresh plasma or albumin.

5. Monoclonal Antibodies

Mechanism of Action: These drugs target specific immune cells or proteins involved in the autoimmune process.
Examples: Rituximab, Eculizumab

Note: The choice of treatment depends on the severity of the disease, the patient's age, and other factors. It is crucial to consult with a healthcare provider to determine the most appropriate treatment plan.

Local Anesthetic Agents

Definition: Local anesthetic agents are drugs that block the conduction of nerve impulses, leading to loss of sensation in a specific area of the body. They are commonly used in dentistry, surgery, and other medical procedures to prevent pain.

Mechanism of Action:

Local anesthetics work by blocking sodium channels in nerve cell membranes. Sodium channels are responsible for the initiation and propagation of action potentials, which are electrical signals that travel along nerve fibers. By blocking these channels, local anesthetics prevent the generation and conduction of nerve impulses, resulting in loss of sensation.

Classification:

Local anesthetics can be classified based on their chemical structure and duration of action:

Ester-Type Local Anesthetics:
- Examples: Procaine, Benzocaine, Tetracaine
- Duration of Action: Short to moderate duration
Amide-Type Local Anesthetics:
- Examples: Lidocaine, Bupivacaine, Ropivacaine
- Duration of Action: Longer duration of action

Pharmacological Actions:

Sensory Nerve Block: Loss of sensation of pain, temperature, and touch
Motor Nerve Block: Loss of muscle function

Dose, Indications, and Contraindications:

The specific dose, indications, and contraindications of local anesthetics vary depending on the individual drug and the clinical condition being treated. It's crucial to consult a healthcare professional for specific dosing and usage instructions.

General Indications:

Dental procedures: Tooth extraction, root canal treatment
Surgical procedures: Minor surgeries, regional anesthesia
Pain management: Postoperative pain, chronic pain conditions

Contraindications:

Allergy to local anesthetics
Severe liver or kidney disease
Certain cardiac conditions

Note: While local anesthetics are generally safe, it's important to use them under the supervision of a healthcare professional to minimize the risk of adverse effects.

Mechanism of Action of Local Anesthetics

Preparations

1. Lidocaine (lignocaine): 0.5–2% for nerve block, 1–5% topically; XYLOCAINE, GESICAIN 4% topical solution, 2% jelly, 2% viscous, 5% ointment, 1% and 2% injection (with or without adrenaline), 5% heavy (for spinal

anaesthesia); 100 mg/ml spray (10 mg per puff)

2. Bupivacaine: 0.25–0.5% for nerve block, 0.5–0.75% for spinal anaesthesia; MARCAIN 0.5%, 1% (hyperbaric for

spinal anaesthesia). SENSORCAINE 0.25%, 0.5% inj, 0.5% heavy inj.

3. Tetracaine (Amethocaine): 0.25% for nerve block, 0.25–0.5% for spinal anaesthesia, 1% topically;

ANETHANE powder for preparing solution, 1% oint.

4. Eutectic Lidocaine-prilocaine: 5% for cutaneous anaesthesia; PRILOX 5% cream

5. Dibucaine: 0.25–0.5% for nerve block and spinal anaesthesia, 1% for surface anaesthesia; NUPERCAINE 0.5%

inj, NUPERCAINAL 1% oint, in OTOGESIC 1% ear drops.

6. Benzocaine: 5–20% topically; in PROCTOQUINOL 5% oint., ZOKEN 20% gel.

7. Butylaminobenzoate: 1–5% topically; in PROCTOSEDYL-M 1% oint with framycetin and hydrocortisone for

anal application.

8. Benoxinate: 0.4% for corneal anaesthesia; BENDZON 0.4% eye drops.

9. Oxethazaine: 0.2% for gastric mucosal anaesthesia;

MUCAINE 0.2% in alumina gel + magnesium hydroxide suspension; 5–10 ml orally.

TRICAINE-MPS: Oxethazaine 10 mg with methyl polysiloxane 125 mg, alum. hydroxide gel 300 mg, mag.

hydroxide 150 mg per 5 ml gel.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Definition:

Non-steroidal anti-inflammatory drugs (NSAIDs) are a group of medications that reduce pain and inflammation. They work by inhibiting the production of prostaglandins, which are chemicals that contribute to pain, inflammation, and fever.

Classification:

NSAIDs can be classified into two main groups:

Traditional NSAIDs:
- Examples: Aspirin, Ibuprofen, Naproxen
- Mechanism of Action: Inhibit both COX-1 and COX-2 enzymes.
Selective COX-2 Inhibitors:
- Examples: Celecoxib, Rofecoxib (withdrawn)
- Mechanism of Action: Primarily inhibit COX-2 enzyme, which is involved in inflammation.

Pharmacological Actions:

Pain Relief: NSAIDs reduce pain by inhibiting the production of prostaglandins, which sensitize pain receptors.
Anti-inflammatory: NSAIDs reduce inflammation by inhibiting the production of prostaglandins, which promote inflammation.
Antipyretic: NSAIDs reduce fever by inhibiting the production of prostaglandins in the hypothalamus, which regulates body temperature.

Dose, Indications, and Contraindications:

The specific dose, indications, and contraindications of NSAIDs vary depending on the individual drug and the clinical condition being treated. It's crucial to consult a healthcare professional for specific dosing and usage instructions.

General Indications:

Pain relief: Headache, muscle pain, dental pain, menstrual cramps
Inflammation: Arthritis, bursitis, tendinitis
Fever: Fever associated with infections

Contraindications:

Peptic ulcer disease: NSAIDs can irritate the stomach lining and worsen ulcers.
Kidney disease: NSAIDs can impair kidney function.
Heart failure: NSAIDs can increase the risk of heart failure.
Allergy to aspirin or other NSAIDs: Can cause allergic reactions.

Note: Long-term use of NSAIDs can increase the risk of cardiovascular events, such as heart attack and stroke. It's important to use NSAIDs as directed and to discuss any concerns with a healthcare provider.

Mechanism of Action of NSAIDs

Preparations

1. Aspirin: Antiinflammatory dose 3–5 g/day (75–100 mg/kg/day); analgesic-antipyretic dose 0.3–0.6 g 6–8 hourly;

antiplatelet dose 75–150 mg/day. ASPIRIN 350 mg tab, COLSPRIN 100, 325 mg tabs, ECOSPRIN 75, 150, 325 mg

tabs, DISPRIN 325 mg (with calcium carbonate 105 mg + citric acid 35 mg) tab, LOPRIN 75, 162.5 mg tabs.

BIOSPIRIN: Lysine acetylsalicylate 900 mg + glycine 100 mg/vial for dissolving in 5 ml water and i.v. injection.

2. Indomethacin: 25–50 mg BD–QID. Those not tolerating the drug orally may be given nightly suppository.

IDICIN, INDOCAP 25 mg cap, 75 mg SR cap, ARTICID 25, 50 mg cap, INDOFLAM 25, 75 mg caps, 1% eye drop.

RECTICIN 50 mg suppository.

3. Ibuprofen: 400–800 mg TDS;

BRUFEN, EMFLAM, IBUSYNTH 200, 400, 600 mg tab, IBUGESIC also 100 mg/5 ml susp.

4. Naproxen: 250 mg BD–TDS;

NAPROSYN, NAXID, ARTAGEN, XENOBID 250 mg tab, NAPROSYN also 500 mg tab.

5. Ketoprofen: 50–100 mg BD–TDS;

KETOFEN 50, 100 mg tab; OSTOFEN 50 mg cap. RHOFENID 100 mg tab, 200 mg SR tab; 100 mg/2 ml amp.

6. Flurbiprofen: 50 mg BD–QID;

ARFLUR 50, 100 mg tab, 200 mg SR tab, FLUROFEN 100 mg tab, OCUFLUR 0.03% eye drops.

7. Mephenamic acid: 250–500 mg TDS; MEDOL 250, 500 mg cap; MEFTAL 250, 500 mg tab, 100 mg/5 ml susp.

PONSTAN 125, 250, 500 mg tab, 50 mg/ml syrup.

8. Diclofenac: 50 mg TDS, then BD oral, 75 mg deep i.m.; VOVERAN, DICLONAC, MOVONAC 50 mg enteric

coated tab, 100 mg S.R. tab, 25 mg/ml in 3 ml amp. for i.m. inj. DICLOMAX 25, 50 mg tab, 75 mg/3 ml inj.

Diclofenac potassium: VOLTAFLAM 25, 50 mg tab, ULTRA-K 50 mg tab; VOVERAN 1% topical gel.

9. Aceclofenac: 100 mg BD; ACECLO, DOLOKIND 100 mg tab, 200 mg SR tab.

10. Piroxicam: 20 mg BD for two days followed by 20 mg OD; DOLONEX, PIROX 10, 20 mg cap, 20 mg dispersible

tab, 20 mg/ml inj in 1 and 2 ml amps; PIRICAM 10, 20 mg cap.

11. Tenoxicam: 20 mg OD; TOBITIL 20 mg tab.

12. Ketorolac: 10–20 mg oral 6 hourly, 15–30 mg i.m./i.v. 6 hourly (max 90 mg/day); KETOROL, ZOROVON,

KETANOV, TOROLAC 10 mg tab, 30 mg in 1 ml amp., KETLUR, ACULAR 0.5% eye drops.

13. Nimesulide: 100 mg BD; NIMULID, NIMEGESIC, NIMODOL 100 mg tab, 50 mg/5 ml susp.

14. Meloxicam: 7.5–15 mg OD; MELFLAM, MEL–OD, MUVIK, M–CAM 7.5 mg, 15 mg tabs.

15. Nabumetone: 500 mg OD; NABUFLAM 500 mg tab.

16. Etodolac: 200-400 mg BD-TDS; ETOVA 200, 300, 400 mg tabs.

17. Celecoxib: 100–200 mg BD; CELACT, CELCOX, COLCIBRA, COBIX 100, 200 mg tabs.

18. Etoricoxib: 60–120 mg OD; TOROCOXIA, ETOXIB, ETOSHINE, NUCOXIA 60, 90, 120 mg tabs.

19. Parecoxib: 40 mg oral/i.m./i.v. repeated after 6–12 hours (max. 80 mg/day); PAROXIB 40 mg tab, REVALDO,

VALTO-P 40 mg/vial inj.

20. Paracetamol: 325–650 mg (children 10–15 mg/kg) 3-5 times a day (max. 2600 mg/day); also 80–250 mg as

suppository in infants and children; CROCIN 0.5 g tab, 125 mg/5 ml and 250 mg/5 ml syr, 100 mg/ml pediatric

drops, CROCIN PAIN RELIEF 650 mg with caffeine 50 mg tab; METACIN, PARACIN 500 mg tab, 125 mg/5 ml

syrup, 150 mg/ml ped. drops, ULTRAGIN, PYRIGESIC, CALPOL 500 mg tab, 125 mg/5 ml syrup, NEOMOL,

FEVASTIN, FEBRINIL 300 mg/2 ml inj. JUNIMOL-RDS 80, 170, 250 mg suppository, PARACETAMOL RECTAL

SUPPOSITORY 80, 170 mg.

21. Metamizol: 0.5–1.5 g oral/i.m./i.v.; ANALGIN 0.5 g tab; NOVALGIN, BARALGAN 0.5 g tab, 0.5 g/ml in 2 ml

and 5 ml amps; ULTRAGIN 0.5 g/ml inj in 2 ml amp and 30 ml vial.

22. Propiphenazone: 300–600 mg TDS; marketed only in combi nation in several ‘over the counter’ preparations–in

SARIDON, ANAFEBRIN: propiphenazone 150 mg + paracetamol 250 mg tab, DART: propiphenazone 150 mg +

paracetamol 300 mg + caffeine 50 mg tab.

23. Nefopam: 30–60 mg TDS oral, 20 mg i.m. 6 hourly; NEFOMAX 30 mg tab, 20 mg in 1 ml amp.

Topical NSAIDs

1. Diclofenac 1% gel: VOLINI GEL, RELAXYL GEL, DICLONAC GEL

2. Ibuprofen 10% gel: RIBUFEN GEL

3. Naproxen 10% gel: NAPROSYN GEL

4. Ketoprofen 2.5% gel: RHOFENID GEL

5. Flurbiprofen 5% gel: FROBEN GEL

6. Nimesulide 1% gel: NIMULID TRANS GEL, ZOLANDIN GEL, NIMEGESIC-T-GEL

7. Piroxicam 0.5% gel: DOLONEX GEL, MOVON GEL, PIROX GEL, MINICAM GEL

Drugs Acting on the Eye

Miotics

Miotics are drugs that cause pupillary constriction (miosis). They are primarily used to treat glaucoma and to facilitate certain eye examinations.

Classification:

Direct-Acting Miotics:
- Cholinergic Agonists: These drugs directly stimulate muscarinic receptors in the eye, leading to pupillary constriction.
  - Examples: Pilocarpine, Carbachol
Indirect-Acting Miotics:
- Cholinesterase Inhibitors: These drugs inhibit the enzyme acetylcholinesterase, leading to increased acetylcholine levels and pupillary constriction.
  - Examples: Physostigmine, Echothiophate iodide

Pharmacological Actions:

Pupillary constriction (miosis): This reduces intraocular pressure.
Accommodation: Focusing on near objects.

Dose, Indications, and Contraindications:

Dose: The dose of miotics varies depending on the specific drug and the clinical condition.
Indications:
- Glaucoma
- Reversal of mydriasis
Contraindications:
- Acute iritis
- Severe macular degeneration

Mydriatics

Mydriatics are drugs that cause pupillary dilation (mydriasis). They are used to dilate the pupil for ophthalmic examinations and to treat certain eye conditions.

Classification:

Adrenergic Agonists:
- Alpha-Adrenergic Agonists: These drugs stimulate alpha-adrenergic receptors in the iris dilator muscle, leading to pupillary dilation.
  - Examples: Phenylephrine, Hydroxyamphetamine
Anticholinergic Agents:
- These drugs block muscarinic receptors in the iris sphincter muscle, preventing pupillary constriction.
  - Examples: Atropine, Tropicamide

Pharmacological Actions:

Pupillary dilation (mydriasis): This allows for better visualization of the fundus.
Cycloplegia: Paralysis of accommodation, leading to difficulty focusing on near objects.

Dose, Indications, and Contraindications:

Dose: The dose of mydriatics varies depending on the specific drug and the clinical condition.
Indications:
- Ophthalmic examinations
- Treatment of uveitis
Contraindications:
- Acute glaucoma
- Narrow-angle glaucoma

Drugs Used in Glaucoma

Glaucoma is a group of eye diseases that damage the optic nerve, often leading to vision loss. Drugs used to treat glaucoma aim to lower intraocular pressure.

Miotics: As mentioned above, miotics like pilocarpine and cholinesterase inhibitors are used to constrict the pupil and increase aqueous humor outflow.
Beta-Blockers:
- Examples: Timolol, Betaxolol
- Mechanism of Action: Reduce aqueous humor production.
Alpha-2 Adrenergic Agonists:
- Examples: Apraclonidine, Brimonidine
- Mechanism of Action: Decrease aqueous humor production and increase outflow.
Carbonic Anhydrase Inhibitors:
- Examples: Dorzolamide, Brinzolamide
- Mechanism of Action: Reduce aqueous humor production.
Prostaglandin Analogs:
- Examples: Latanoprost, Bimatoprost
- Mechanism of Action: Increase outflow of aqueous humor.

The choice of drug and treatment regimen for glaucoma depends on the type of glaucoma, the severity of the disease, and the patient's individual needs. It's important to consult with an ophthalmologist to determine the most appropriate treatment plan.

Preparations

1. Timolol: Start with 0.25% eye drops BD, change to 0.5% drops in case of inadequate response. 0.5% OD as gel

forming solution. GLUCOMOL, OCUPRES, IOTIM, LOPRES 0.25% and 0.5% eye drops. TIMOLAST 0.5% gel

forming eye drops (long acting).

Timolol 0.5% + Latanoprost 0.005%: LAPROST PLUS, LATOCHEK-T eye drops.

2. Betaxolol: 0.5% topically in eye BD; OPTIPRES, IOBET, OCUBETA 0.5% eye drops.

3. Levobunolol: 0.5% topically in eye OD; BETAGAN 0.5% ophthalmic solution.

4. Dipivefrine: 0.1% topically in eye BD; PROPINE 0.1% eye drops.

5. Apraclonidine: 0.5–1.0% topically in eye; ALFADROPS-DS 1% eye drops.

6. Brimonidine: 0.2% topically in eye TDS;

ALPHAGAN-P, BRIMODIN-P 0.15% eye drops, IOBRIM 0.2% eye drops.

7. Latanoprost: 0.005% topically in eye OD in evening;

LACOMA, XALATAN, LATOPROST, 9 PM 50 µg/ml eye drops; LACOMA-T, LAPROST-PLUS, LATOCHEK-T

with timolol 0.5% eye drops (store in cold place).

8. Travoprost: 0.004% topically in eye OD in evening; TRAVATAN 0.004% eye drops (refrigeration of the eye

drops not required); TRAVACOM 0.004% with timolol 0.5% eye drops.

9. Bimatoprost: 0.03% as eye drops OD in evening; LUMIGAN, CAREPROST 0.03% eye drops; the eye drop need not

be stored in refrigerator; CAREPROST-PLUS, GANFORT with timolol 0.5% eye drop.

10. Pilocarpine: 0.5%–4% topically in eye; CARPINE, PILOCAR 0.5%, 1%, 2%, 4% eye drops.

11. Dorzolamide: 2% topically in eye BD–TDS; DORTAS, DORZOX 2% eye drops.

General Anesthetics

Definition: General anesthetics are drugs that induce a reversible loss of consciousness and sensation. They are used to facilitate surgical procedures and other medical interventions.

Classification:

General anesthetics can be classified into two main categories:

Inhaled Anesthetics:
- These drugs are administered through inhalation and are rapidly absorbed into the bloodstream.
- Examples: Nitrous oxide, Halothane, Isoflurane, Sevoflurane, Desflurane
Intravenous Anesthetics:
- These drugs are administered directly into a vein and quickly reach the brain.
- Examples: Propofol, Thiopental, Ketamine

Pharmacological Actions:

General anesthetics act on various targets in the central nervous system, including:

GABA receptors: Enhance the inhibitory effects of GABA, leading to sedation and hypnosis
NMDA receptors: Block the excitatory effects of glutamate, reducing neuronal activity
Voltage-gated ion channels: Alter the function of ion channels, affecting neuronal excitability

Dose, Indications, and Contraindications:

The specific dose, indications, and contraindications of general anesthetics vary depending on the individual drug and the clinical condition being treated. It's crucial to consult a healthcare professional for specific dosing and usage instructions.

General Indications:

General anesthesia for surgery
Sedation for diagnostic procedures

Contraindications:

Severe cardiac disease
Severe respiratory disease
Hypersensitivity to the anesthetic agent

Note: General anesthetics can have significant side effects, including respiratory depression, hypotension, and cardiac arrhythmias. They should be administered by trained professionals in a controlled setting.

Preparations

1. Thiopentone sod.: 3–5 mg/kg i.v. for induction;

PENTOTHAL, INTRAVAL SODIUM 0.5, 1.0 g for preparing injectable solution freshly.

2. Propofol: 2 mg/kg bolus i.v. injection for induction, 9 mg/kg/hr for maintenance;

PROPOVAN 10 mg/ml and 20 mg/ml in 10, 20 ml vials.

3. Diazepam: 0.25–0.5 mg/kg by slow injection in a running i.v. drip; VALIUM, CALMPOSE 10 mg/2 ml inj.

4. Lorazepam: 0.04 mg/kg (2–4 mg total for adult) i.v.; CALMESE 4 mg/2 ml inj.

5. Midazolam: 1–2.5 mg i.v. bolus injection, 0.02–0.1 mg/kg/hour i.v. infusion for maintenance;

MEZOLAM, FULSED, SHORTAL 1 mg/ml and 5 mg/ml inj.

6. Ketamine: 1–3 mg/kg i.v., 5 mg/kg i.m.; KETMIN, KETAMAX, ANEKET 50 mg/ml in 2 ml amp, 10 ml vial.

7. Fentanyl: 2–4 µg/kg i.v.; TROFENTYL, FENT, FENDOP 50 µg/ml in 2 ml amp, 10 ml vial.

Hypnotics and Sedatives

Definition: Hypnotics and sedatives are classes of drugs that act on the central nervous system (CNS) to produce calming effects, induce sleep, or relieve anxiety. While the terms are sometimes used interchangeably, hypnotics specifically refer to drugs that promote sleep, whereas sedatives primarily reduce agitation and anxiety.

Classification:

Benzodiazepines
- Examples: Diazepam, Lorazepam, Temazepam
- Mechanism: Enhance GABA (gamma-aminobutyric acid) activity.
Barbiturates
- Examples: Phenobarbital, Secobarbital
- Mechanism: Depress CNS activity, affecting GABA receptors.
Non-benzodiazepine Hypnotics
- Examples: Zolpidem, Zaleplon, Eszopiclone
- Mechanism: Selectively bind to GABA receptors but have different chemical structures.
Antihistamines
- Examples: Diphenhydramine, Doxylamine
- Mechanism: Block histamine receptors, leading to sedation.
Melatonin Receptor Agonists
- Example: Ramelteon
- Mechanism: Mimics the action of melatonin, regulating sleep-wake cycles.
Other Agents
- Examples: Chloral hydrate, Buspirone (anxiolytic)
- Mechanism: Varies depending on the specific agent.

Pharmacological Actions:

Sedation: Reduces agitation and anxiety.
Hypnosis: Induces sleep.
Anxiolysis: Alleviates anxiety.
Muscle Relaxation: Some agents have muscle-relaxant properties.
Amnesia: Certain drugs may cause anterograde amnesia.

Dosing:

Dosing varies based on the specific drug, the condition being treated, and individual patient factors (age, weight, health status).
Benzodiazepines: Common doses for insomnia might range from 5 to 30 mg.
Non-benzodiazepines: Typically prescribed in lower doses (e.g., Zolpidem 5-10 mg).
Barbiturates: Generally lower doses are used due to the risk of respiratory depression and dependency.

Indications:

Insomnia: Difficulty falling or staying asleep.
Anxiety Disorders: Short-term management of anxiety symptoms.
Preoperative Sedation: To relax patients prior to surgical procedures.
Seizure Disorders: Some agents can be used in seizure management.
Alcohol Withdrawal: To alleviate withdrawal symptoms.

Contraindications:

Pregnancy and Breastfeeding: Many hypnotics/sedatives can affect fetal development or pass into breast milk.
Severe Respiratory Insufficiency: Increased risk of respiratory depression.
History of Substance Abuse: Higher risk of dependence and addiction.
Sleep Apnea: Can worsen airway obstruction during sleep.
Glaucoma: Certain agents may increase intraocular pressure.

Preparations

1. Phenobarbitone: 30–60 mg OD–TDS (as antiepileptic) 100–200 mg i.m./i.v.;

GARDENAL 30, 60 mg tab; LUMINAL 30 mg tab; PHENOBARBITONE SOD 200 mg/ml inj.

2. Diazepam: 2.5–10 mg (as hypnotic), 5–30 mg/day (as antianxiety);

VALIUM 2, 5, 10 mg tab., 10 mg/2 ml inj., CALMPOSE 5, 10 mg tab, 2 mg/5 ml syr, 10 mg/2 ml inj.

3. Flurazepam: 15–30 mg (as hypnotic); NINDRAL, FLURAZ 15 mg cap.

4. Nitrazepam: 5–10 mg (as hypnotic); SEDAMON, HYPNOTEX, NITRAVET 5, 10 mg tab/cap.

5. Alprazolam: 0.25–1.0 mg (hypnotic dose), 0.25–1.0 mg TDS for anxiety; ALPRAX 0.25, 0.5, 1.0 mg tabs., 0.5, 1.0,

1.5 mg SR tabs; ALZOLAM 0.25, 0.5, 1.0 mg tabs; 1.5 mg SR tab, RESTYL 0.25, 0.5, 1.0 mg tab, RESTYL-SR 0.5,

1.0, 1.5 mg SR tab, ALPROCONTIN 0.5, 1.0, 1.5 mg CR tabs.

6. Temazepam: 10–20 mg (as hypnotic).

7. Triazolam: 0.125–0.25 mg (as hypnotic).

8. Zopiclone: 7.5 mg (hypnotic dose), elderly 3.75 mg; ZOPICON, ZOLIUM, ZOPITRAN 7.5 mg tab.

9. Zolpidem: 5–10 mg (max 20 mg) as hypnotic; elderly and liver disease patients 2.5–10 mg;

NITREST, ZOLDEM, DEM 5, 10 mg tabs.

10. Zaleplon: 5–10 mg (max 20 mg) hypnotic dose; ZAPLON, ZASO, ZALEP 5, 10 mg tabs.

Note: See Index for preparations of other drugs.

Anti-Convulsant Drugs

Definition: Anti-convulsant drugs, also known as anticonvulsants or anti-seizure medications, are used to prevent or control seizures in various types of epilepsy and other conditions characterized by abnormal electrical activity in the brain.

Classification:

Traditional Anti-Convulsants:
- Examples:
  - Phenytoin
  - Carbamazepine
  - Valproate (Valproic acid)
  - Phenobarbital
  - Ethosuximide
Newer Anti-Convulsants:
- Examples:
  - Lamotrigine
  - Levetiracetam
  - Topiramate
  - Oxcarbazepine
  - Zonisamide
  - Pregabalin

Pharmacological Actions:

Sodium Channel Blockade: Inhibits the influx of sodium ions during action potentials, stabilizing neuronal membranes (e.g., Phenytoin, Carbamazepine).
GABA Enhancement: Increases the action of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, reducing neuronal excitability (e.g., Valproate, Phenobarbital).
Calcium Channel Blockade: Reduces calcium influx, thereby decreasing neurotransmitter release (e.g., Ethosuximide).
Glutamate Inhibition: Modulates excitatory neurotransmitter activity (e.g., Lamotrigine, Levetiracetam).

Dose:

Phenytoin:
- Initial: 15-20 mg/kg loading dose; maintenance: 300-400 mg/day.
Carbamazepine:
- Initial: 200 mg bid; maintenance: 800-1200 mg/day.
Valproate:
- Initial: 10-15 mg/kg/day; maintenance: 20-30 mg/kg/day.
Lamotrigine:
- Initial: 25 mg/day; maintenance: 100-400 mg/day (titrated).
Levetiracetam:
- Initial: 500 mg bid; maintenance: 1000-3000 mg/day.

(Dosing can vary based on the specific formulation, patient factors, and clinical response.)

Indications:

Epilepsy: Management of various seizure types (generalized tonic-clonic, focal seizures, absence seizures).
Status Epilepticus: Acute management of prolonged seizures.
Neuropathic Pain: Certain anticonvulsants (e.g., Gabapentin, Pregabalin) are also used for nerve pain management.
Bipolar Disorder: Valproate and Lamotrigine can be used as mood stabilizers.

Contraindications:

Phenytoin:
- Hypersensitivity, bradycardia, and certain cardiac conditions.
Carbamazepine:
- History of bone marrow suppression, hypersensitivity, and concomitant use of monoamine oxidase inhibitors (MAOIs).
Valproate:
- Liver disease, urea cycle disorders, and pregnancy (risk of teratogenic effects).
Lamotrigine:
- Hypersensitivity reactions, especially in patients with a history of rash with other antiepileptics.
Levetiracetam:
- Generally well-tolerated but caution in renal impairment.

Preparations

1. Phenobarbitone: 60 mg OD–TDS (child 3–6 mg/kg/day), 100–200 mg i.m./i.v.;

GARDENAL 30, 60 mg tab; LUMINAL 30 mg tab; PHENOBARBITONE SOD 200 mg/ml inj.

2. Primidone: 250–500 mg BD (child 10–20 mg/kg/day); MYSOLINE 250 mg tab.

3. Phenytoin: 100–200 mg BD (child 5–8 mg/kg/day) oral, 25 mg/min slow i.v. injection (max 1.0 g);

DILANTIN 25 mg, 100 mg cap., 100 mg/4 ml oral suspension, 100 mg/2 ml inj.; EPTOIN 50, 100 mg tab, 25 mg/

ml syr; FENTOIN-ER 100 mg extended release cap.

4. Fosphenytoin: 25-100 mg (as phenytoin sod. equivalent)/min i.v. injection (max 1.0 g) for generalized convulsive status epilepticus; FOSOLIN 50 mg/ml inj in 2 ml and 10 ml amp.

5. Carbamazepine: 200–400 mg TDS, children 15–30 mg/kg/day;

TEGRETOL, MAZETOL 100, 200, 400 mg tab, 100 mg/5 ml syr; CARBATOL 100, 200, 400 mg tab; MAZETOL-SR,

TEGRITAL-CR 200, 400 mg sustained release tabs.

6. Oxcarbazepine: 300–600 mg BD; OXCARB, OXEP, OXETOL 150, 300, 600 mg tabs.

7. Ethosuximide: 20–30 mg/kg/day; ZARONTIN 250 mg/5 ml syr.

8. Valproic acid (Sodium valproate): Adults—start with 200 mg TDS, maximum 800 mg TDS; children—15–30

mg/kg/day; VALPARIN CHRONO 200, 300, 500 mg tabs, 200 mg/5 ml syr, ENCORATE 200, 300, 500 mg regular

tabs and controlled release tabs, 200 mg/5 ml syr, 100 mg/ml inj.

9. Divalproex: Epilepsy—initially 15 mg/kg/day, increase gradually as required (max 60 mg/kg/day);

Bipolar disorder—250–500 mg TDS;

Migraine 250–500 mg BD; DIPROEX, VALANCE, DEPAKOTE 125, 250, 500 mg tabs.

10. Clonazepam: Adults 0.5–5 mg TDS, children 0.02–0.2 mg/kg/day; status epilepticus 1–2 mg slow i.v. inj;

LONAZEP, CLONAPAX, RIVOTRIL 0.5, 1.0, 2.0 mg tab.

11. Diazepam: for status epilepticus—10 mg (0.2–0.3 mg/kg) slow i.v. injection (2 mg/min), repeat fractional doses

as required (max 100 mg/day); for febrile convulsions 0.5 mg/kg rectal instillation, repeat 12 hourly for 48 hours;

VALIUM, CALMPOSE, PLACIDOX 10 mg/2 ml inj.

12. Lorazepam: for status epilepticus—4 mg (0.1 mg/kg in children) slow i.v. injection (2 mg/min);

CALMESE 4 mg/2 ml inj.

13. Clobazam: start with 10–20 mg at bed time, can be increased upto 60 mg/day;

FRISIUM, LOBAZAM, CLOZAM 5, 10, 20 mg cap.

14. Lamotrigine: 50 mg/day initially, increase upto 300 mg/day as needed.

LAMITOR, LAMETEC, LAMIDUS 25, 50, 100 mg tabs.

15. Gabapentin: start with 300 mg OD, increase to 300–600 mg TDS as required;

NEURONTIN, GABANTIN 300 mg, 400 mg cap, GABAPIN 100, 300, 400 mg cap.

16. Pregabalin: 75–150 mg BD, max. 600/day (used primarily for neuropathic pain).

PREEGA, NEUGABA, TRUGABA 75, 150 mg caps.

17. Vigabatrin: 2–4 g/day, child 40–100 mg/kg/day.

18. Topiramate: Initially 25 mg OD, increase weekly upto 100–200 mg BD as required, child 5–10 mg/kg/day.

TOPEX, EPITOP, TOPAMATE, NEXTOP 25, 50, 100 mg tabs.

19. Zonisamide: 25–100 mg BD (not for children); ZONISEP, ZONICARE, ZONIT 50, 100 mg cap.

20. Levetiracetam: 0.5 g BD, increase upto 1.0 g BD; children 4–15 years 10–30 mg/kg/day.

EPIFAST, TORLEVA, LEVROXA, LEVTAM 250, 500, 750 mg tabs.

Anti-Anxiety Drugs

Definition: Anti-anxiety drugs, also known as anxiolytics, are medications used to relieve symptoms of anxiety, such as excessive worry, tension, and agitation. They are commonly prescribed for various anxiety disorders and can also be used for conditions like insomnia and muscle spasms.

Classification:

Benzodiazepines:
- Examples:
  - Diazepam (Valium)
  - Lorazepam (Ativan)
  - Alprazolam (Xanax)
  - Clonazepam (Klonopin)
Non-Benzodiazepine Anxiolytics:
- Examples:
  - Buspirone (Buspar)
Antidepressants (used for anxiety):
- SSRIs:
  - Sertraline (Zoloft)
  - Escitalopram (Lexapro)
- SNRIs:
  - Venlafaxine (Effexor XR)
  - Duloxetine (Cymbalta)
Beta-Blockers:
- Examples:
  - Propranolol (Inderal) - primarily for performance anxiety.
Antihistamines:
- Examples:
  - Hydroxyzine (Vistaril, Atarax)

Pharmacological Actions:

Benzodiazepines: Enhance the effect of GABA (gamma-aminobutyric acid), an inhibitory neurotransmitter, leading to sedation, muscle relaxation, and anxiolytic effects.
Buspirone: Acts on serotonin receptors (5-HT1A) and has anxiolytic properties without the sedative effects of benzodiazepines.
Antidepressants: SSRIs and SNRIs increase serotonin and norepinephrine levels, helping to alleviate anxiety symptoms.
Beta-Blockers: Reduce physical symptoms of anxiety (e.g., heart rate, tremors) by blocking adrenergic receptors.
Antihistamines: Provide mild sedation and anxiolytic effects through antihistaminic action.

Dosage:

Benzodiazepines:
- Diazepam: 2-10 mg 2-4 times daily.
- Lorazepam: 1-10 mg daily in divided doses.
- Alprazolam: 0.25-4 mg per day in divided doses.
Buspirone: 15-60 mg/day in divided doses.
SSRIs:
- Sertraline: 50-200 mg/day.
- Escitalopram: 10-20 mg/day.
Beta-Blockers:
- Propranolol: 40-160 mg/day for performance anxiety.
Antihistamines:
- Hydroxyzine: 25-100 mg daily as needed.

(Doses may vary based on patient factors and specific clinical scenarios.)

Indications:

Generalized Anxiety Disorder (GAD)
Panic Disorder
Social Anxiety Disorder
Performance Anxiety
Insomnia (when related to anxiety)
Post-Traumatic Stress Disorder (PTSD) (SSRIs/SNRIs)

Contraindications:

Benzodiazepines:
- Severe respiratory insufficiency, sleep apnea, history of substance abuse, and acute narrow-angle glaucoma.
Buspirone:
- Hypersensitivity and use of monoamine oxidase inhibitors (MAOIs) within the last 14 days.
Antidepressants:
- Caution in patients with bipolar disorder (risk of mania).
Beta-Blockers:
- Asthma, certain cardiac conditions (e.g., bradycardia).
Antihistamines:
- Caution in elderly patients (risk of sedation and confusion).

Preparations

1. Diazepam: 5–30 mg/day in 2–3 divided doses;

VALIUM, PLACIDOX 2, 5, 10 mg tabs; CALMPOSE 5, 10 mg tab, 2 mg/5 ml syr.

2. Chlordiazepoxide: 20–100 mg/day in 2–3 divided doses, LIBRIUM 10, 25 mg tabs; EQUILIBRIUM 10 mg tab.

3. Oxazepam: 30–60 mg/day in 2–3 divided doses; SEREPAX 15, 30 mg tabs.

4. Lorazepam: 1–6 mg/day in 1–2 divided doses; LARPOSE, ATIVAN 1, 2 mg tab. CALMESE 1, 2 mg tabs,

4 mg/2 ml inj.

5. Alprazolam: 0.25–1.0 mg TDS; upto 6 mg/day in panic disorder; ALPRAX 0.25, 0.5, 1.0 mg tabs.,

0.5, 1.0, 1.5 mg SR tabs; ALZOLAM 0.25, 0.5, 1.0 mg tabs; 1.5 mg SR tab, ALPROCONTIN 0.5, 1.0,

1.5 mg CR tabs. RESTYL-SR 0.5, 1.0, 1.5 mg SR tabs.

6. Buspirone: 5–15 mg 1–3 times daily; BUSCALM, ANXIPAR, BUSPIN 5, 10 mg tabs.

7. Hydroxyzine: 50–200 mg/day; ATARAX 10, 25 mg tabs, 10 mg/5 ml syr, 25 mg/2 ml inj.

Anti-Depressant Drugs

Definition: Antidepressant drugs are medications used to treat depressive disorders and other conditions, such as anxiety disorders, chronic pain, and certain hormonal disorders. They work by altering neurotransmitter levels in the brain to improve mood and alleviate depressive symptoms.

Classification:

Selective Serotonin Reuptake Inhibitors (SSRIs):
- Examples:
  - Fluoxetine (Prozac)
  - Sertraline (Zoloft)
  - Escitalopram (Lexapro)
  - Paroxetine (Paxil)
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs):
- Examples:
  - Venlafaxine (Effexor XR)
  - Duloxetine (Cymbalta)
Tricyclic Antidepressants (TCAs):
- Examples:
  - Amitriptyline
  - Nortriptyline (Pamelor)
  - Imipramine (Tofranil)
Monoamine Oxidase Inhibitors (MAOIs):
- Examples:
  - Phenelzine (Nardil)
  - Tranylcypromine (Parnate)
Atypical Antidepressants:
- Examples:
  - Bupropion (Wellbutrin)
  - Mirtazapine (Remeron)

Pharmacological Actions:

SSRIs: Inhibit the reuptake of serotonin in the brain, increasing serotonin levels and improving mood.
SNRIs: Inhibit the reuptake of both serotonin and norepinephrine, addressing a broader range of depressive symptoms.
TCAs: Block the reuptake of norepinephrine and serotonin; also have effects on various receptors, leading to side effects.
MAOIs: Inhibit the monoamine oxidase enzyme, increasing levels of serotonin, norepinephrine, and dopamine.
Atypical Antidepressants: Act through various mechanisms; for example, bupropion increases dopamine and norepinephrine activity, while mirtazapine enhances norepinephrine and serotonin release.

Dosage:

SSRIs:
- Fluoxetine: 20-80 mg/day.
- Sertraline: 50-200 mg/day.
- Escitalopram: 10-20 mg/day.
SNRIs:
- Venlafaxine: 75-375 mg/day (XR formulation).
- Duloxetine: 30-60 mg/day.
TCAs:
- Amitriptyline: 25-300 mg/day.
- Nortriptyline: 25-150 mg/day.
MAOIs:
- Phenelzine: 15-90 mg/day.
Atypical Antidepressants:
- Bupropion: 150-400 mg/day.
- Mirtazapine: 15-45 mg/day.

(Dosing may vary based on individual response and specific clinical considerations.)

Indications:

Major Depressive Disorder (MDD)
Generalized Anxiety Disorder (GAD)
Obsessive-Compulsive Disorder (OCD)
Panic Disorder
Post-Traumatic Stress Disorder (PTSD)
Chronic Pain Conditions
Bipolar Disorder (as adjunctive treatment)

Contraindications:

SSRIs/SNRIs:
- Hypersensitivity, use of MAOIs within 14 days, and certain bleeding disorders.
TCAs:
- History of cardiac issues, glaucoma, and urinary retention.
MAOIs:
- Use with certain medications (e.g., SSRIs, SNRIs) can cause serious interactions, such as serotonin syndrome.
Bupropion:
- History of seizures or eating disorders.
Mirtazapine:
- Caution in patients with a history of hypersensitivity.

Preparations

1. Moclobemide: 150 mg BD–TDS (max. 600 mg/day); RIMAREX, TRIMA 150, 300 mg tabs.

2. Imipramine: 50–200 mg/day; DEPSONIL, ANTIDEP 25 mg tab, 75 mg SR cap.

3. Amitriptyline: 50–200 mg/day; AMLINE, SAROTENA, TRYPTOMER, 10, 25, 75 mg tabs.

4. Trimipramine: 50–150 mg/day; SURMONTIL 10, 25 mg tab.

5. Doxepin: 50–150 mg/day; SPECTRA, DOXIN, DOXETAR 10, 25, 75 mg tab/cap; NOCTADERM 5% cream (to

relieve itching).

6. Clomipramine: 50–150 mg/day; CLOFRANIL 10, 25, 50 mg tab, 75 mg SR tab, CLONIL, ANAFRANIL 10,

25 mg tab;

7. Dothiepin (Dosulpin): 50–150 mg/day; PROTHIADEN, DOTHIN 25, 75 mg tab.

8. Nortriptyline: 50–150 mg/day; SENSIVAL, PRIMOX 25 mg tab.

9. Amoxapine: 100–300 mg/day; DEMOLOX 50, 100 mg tab.

10. Reboxetine: 4–8 mg/day; NAREBOX 4, 8 mg tabs.

11. Fluoxetine: 20–40 mg/day; FLUDAC 20 mg cap, 20 mg/5 ml susp; FLUNIL 10, 20 mg caps; FLUPAR, PRODAC

20 mg cap.

12. Fluvoxamine: 50–200 mg/day; FLUVOXIN 50, 100 mg tab.

13. Paroxetine: 20–50 mg/day; XET 10, 20, 30, 40 mg tabs.

14. Sertraline: 50–150 mg/day; SERENATA, SERLIN, SERTIL 50, 100 mg tabs.

15. Citalopram: 20–40 mg/day; CELICA 10, 20, 40 mg tabs.

16. Escitalopram: 10–20 mg OD; ESDEP, FELIZ-S 5, 10, 20 mg tabs.

17. Dapoxetine: 60 mg 1 hour before intercourse, elderly 30 mg; SUSTINEX, DURALAST, KUTUB 30, 60 mg tabs.

18. Trazodone: 50–200 mg/day; TRAZODAC 25, 50 mg tab, TRAZONIL, TRAZALON 25, 50, 100 mg tabs.

19. Mianserin: 30–100 mg/day; TETRADEP 10, 20, 30 mg tab, SERIDAC 10, 30 mg tab.

20. Bupropion: 150–300 mg/day; SMOQUIT–SR, BUPRON–SR 150 mg tab.

21. Mirtazapine: 15–45 mg/day; MIRT 15, 30, 45 mg tabs, MIRTAZ 15, 30 mg tab.

22. Venlafaxine: 75–150 mg/day; VENLOR 25, 37.5, 75 mg tabs, VENIZ-XR 37.5, 75, 150 mg ER caps.

23. Tianeptine: 12.5 mg BD–TDS; STABLON 12.5 mg tab.

24. Amineptine: 100 mg BD at breakfast and lunch; SURVECTOR 100 mg tab.

25. Duloxetine: 30–80 mg/day; DELOK, DULANE, DUZAC 20, 30, 40 mg caps.

Anti-Psychotic Drugs

Definition: Anti-psychotic drugs, also known as neuroleptics, are medications used to manage symptoms of psychosis, such as delusions, hallucinations, and disorganized thinking. They are primarily used in the treatment of schizophrenia and other severe mental health conditions.

Classification:

Typical Anti-Psychotics (First Generation):
- Examples:
  - Haloperidol (Haldol)
  - Chlorpromazine (Thorazine)
  - Fluphenazine (Prolixin)
Atypical Anti-Psychotics (Second Generation):
- Examples:
  - Risperidone (Risperdal)
  - Olanzapine (Zyprexa)
  - Quetiapine (Seroquel)
  - Aripiprazole (Abilify)
  - Lurasidone (Latuda)

Pharmacological Actions:

Typical Anti-Psychotics: Primarily block dopamine D2 receptors in the brain, which helps reduce positive symptoms of psychosis (e.g., hallucinations, delusions). However, they may also cause extrapyramidal symptoms (EPS) due to their action on the dopaminergic pathways.
Atypical Anti-Psychotics: Block D2 receptors but also have significant effects on serotonin receptors (5-HT2A). This broader action may help alleviate both positive and negative symptoms of schizophrenia with a lower risk of EPS.

Dosage:

Typical Anti-Psychotics:
- Haloperidol: 1-30 mg/day, depending on severity.
- Chlorpromazine: 200-800 mg/day, divided doses.
Atypical Anti-Psychotics:
- Risperidone: 1-6 mg/day.
- Olanzapine: 5-20 mg/day.
- Quetiapine: 150-800 mg/day.
- Aripiprazole: 10-30 mg/day.
- Lurasidone: 40-160 mg/day.

(Doses may vary based on individual patient factors and clinical response.)

Indications:

Schizophrenia
Bipolar Disorder
Severe Depression (as an adjunct)
Delusional Disorder
Schizoaffective Disorder
Acute Psychosis or agitation

Contraindications:

Typical Anti-Psychotics:
- Known hypersensitivity, severe CNS depression, and Parkinson’s disease.
Atypical Anti-Psychotics:
- Known hypersensitivity, certain metabolic disorders, and caution in elderly patients (increased risk of cerebrovascular events).

Side Effects:

Typical Anti-Psychotics:
- Extrapyramidal symptoms (tremors, rigidity, bradykinesia)
- Tardive dyskinesia
- Sedation
- Anticholinergic effects (dry mouth, constipation)
Atypical Anti-Psychotics:
- Weight gain
- Metabolic syndrome (increased blood sugar and cholesterol)
- Sedation
- Less risk of EPS compared to typicals, but still possible.

Preparations

1. Chlorpromazine: 100–800 mg/day; CHLORPROMAZINE, LARGACTIL 10, 25, 50, 100 mg tab. 5 mg/5 ml

(pediatric) & 25 mg/5 ml (adult) syr., 50 mg/2 ml inj.

2. Triflupromazine: 50–200 mg/day; SIQUIL 10 mg tab; 10 mg/ml inj.

3. Thioridazine: 100–400 mg/day; MELLERIL 25, 100 mg tab, THIORIL 10, 25, 50 mg tab.

4. Trifluoperazine: 2–20 mg/day; TRINICALM 1, 5 mg tab, NEOCALM 5, 10 mg tab.

5. Fluphenazine: 1–10 mg/day; ANATENSOL 1 mg tab, 0.5 mg/ml elixir; ANATENSOL DECANOATE

25 mg/ml (as decanoate) for i.m. injection, 1–2 ml every 2–4 weeks.

6. Haloperidol: 2–20 mg/day; SERENACE 1.5, 5, 10, 20 mg tab; 2 mg/ml liq, 5 mg/ml inj., SENORM 1.5, 5,

10 mg tab, 5 mg/ml inj., HALOPIDOL 2, 20 mg tab, 2 mg/ml liq, 10 mg/ml drops.

7. Trifluperidol: 1–8 mg/day; TRIPERIDOL 0.5 mg tab, 2.5 mg/ml inj.

8. Penfluridol: 20–60 mg (max. 120 mg) once weekly; SEMAP, FLUMAP, PENFLUR 20 mg tab.

9. Flupenthixol: 3–15 mg/day; FLUANXOL 0.5, 1, 3 mg tab; FLUANXOL DEPOT 20 mg/ml in 1 and 2 ml amp.

10. Pimozide: 2–6 mg/day; ORAP, NEURAP, PIMODAC 2, 4 mg tab.

11. Loxapine: 20–50 mg/day; LOXAPAC 10, 25, 50 mg caps, 25 mg/ 5 ml liquid.

12. Clozapine: 100–300 mg/day; LOZAPIN, SIZOPIN, SKIZORIL 25, 100 mg tabs.

13. Risperidone: 2–8 mg/day; RESPIDON, SIZODON, RISPERDAL 1, 2, 3, 4 mg tabs.

14. Olanzapine: 2.5–20 mg/day; OLACE, OLANDUS 2.5, 5, 7.5, 10 mg tabs, OLZAP 5, 10 mg tab.

15. Quetiapine: 50–400 mg/day; QUEL, SOCALM, SEROQUIN 25, 100, 200 mg tabs.

16. Aripiprazole: 10–30 mg/day; ARIPRA, ARILAN, BILIEF 10, 15 mg tabs, ARIVE 10, 15, 20, 30 mg tabs.

Nootropic Agents

Definition: Nootropic agents, often referred to as "smart drugs" or cognitive enhancers, are substances that purportedly improve cognitive function, including memory, creativity, motivation, and attention. They are used both in clinical settings and by healthy individuals seeking to enhance cognitive performance.

Classification:

Prescription Nootropics:
- Examples:
  - Racetams:
    - Piracetam
    - Aniracetam
    - Oxiracetam
  - Stimulants:
    - Modafinil (Provigil)
    - Armodafinil (Nuvigil)
  - Other Prescription Agents:
    - Donepezil (Aricept) - primarily for Alzheimer's disease.
    - Methylphenidate (Ritalin) - used for ADHD.
Natural Nootropics:
- Examples:
  - Herbal Supplements:
    - Ginkgo Biloba
    - Bacopa Monnieri
    - Rhodiola Rosea
  - Amino Acids:
    - L-theanine (found in tea)
    - Acetyl-L-carnitine
  - Vitamins and Nutrients:
    - Omega-3 fatty acids
    - B vitamins
Other Compounds:
- Creatine: Commonly used in fitness but also shown to have cognitive benefits.
- Lion's Mane Mushroom: Believed to promote nerve growth factor (NGF) production.

Pharmacological Actions:

Enhancement of Neurotransmitter Activity: Many nootropics increase the availability of neurotransmitters (e.g., acetylcholine, dopamine, serotonin), which can improve cognitive functions like memory and attention.
Neuroprotection: Some agents may help protect neurons from damage and promote brain health.
Increased Blood Flow: Certain nootropics may enhance cerebral blood flow, providing more oxygen and nutrients to the brain.
Mood Enhancement: Some nootropics can also have anxiolytic effects, reducing anxiety and improving overall mood, which can contribute to better cognitive performance.

Dosage:

Piracetam: 1,200–4,800 mg/day in divided doses.
Modafinil: 100–200 mg/day for cognitive enhancement; higher doses for narcolepsy.
Ginkgo Biloba: 120–240 mg/day in divided doses.
Bacopa Monnieri: 300–600 mg/day.
L-theanine: 100–200 mg, often taken with caffeine for synergy.

(Dosing can vary based on individual needs and specific formulations.)

Indications:

Cognitive Decline: Conditions like Alzheimer’s or age-related cognitive decline.
Attention Deficit Hyperactivity Disorder (ADHD): Some nootropics may help improve focus and attention.
Sleep Disorders: Modafinil for narcolepsy; L-theanine for relaxation and sleep support.
Mood Disorders: Some natural nootropics can help alleviate symptoms of anxiety and depression.

Contraindications:

Prescription Nootropics: Generally contraindicated in individuals with a history of substance abuse, certain psychiatric disorders, or cardiovascular issues.
Natural Nootropics: Potential interactions with medications; consult a healthcare provider if pregnant, nursing, or taking other medications.

Side Effects:

Prescription Nootropics: Can include headaches, nausea, insomnia, anxiety, and dependence (especially with stimulants).
Natural Nootropics: Generally well-tolerated but can cause gastrointestinal discomfort or allergic reactions in some individuals.

Centrally Acting Muscle Relaxants

Definition: Centrally acting muscle relaxants are medications that alleviate muscle spasms and spasticity by acting on the central nervous system (CNS). They are commonly used to treat conditions associated with acute muscle pain, spasms, and certain neurological disorders.

Classification:

Benzodiazepines:
- Examples:
  - Diazepam (Valium)
  - Lorazepam (Ativan)
Cyclobenzaprine:
- A widely used muscle relaxant for acute muscle spasms.
Carisoprodol:
- Often used for short-term relief of muscle pain and discomfort.
Methocarbamol:
- Commonly used for muscle relaxation and to relieve pain.
Orphenadrine:
- Used for muscle spasms and as an adjunct in pain relief.
Tizanidine:
- Primarily used to manage spasticity in conditions like multiple sclerosis or spinal cord injuries.
Baclofen:
- A muscle relaxant used for spasticity, particularly in spinal cord injuries and multiple sclerosis.

Pharmacological Actions:

CNS Depression: These agents work by depressing the CNS, leading to decreased muscle tone and reduced reflexes, which helps to alleviate muscle spasms.
GABA Receptor Modulation: Some (like benzodiazepines) enhance the effects of GABA, an inhibitory neurotransmitter, leading to muscle relaxation.
Alpha-2 Adrenergic Agonism: Tizanidine acts on alpha-2 adrenergic receptors, reducing motor neuron activity and providing muscle relaxation.

Dosage:

Diazepam: 2-10 mg 2-4 times daily, depending on the severity of symptoms.
Cyclobenzaprine: 5-10 mg three times daily.
Carisoprodol: 250-350 mg three times daily and at bedtime.
Methocarbamol: 1,500 mg four times daily for the first 48-72 hours, then adjust as needed.
Orphenadrine: 100 mg twice daily.
Tizanidine: 2-4 mg every 6-8 hours, max 36 mg/day.
Baclofen: 5-20 mg three times daily, titrated as needed.

(Doses may vary based on individual patient factors and clinical response.)

Indications:

Muscle Spasms: Acute musculoskeletal conditions (e.g., strains, sprains).
Spasticity: Conditions like multiple sclerosis, spinal cord injuries, or cerebral palsy.
Pain Relief: As an adjunct in the management of pain.

Contraindications:

Benzodiazepines: Caution in patients with a history of substance abuse, respiratory depression, or severe hepatic impairment.
Cyclobenzaprine: Contraindicated in patients with a history of arrhythmias or heart block.
Tizanidine: Caution in patients with liver dysfunction or hypotension.
Carisoprodol: Caution in patients with a history of seizures or substance abuse.

Side Effects:

Common Side Effects: Drowsiness, dizziness, dry mouth, fatigue, and confusion.
Benzodiazepines: Risk of dependence, withdrawal symptoms, and sedation.
Tizanidine: Hypotension, dry mouth, and sedation.
Cyclobenzaprine: Anticholinergic effects like blurred vision and constipation.

Preparations

CNS Stimulants

1. Doxapram: 40–80 mg i.m. or i.v.; 0.5–2 mg/kg/hr i.v. infusion. CAROPRAM 20 mg/ml in 5 ml amp.

2. Methylphenidate: Adults 5–10 mg BD, child 0.25 mg/kg/day (max 1 mg/kg/day); RETALIN 5, 10, 20, 30 mg tab.

3. Atomoxetine: 0.5 mg/kg OD in the morning (max 1.2 mg/kg/day) in children; adults 40 mg OD (max. 100

mg OD). ATTENTROL 10, 18, 25, 40 mg caps; AXEPTA 18, 25 mg cap.

4. Modafinil: 100-200 mg morning and afternoon (for day time sleepiness), 200 mg 1 hour before starting night

shift. MODALERT, PROVAKE 100, 200 mg tabs.

5. Caffeine: 20–100 mg oral; in CAFERGOT: Caffeine 100 mg + ergotamine 1 mg tab. MICROPYRIN: Caffeine

20 mg + aspirin 350 mg tab.

Cognition Enhancers

1. Rivastigmine: Start with 1.5 mg BD, increase every 2 weeks by 1.5 mg/day upto 6 mg/day;

EXELON, RIVAMER 1.5, 3.0, 6.0 mg caps.

2. Donepezil: 5 mg once at bed time (max. 10 mg OD); DONECEPT, DOPEZIL, DORENT 5, 10 mg tabs.

3. Galantamine: 4 mg BD (max. 12 mg BD); GALAMER 4, 8, 12 mg tabs.

4. Memantine: 5 mg OD, increase up to 10 mg BD; ADMENTA, MENTADEM 5, 10 mg tabs, ALMANTIN 5 mg tab.

5. Piracetam: 0.8–1 g TDS; children 20 mg/kg BD–TDS; 1–3 g i.m. 6 hourly in stroke/head injury;

NORMABRAIN, NEURO CE TAM, NOOTROPIL 400, 800 mg cap, 500 mg/5 ml syr., 300 mg/ml inj.

6. Pyritinol (Pyrithioxine): 100–200 mg TDS, child 50–100 mg TDS oral, 200–400 mg 6 hourly (max. 1 g/day) i.v.;

ENCEPHABOL 100, 200 mg tab, 100 mg/5 ml susp, 200 mg dry powder in vial with solvent for i.v. infusion.

7. Dihydroergotoxine (Codergocrine): 1–1.5 mg TDS oral/sublingual, 0.3 mg i.m. OD;

HYDERGINE 1 mg tab, 0.3 mg/ml inj, CERELOID 1 mg tab.

8. Piribedil: 50 mg OD–BD; TRIVASTAL-LA 50 mg tab.

9. Ginkgo biloba: 40–80 mg TDS; GINKOCER, BILOVAS, GINKOBA 40 mg tab.

10. Citicoline: Oral 200–600 mg/day in divided doses;

Parenteral 0.5–1.0 g/day i.m./i.v.

STROLIN 500 mg tab, CITILIN, CITINOVA 500 mg tab, 500 mg/2 ml inj.

Opioid Analgesics

Definition: Opioid analgesics are a class of medications used to manage moderate to severe pain. They work by binding to specific receptors in the brain, spinal cord, and other areas of the body, thereby blocking pain signals and altering the perception of pain.

Classification:

Natural Opioids:
- Examples:
  - Morphine
  - Codeine
Semi-Synthetic Opioids:
- Examples:
  - Oxycodone (OxyContin, Percocet)
  - Hydrocodone (Vicodin, Norco)
  - Heroin (diacetylmorphine)
Synthetic Opioids:
- Examples:
  - Fentanyl (Duragesic, Sublimaze)
  - Methadone
  - Tramadol (Ultram)
Combination Products:
- Examples:
  - Oxycodone/acetaminophen (Percocet)
  - Hydrocodone/acetaminophen (Vicodin)

Pharmacological Actions:

Analgesic Effect: Opioids primarily reduce the perception of pain by binding to mu, delta, and kappa opioid receptors in the CNS, leading to decreased pain signaling.
Euphoria: Some opioids produce feelings of euphoria, which can contribute to their potential for misuse and addiction.
Sedation: Opioids can cause sedation, leading to a decrease in anxiety and agitation.
Respiratory Depression: Opioids can depress the respiratory center in the brain, which can be a serious side effect.
Constipation: Opioids often decrease gastrointestinal motility, leading to constipation.

Dosage:

Morphine: 10-30 mg every 4 hours as needed for pain (oral); 2-10 mg IV/IM.
Oxycodone: 5-15 mg every 4-6 hours as needed (oral).
Hydrocodone: 5-10 mg every 4-6 hours as needed (oral).
Fentanyl:
- Transdermal patch: 12-100 mcg/hour every 72 hours.
- IV: 25-100 mcg (titrated according to response).
Methadone: Dosing varies widely; often started at 2.5-10 mg every 8-12 hours.

(Doses vary based on individual patient needs, pain severity, and opioid tolerance.)

Indications:

Acute Pain: Post-surgical pain, trauma, and other short-term pain management.
Chronic Pain: Cancer pain, severe chronic non-cancer pain when other treatments fail.
Palliative Care: Management of severe pain in terminal illness.
Cough Suppression: Codeine is sometimes used for cough relief.

Contraindications:

Severe Respiratory Insufficiency: Increased risk of respiratory depression.
Acute or Severe Asthma: Risk of respiratory failure.
Use with Caution in: Patients with a history of substance abuse, pregnancy, or certain CNS depressants.

Side Effects:

Common Side Effects: Drowsiness, constipation, nausea, vomiting, and dry mouth.
Serious Side Effects: Respiratory depression, hypotension, dependence, and overdose.
Withdrawal Symptoms: Anxiety, muscle aches, sweating, and gastrointestinal upset if opioids are suddenly discontinued after prolonged use.

Preparations

Opioid Analgesics

1. Morphine: 10–50 mg oral, 10–15 mg i.m. or s.c., 2–6 mg i.v.; 2–3 mg epidural/intrathecal; children 0.1–0.2 mg/

kg i.m. or s.c. MORPHINE SULPHATE 10 mg/ml inj; MORCONTIN 10, 30, 60, 100 mg continuous release tabs;

30–100 mg BD; RILIMORF 10, 20 mg tabs, 60 mg SR tab.

Opioid Analgesics and Antagonists

84 Drugs Acting on Central Nervous System

2. Codeine: 30–60 mg oral; CODEINE 15 mg tab, 15 mg/5 ml syr.

3. Pethidine: 50–100 mg oral/i.m./s.c., 10–15 mg i.v. (rarely); PETHIDINE 50, 100 mg tabs, 100 mg/2 ml inj.

4. Fentanyl: 2–4 µg/kg i.v.; 12.5–100 µg/hr transdermal; TROFENTYL, FENT 50 µg/ml in 2 ml amp and 10 ml

vial, DUROGESIC transdermal patch delivering 12.5 µg/hr, 25 µg/hr, 50 µg/hr, 75 µg/hr and 100 µg per hour;

the patch is changed every 3 days.

5. Methadone: As analgesic 2.5–10 mg oral/i.m. (not s.c.); for methadone maintenance therapy 5-40 mg per day;

METHADONE 5 mg/ml and 10 mg/ml syr; 5, 10, 20, 40 mg tabs.

6. Dextropropoxyphene: 60–120 mg oral; PARVODEX 60 mg cap; PARVON, PROXYVON, WALAGESIC:

dextropropoxy phene 65 mg + paracetamol 400 mg cap; WYGESIC, SUDHINOL 65 mg + paracetamol 650 mg cap.

7. Tramadol: 50–100 mg oral/i.m./slow i.v. infusion (children 1–2 mg/kg) 4–6 hourly. CONTRAMAL, DOMADOL,

TRAMAZAC 50 mg cap, 100 mg SR tab; 50 mg/ml inj in 1 and 2 ml amps.

Opioid Agonist-Antagonists and Pure Antagonists

1. Pentazocine: 50–100 mg, oral, 30–60 mg i.m., s.c., FORTWIN 25 mg tab., 30 mg/ml inj., FORTSTAR, SUSEVIN

30 mg/ml inj; FORTAGESIC pentazocine 15 mg + paracetamol 500 mg tab.

2. Butorphanol: 1–4 mg i.m./i.v.; BUTRUM 1 mg/ml and 2 mg/ml inj.

3. Buprenorphine: 0.3–0.6 mg i.m., s.c. or slow i.v., also sublingual 0.2–0.4 mg 6–8 hourly; NORPHIN, TIDIGESIC

0.3 mg/ml inj. 1 and 2 ml amps. 0.2 mg sublingual tab; BUPRIGESIC, PENTOREL 0.3 mg/ml inj in 1, 2 ml amp.

4. Naloxone: Adults 0.4–0.8 mg i.v. every 2–3 min (max 10 mg); neonates 10 µg/kg in the umbilical cord; NARCOTAN 0.4 mg in 1 ml (adult) and 0.04 mg in 2 ml (infant) amps; NALOX, NEX 0.4 mg inj.

5. Naltrexone: 50 mg/day oral; NALTIMA, NALTROX 50 mg tab.

1. Anti-hypertensive Drugs

Definition: Medications used to lower high blood pressure.

Classification:

Diuretics: Thiazides (e.g., Hydrochlorothiazide), Loop diuretics (e.g., Furosemide).
ACE Inhibitors: (e.g., Lisinopril, Enalapril).
ARBs (Angiotensin II Receptor Blockers): (e.g., Losartan, Valsartan).
Calcium Channel Blockers: (e.g., Amlodipine, Diltiazem).
Beta-blockers: (e.g., Atenolol, Metoprolol).
Alpha-2 Agonists: (e.g., Clonidine).
Vasodilators: (e.g., Hydralazine).

Pharmacological Actions: Decrease peripheral vascular resistance and cardiac output, leading to lower blood pressure.

Dosage: Varies widely based on the specific drug and patient condition; typically starts low and is titrated.

Indications: Hypertension, heart failure, post-myocardial infarction, certain arrhythmias.

Contraindications: Severe renal impairment (specific diuretics), pregnancy (ACE inhibitors), hypersensitivity.

Side Effects: Dizziness, orthostatic hypotension, fatigue, electrolyte imbalance (with diuretics), cough (with ACE inhibitors), swelling (with ARBs).

Preparations

1. Captopril: Initially 25 mg BD, increase upto 50 mg TDS as needed. To be taken 1 hr before or 2 hr after a meal;

ANGIOPRIL 25 mg tab, ACETEN, CAPOTRIL 12.5, 25 mg tabs.

2. Enalapril: 2.5 mg OD–20 mg BD; ENAPRIL, ENVAS, ENAM 2.5, 5, 10, 20 mg tabs.

3. Lisinopril: 5 mg OD–20 mg BD; LINVAS, LISTRIL, LIPRIL 2.5, 5, 10 mg tabs, LISORIL 2.5, 5, 10, 20 mg tabs.

4. Perindopril: 2 mg OD–4 mg BD; COVERSYL 2, 4 mg tabs.

5. Ramipril: 1.25 mg OD–5 mg BD; CARDACE, RAMIRIL, CORPRIL, RPRIL 1.25, 2.5, 5 mg caps.

6. Benazepril: 10 mg OD–20 mg BD; BENACE 5, 10, 20 mg tabs.

7. Trandolapril: 2 mg OD–4 mg BD; ZETPRIL 1, 2 mg tabs.

8. Fosinopril: 10–40 mg OD; FOSINACE, FOVAS 10, 20 mg tabs.

9. Imidapril: Start with 5 mg (elderly 2.5 mg) OD, max. 10 mg BD; TANATRIL 5, 10 mg tabs.

10. Quinapril: 10–40 mg/day; ACCUPRIL-H Quinapril 20 mg + hydrochlorothiazide 12.5 mg tab.

11. Losartan: 50 mg OD (max. 50 mg BD), liver disease and volume depleted patients 25 mg OD;

LOSAR, LOSACAR, TOZAR, ALSARTAN 25, 50 mg tabs.

12. Candesartan: 8 mg OD (max. 8 mg BD), liver/kidney disease patients 4 mg OD;

CANDESAR 4, 8, 10 mg tabs, CANDILONG, CANDESTAN 4, 8 mg tabs.

13. Irbesartan: 150–300 mg OD; IROVEL, IRBEST 150, 300 mg tabs.

14. Valsartan: 80–160 mg OD; DIOVAN 40, 80, 160 mg tabs. STARVAL, VALZAAR 80, 160 mg tabs.

15. Telmisartan: 20–80 mg OD; TELMA, TELSAR, TELVAS 20, 40 mg tabs.

16. Olmesartan medoxomil: 20–40 mg OD; OLMAT 20, 40 mg tabs.

17. Aliskiren: 150–300 mg OD; RASILEZ 150 mg tab; RASILEZ-HC alongwith hydrochlorothiazide 12.5 mg.

18. Verapamil: 40–160 mg TDS oral, 5 mg by slow i.v. inj; CALAPTIN 40, 80 mg tab, 120, 240 mg SR tab; VPL

5 mg/2 ml inj, VASOPTEN 40, 80, 120 mg tabs.

19. Diltiazem: 30–60 mg TDS–QID oral; DILZEM 30, 60 mg tabs, 90 mg SR tab; 25 mg/5 ml inj; ANGIZEM 30, 60,

90, 120, 180 mg tab, DILTIME 30, 60 mg tab; 90, 120 mg SR tab.

20. Nifedipine: 5–20 mg BD–TDS oral; CALCIGARD, DEPIN, NIFELAT 5, 10 mg cap, also 10 mg, 20 mg SR (RETARD) tab.,

ADALAT RETARD 10, 20 mg SR tab.

21. Felodipine: 5–10 mg OD (max. 10 mg BD); FELOGARD, PLENDIL, RENDIL 2.5, 5, 10 mg ER tab.

22. Amlodipine: 5–10 mg OD; AMLOPRES, AMCARD, AMLOPIN, MYODURA 2.5, 5, 10 mg tabs.

23. S(–) Amlodipine: 2.5–5 mg OD; S-NUMLO 1.25, 2.5, 5.0 mg tabs; ESAM, S-AMCARD, ASOMEX 2.5, 5.0 mg tabs.

24. Nitrendipine: 5–20 mg OD (max. 20 mg BD); CARDIF, NITREPIN 10, 20 mg tab.

25. Lacidipine: 4–6 mg OD; LACIVAS, SINOPIL 2, 4 mg tabs.

26. Benidipine: 4–8 mg OD; CARITEC 4, 8 mg tabs.

27. Lercanidipine: 10–20 mg OD; LERKA, LEREZ 10, 20 mg tabs.

28. Hydrochlorothiazide: 12.5–50 mg OD; AQUAZIDE. HYDRAZIDE, HYDRIDE 12.5, 25, 50 mg tabs.

29. Chlorthalidone: 25–100 mg OD; HYTHALTON 100 mg tab.

30. Indapamide: 2.5 mg OD; LORVAS, NATRILIX 2.5 mg tab, NATRILIX-SR, DIURIX-SR 1.5 mg tab.

31. Clonidine: Start with 100 µg OD or BD, max 300 µg TDS, orally or i.m.; CATAPRES 150 µg tab, ARKAMIN 100 µg tab.

32. Methyldopa: 0.25–0.5 g BD–QID; EMDOPA, ALPHADOPA 250 mg tab.

33. Hydralazine: 25–50 mg OD–TDS; NEPRESOL 25 mg tab.

34. Sodium nitroprusside: Initiate i.v. infusion with 0.02 mg/min, titrate with lowering of blood pressure upto

0.1–0.3 mg/min; SONIDE, PRUSIDE, NIPRESS 50 mg in 5 ml inj.

Anti-hypertensive Drugs

Anti-Anginal Drugs

Definition

Anti-anginal drugs are medications used to alleviate chest pain (angina) associated with coronary artery disease.

Classification

Nitrates
- Short-acting (e.g., Nitroglycerin)
- Long-acting (e.g., Isosorbide dinitrate)
Beta-Blockers
- (e.g., Metoprolol, Atenolol)
Calcium Channel Blockers
- Dihydropyridines (e.g., Amlodipine)
- Non-dihydropyridines (e.g., Diltiazem, Verapamil)
Ranolazine
- A newer agent that works differently from traditional anti-anginals.

Pharmacological Actions

Nitrates: Vasodilate coronary arteries, increasing blood flow to the heart and reducing preload.
Beta-Blockers: Decrease heart rate and myocardial oxygen demand.
Calcium Channel Blockers: Prevent calcium influx into cardiac and vascular smooth muscle, causing relaxation and vasodilation.

Indications

Angina pectoris (stable and unstable)
Myocardial infarction prophylaxis

Contraindications

Severe hypotension (with nitrates)
Severe bradycardia (with beta-blockers)
Heart block (with non-dihydropyridine calcium channel blockers)

Preparations

1. Glyceryl trinitrate (GTN), Nitroglycerine:

0.5 mg sublingual, 5–15 mg oral; ANGISED 0.5 mg tab, NITROLINGUAL spray, GTN spray 0.4 mg per spray;

ANGISPAN-TR 2.5, 6.5 mg SR cap, NITROCONTIN, CORODIL 2.6, 6.4 mg CR tabs; One transdermal patch for

14–16 hr per day; NITRODERM-TTS 5 or 10 mg patch; 5–20 µg/min i.v.; MYOVIN, MILLISROL, NITROJECT

5 mg/ml inj.

2. Isosorbide dinitrate:

5–10 mg sublingual; SORBITRATE 5, 10 mg tab; 10–20 mg oral; ISORDIL 5 mg sublingual & 10 mg oral tab;

20–40 mg sustained release oral; DITRATE 5, 10 mg tab; 20, 40 mg SR tab.

3. Isosorbide-5-mononitrate: 20–40 mg oral; MONOTRATE 10, 20, 40 mg tab, 50 mg SR tab, 5-MONO,

MONOSORBITRATE 10, 20, 40 mg tab.

4. Erythrityl tetranitrate: 15–60 mg oral; CARDILATE 5, 15 mg tab.

5. Pentaerythritol tetranitrate: 10–40 mg oral; PERITRATE 10 mg tab; 80 mg sustained release oral;

PERITRATE-SA 80 mg SR tab.

6. Nicorandil: 5–20 mg BD; NIKORAN, 5, 10 mg tabs, 2 mg/vial and 48 mg/multidose vial inj; KORANDIL

5, 10 mg tabs.

7. Trimetazidine: 20 mg TDS after meals; FLAVEDON, CARVIDON, TRIVEDON 20 mg tabs, 35 mg modified

release tab.

8. Ranolazine: 0.5–1.0 g BD as SR tab; RANOZEX, REVULANT, RANX, CARTINEX, RANOLAZ 500 mg SR tab.

9. Ivabradine: 5–7.5 mg BD, elderly 2.5 mg BD; IVABRAD, BRADIA 5, 7.5 mg tab.

10. Oxyphedrine: 8–24 mg TDS oral, 4–8 mg i.v. OD–BD; ILDAMEN 8, 24 mg tab., 4 mg/2 ml inj.

Anti-Arrhythmic Drugs

Definition

Anti-arrhythmic drugs are medications designed to treat and prevent abnormal heart rhythms (arrhythmias) by modifying the electrical conduction system of the heart.

Classification

Anti-arrhythmic drugs are categorized primarily into four classes based on their mechanisms of action, as per the Vaughan Williams classification:

Class I: Sodium Channel Blockers
- IA: Moderate blockade; prolongs action potential.
  - Examples: Quinidine, Procainamide, Disopyramide
- IB: Weak blockade; shortens action potential.
  - Examples: Lidocaine, Mexiletine
- IC: Strong blockade; minimal effect on action potential duration.
  - Examples: Flecainide, Propafenone
Class II: Beta-Blockers
- Decrease heart rate and myocardial contractility by blocking beta-adrenergic receptors.
- Examples: Metoprolol, Propranolol, Atenolol
Class III: Potassium Channel Blockers
- Prolong action potential duration and refractory period.
- Examples: Amiodarone, Sotalol, Dofetilide
Class IV: Calcium Channel Blockers
- Decrease heart rate and AV node conduction by blocking calcium channels.
- Examples: Diltiazem, Verapamil
Other Agents
- Adenosine: Used for acute SVT.
- Digoxin: Increases vagal tone, used for atrial fibrillation and heart failure.

Pharmacological Actions

Class I: Block sodium channels, affecting depolarization and conduction velocity.
Class II: Block beta-adrenergic receptors, decreasing heart rate and myocardial contractility.
Class III: Block potassium channels, prolonging repolarization and refractory period.
Class IV: Block calcium channels, reducing heart rate and conduction through the AV node.

Dosing

Doses vary based on the drug and patient characteristics, but here are some common starting doses:

Quinidine: 200-400 mg orally every 6-8 hours.
Lidocaine: 1-1.5 mg/kg IV bolus, then 1-4 mg/min infusion.
Amiodarone: 150 mg IV over 10 minutes, followed by 1 mg/min for 6 hours, then 0.5 mg/min.
Metoprolol: 25-100 mg orally daily, or 5 mg IV every 5 minutes up to 15 mg.
Diltiazem: 30 mg orally three times daily, or 15-20 mg IV bolus.

Indications

Atrial Fibrillation: Rate control or rhythm conversion.
Ventricular Tachycardia: Acute management and prevention.
Supraventricular Tachycardia (SVT): Termination and prevention.
Bradyarrhythmias: Often treated with digoxin in heart failure.
Prevention of arrhythmias post-myocardial infarction.

Contraindications

Class I: Heart block (especially IA and IC), significant hypotension, hypersensitivity.
Class II: Severe bradycardia, heart block, asthma (non-selective beta-blockers).
Class III: Pre-existing QT prolongation, severe renal impairment (for some).
Class IV: Severe hypotension, heart block, heart failure with reduced ejection fraction.

Side Effects

Class I: Risk of new arrhythmias, hypotension, dizziness, and CNS effects.
Class II: Bradycardia, fatigue, bronchospasm (non-selective).
Class III: QT prolongation, thyroid dysfunction (with amiodarone).
Class IV: Bradycardia, hypotension, peripheral edema.

Monitoring

ECG: Monitor for arrhythmias and QT prolongation.
Electrolytes: Regularly check potassium and magnesium levels.
Liver and Renal Function: Particularly for drugs with significant metabolism or excretion through these organs.

Preparations

1. Quinidine: 100–200 mg TDS oral: rarely 100–300 mg slow i.v. inj. QUINIDINE SULPHATE 200 mg tab;

QUININGA 300 mg tab, 600 mg/2 ml inj, NATCARDINE 100 mg tab.

2. Procainamide: for abolition of arrhythmia—0.5–1 g oral or i.m. followed by 0.25–0.5 g every 2 hours; or

500 mg i.v. loading dose (25 mg/min injection) followed by 2mg/kg/hour.

Maintenance dose—0.5 g every 4–6 hours;

PRONESTYL 250 mg tab., 1 g/10 ml inj.

3. Disopyramide: 100–150 mg 6 hourly oral; rarely 2 mg/kg by slow i.v. injection;

NORPACE, 100, 150 mg cap, REGUBEAT 100 mg tab.

4. Lidocaine (Lignocaine): 50–100 mg bolus followed by 20–40 mg every 10–20 min or 1–3 mg/min infusion;

XYLOCARD, GESICARD 20 mg/ml inj. (5, 50 ml vials). These preparations for cardiac use contain no preservative. The local anaesthetic preparations should not be used for this purpose.

5. Mexiletine: 100–250 mg i.v. over 10 min, 1 mg/min i.v. infusion. Oral: 150–200 mg TDS with meals;

MEXITIL 50, 150 mg caps, 250 mg/10 ml inj.

6. Propafenone: 150 mg BD–300 mg TDS oral; RHYTHMONORM 150 mg tab.

7. Propranolol: 1 mg/min (max 5 mg) i.v. injection under close monitoring; 40–80 mg (max 160 mg) BD to QID

oral; INDERAL, CIPLAR 10, 40, 80 mg tabs, 1 mg/ml inj, BETABLOCK 10, 40 mg tabs.

8. Sotalol: 40–80 mg BD–QID oral; SOTAGARD 40, 80 mg tabs.

9. Esmolol: 0.5 mg/kg in 1 min followed by 0.05–0.2 mg/kg/min i.v. infusion;

MINIBLOCK 100 mg/10 ml, 250 mg/10 ml inj.

10. Amiodarone: 400–600 mg/day orally for few weeks, followed by 100–200 mg OD for maintenance;

100–300 mg (5 mg/kg) slow i.v. injection over 30–60 min;

CORDARONE, ALDARONE, EURYTHMIC 100, 200 mg tabs, 150 mg/3 ml inj.

11. Verapamil: 5 mg slow i.v. injection over 2–3 min (to terminate PSVT), 60–120 mg TDS orally for maintenance

and to control ventricular rate in atrial fibrillation or flutter;

CALAPTIN 40, 80 mg tab; 120, 240 mg SR tab, 5 mg/2 ml inj.

12. Diltiazem: 25 mg by slow i.v. inj (to terminate PSVT and to rapidly control ventricular rate in atrial fibrillation

or flutter), 30–60 mg TDS orally for maintenance;

DILZEM 30, 60 mg tabs, 90 mg SR tab; 25 mg/5 ml inj.

13. Adenosine: 6–12 mg (free base) by rapid i.v. injection in a central vein;

ADENOJECT, ADENOCOR, 3 mg adenosine base per ml in 2 ml and 10 ml amp.

Drugs Used in Atherosclerosis

Definition

Drugs used in atherosclerosis are medications that help manage lipid levels and reduce the risk of cardiovascular diseases associated with plaque buildup in the arteries.

Classification

Drugs used to treat atherosclerosis can be classified into several categories based on their mechanism of action:

Statins
- (e.g., Atorvastatin, Simvastatin, Rosuvastatin)
Fibrates
- (e.g., Fenofibrate, Gemfibrozil)
Bile Acid Sequestrants
- (e.g., Cholestyramine, Colestipol)
Cholesterol Absorption Inhibitors
- (e.g., Ezetimibe)
PCSK9 Inhibitors
- (e.g., Alirocumab, Evolocumab)
Omega-3 Fatty Acid Supplements
- (e.g., Omega-3-acid ethyl esters)

Pharmacological Actions

Statins: Inhibit HMG-CoA reductase, reducing LDL cholesterol production in the liver and increasing hepatic uptake of circulating LDL.
Fibrates: Activate peroxisome proliferator-activated receptors (PPARs) to decrease triglyceride levels and increase HDL cholesterol.
Bile Acid Sequestrants: Bind bile acids in the intestine, reducing cholesterol reabsorption and increasing bile acid excretion.
Cholesterol Absorption Inhibitors: Block the absorption of dietary cholesterol in the intestine.
PCSK9 Inhibitors: Inhibit PCSK9, leading to increased LDL receptor availability and enhanced LDL clearance from the blood.
Omega-3 Fatty Acids: Reduce triglyceride levels and have anti-inflammatory effects.

Dosing

Dosing varies by drug and patient specifics, but here are common starting doses:

Atorvastatin: 10-80 mg once daily.
Simvastatin: 5-40 mg once daily in the evening.
Rosuvastatin: 5-40 mg once daily.
Fenofibrate: 48-145 mg once daily.
Ezetimibe: 10 mg once daily.
Alirocumab: 75-150 mg subcutaneously every 2 weeks.

Indications

Hyperlipidemia: Elevated LDL and/or triglycerides.
Prevention of Cardiovascular Events: In patients with a history of heart disease or stroke.
Familial Hypercholesterolemia: In cases of genetic dyslipidemia.
Combination Therapy: With statins for patients who do not reach lipid goals.

Contraindications

Statins: Active liver disease, pregnancy, and breastfeeding.
Fibrates: Severe renal or hepatic impairment, gallbladder disease.
Bile Acid Sequestrants: Complete biliary obstruction.
Cholesterol Absorption Inhibitors: Hypersensitivity reactions.
PCSK9 Inhibitors: Hypersensitivity; not studied in severe renal impairment.

Side Effects

Statins: Myopathy, rhabdomyolysis, liver enzyme elevation, gastrointestinal symptoms.
Fibrates: Gastrointestinal discomfort, myopathy, and risk of gallstones.
Bile Acid Sequestrants: Constipation, bloating, and interference with the absorption of other medications.
Cholesterol Absorption Inhibitors: Rarely causes liver enzyme elevation or gastrointestinal symptoms.
PCSK9 Inhibitors: Injection site reactions, hypersensitivity, and potential neurocognitive effects.

Monitoring

Lipid Levels: Regular checks to assess treatment efficacy.
Liver Function Tests: Especially for statins before and during therapy.
Renal Function: Particularly for fibrates and PCSK9 inhibitors.
Creatine Kinase (CK): If muscle symptoms occur while on statins or fibrates.

Preparations

1. Lovastatin: 10–40 mg/day; ROVACOR, AZTATIN, LOVAMEG 10, 20 mg tabs.

2. Simvastatin: 5–20 mg/day (max 80 mg); SIMVOTIN, SIMCARD, ZOSTA 5, 10, 20 mg tabs.

3. Pravastatin: 10–40 mg/day; PRAVATOR 10, 20 mg tabs.

4. Atorvastatin: 10–40 mg/day (max 80 mg); AZTOR, ATORVA, ATORLIP 5, 10, 20 mg tabs.

5. Rosuvastatin: 5–20 mg/day (max. 40 mg/day); ROSUVAS, ROSYN 5, 10, 20 mg tab.

6. Pitavastatin: 1–4 mg/day; FLOVAS 1.0, 2.0 mg tabs.

7. Gemfibrozil: 600 mg BD; GEMPAR, NORMOLIP, 300 mg cap., LOPID 300 mg cap, 600 mg and 900 mg tabs.

8. Bezafibrate: 200 mg TDS with meals; BEZALIP 200 mg tab, 400 mg (retard) tab.

9. Fenofibrate: 200 mg OD with meals; FENOLIP, LIPICARD 200 mg cap.

10. Nicotinic acid: Start with 100 mg TDS, gradually increase to 2–6 g per day in divided doses. It should be taken

just after food to minimize flushing and itching;

NIALIP, NEASYN-SR, 375, 500 mg tabs.

11. Ezetimibe: 10 mg OD; ZETICA, EZEDOC 10 mg tab.

Ezetimibe 10 mg + atorvastatin 10 mg: BITORVA, LIPIVAS-EZ, LIPONORM-EZ;

Ezetimibe 10 mg + simvastatin 10 mg: STARSTAT-EZ, SIMVAS-EZ.

Congestive Heart Failure (CHF)

Definition

Congestive heart failure (CHF) is a chronic condition in which the heart is unable to pump sufficiently to maintain adequate blood flow to meet the body's needs, leading to symptoms of fluid overload and reduced cardiac output.

Classification

CHF can be classified based on:

Systolic Heart Failure (HFrEF): Reduced ejection fraction (EF < 40%).
Diastolic Heart Failure (HFpEF): Preserved ejection fraction (EF ≥ 50%).

Pharmacological Actions

ACE Inhibitors: Reduce afterload and preload by inhibiting the renin-angiotensin-aldosterone system (RAAS).
ARBs: Similar to ACE inhibitors, but block the angiotensin II receptor.
Beta-Blockers: Decrease heart rate, reduce myocardial oxygen demand, and improve heart function over time.
Diuretics: Reduce fluid overload by increasing urine production.
Aldosterone Antagonists: Block aldosterone effects, reducing fluid retention and myocardial remodeling.
Inotropes: Increase myocardial contractility (used in acute settings).

Dosing

ACE Inhibitors (e.g., Lisinopril): 5-40 mg once daily.
ARBs (e.g., Losartan): 50-150 mg once daily.
Beta-Blockers (e.g., Carvedilol): 3.125-25 mg twice daily.
Diuretics (e.g., Furosemide): 20-80 mg daily, adjusted based on fluid status.
Aldosterone Antagonists (e.g., Spironolactone): 12.5-50 mg once daily.

Indications

Chronic heart failure with reduced ejection fraction (HFrEF).
Symptomatic heart failure (e.g., dyspnea, edema).
Prevention of hospitalization and cardiovascular events.

Contraindications

ACE Inhibitors: Angioedema, pregnancy, bilateral renal artery stenosis.
ARBs: Similar to ACE inhibitors.
Beta-Blockers: Severe bradycardia, heart block, asthma (non-selective).
Diuretics: Anuria, severe electrolyte imbalance.
Aldosterone Antagonists: Hyperkalemia, severe renal impairment.

Preparations

1. Digoxin: 0.25–0.5 mg/day (elderly 0.125–0.25 mg/day) oral adjusted according to response, 0.25 mg slow i.v.

injection followed by 0.1 mg 1–2 hourly as needed; DIGOXIN 0.25 mg tab, 0.05 mg/ml pediatric elixir, 0.5 mg/

2 ml inj. LANOXIN 0.25 mg tab, CARDIOXIN, DIXIN 0.25 mg tab, 0.5 mg/2 ml inj.

2. Inamrinone (Amrinone): 0.5 mg/kg i.v. bolus injection followed by 5–10 µg/kg/min i.v. infusion (max. 10

mg/kg in 24 hours). AMICOR, CARDIOTONE 5 mg/ml (as lactate) 20 ml amp.

3. Milrinone: 50 µg/kg i.v. bolus followed by 0.4–1.0 µg/kg/min infusion; PRIMACOR IV 10 mg/10 ml inj.

Drug Therapy for Shock

Definition

Shock is a life-threatening condition characterized by inadequate tissue perfusion and oxygenation, leading to organ dysfunction.

Classification

Hypovolemic Shock: Due to loss of blood volume (e.g., hemorrhage, dehydration).
Cardiogenic Shock: Due to the heart's inability to pump effectively (e.g., myocardial infarction).
Distributive Shock: Due to vasodilation (e.g., septic shock, anaphylactic shock).
Obstructive Shock: Due to physical obstruction to blood flow (e.g., pulmonary embolism).

Pharmacological Actions

Vasopressors: Increase systemic vascular resistance and blood pressure.
Inotropes: Enhance myocardial contractility and cardiac output.
Fluid Resuscitation: Restore intravascular volume and improve perfusion.

Dosing

Norepinephrine: Start at 0.05-0.5 mcg/kg/min, titrate to desired blood pressure.
Epinephrine: Start at 0.01-0.5 mcg/kg/min for cardiogenic shock; titrate as needed.
Dopamine: 2-20 mcg/kg/min (low doses for renal perfusion; higher doses for inotropic effect).
Fluid Resuscitation (Crystalloids): 1-2 liters in the first hour, then reassess.

Indications

Hypovolemic Shock: Fluid resuscitation and vasopressors if needed.
Cardiogenic Shock: Inotropes and vasopressors to support cardiac output.
Septic Shock: Vasopressors after adequate fluid resuscitation.
Anaphylactic Shock: Epinephrine for immediate response.

Contraindications

Vasopressors: Severe hypovolemia without fluid resuscitation; peripheral ischemia (in high doses).
Inotropes: Severe aortic stenosis (for some), significant hypotension without volume support.
Fluid Resuscitation: Heart failure with fluid overload.

Monitoring

Hemodynamic Monitoring: Blood pressure, heart rate, and urine output.
Electrolytes: Monitor for imbalances, especially with inotropes and vasopressors.
Lactate Levels: To assess tissue perfusion and response to treatment.

Hematinic Agents:

Definition: Hematinic agents are substances that enhance the production of red blood cells (RBCs) and increase hemoglobin levels. They are primarily used to treat or prevent anemia, particularly iron-deficiency anemia.

Classification:

Iron Preparations:
- Ferrous sulfate
- Ferrous gluconate
- Ferrous fumarate
- Iron dextran (injectable)
Vitamin B12 Preparations:
- Cyanocobalamin
- Hydroxocobalamin
Folic Acid Preparations:
- Folic acid (Vitamin B9)
Erythropoiesis-Stimulating Agents:
- Epoetin alfa
- Darbepoetin alfa

Pharmacological Actions:

Iron Preparations: Increase iron availability for hemoglobin synthesis; essential for RBC production.
Vitamin B12: Necessary for DNA synthesis and normal maturation of RBCs; prevents megaloblastic anemia.
Folic Acid: Crucial for DNA synthesis and cell division; deficiency can lead to macrocytic anemia.
Erythropoiesis-Stimulating Agents: Stimulate erythropoiesis by mimicking erythropoietin, promoting RBC production in the bone marrow.

Dosage:

Iron Preparations:
- Ferrous sulfate: 325 mg (65 mg elemental iron) 1-3 times daily.
Vitamin B12:
- Cyanocobalamin: 1000 mcg intramuscularly monthly; oral doses may vary.
Folic Acid:
- 400-1000 mcg daily, depending on the severity of the deficiency.
Erythropoiesis-Stimulating Agents:
- Epoetin alfa: Typically 50-100 units/kg 3 times weekly.

Indications:

Iron Preparations:
- Iron-deficiency anemia, pregnancy, and during periods of rapid growth or blood loss.
Vitamin B12:
- Megaloblastic anemia, pernicious anemia, and malabsorption syndromes.
Folic Acid:
- Preventing neural tube defects, treating megaloblastic anemia.
Erythropoiesis-Stimulating Agents:
- Chronic kidney disease, cancer-related anemia, and certain types of anemia.

Contraindications:

Iron Preparations:
- Hemochromatosis, hemosiderosis, or known hypersensitivity to iron products.
Vitamin B12:
- Hypersensitivity; caution in patients with Leber’s disease (hereditary optic neuropathy).
Folic Acid:
- May mask Vitamin B12 deficiency symptoms; should not be used in megaloblastic anemia without confirming B12 status.
Erythropoiesis-Stimulating Agents:
- Uncontrolled hypertension, known hypersensitivity, and certain types of cancer (e.g., when used inappropriately).

Parenteral Iron

1. Iron-dextran: 50 mg elemental iron/ml in colloidal solution; 2 ml deep i.m. injection by ‘Z’ track technique,

daily or on alternate days; 2 ml by slow i.v. injection (taking 10 min) daily;

IMFERON, FERRI INJ: 2 ml amp.

2. Iron-sorbitol-citric acid: 50 mg elemental iron/ml; 1.5 ml daily or on alternate days by deep i.m. injection

using ‘Z’ track technique;

FERIMAX: iron sorbitol-citric acid 75 mg, folic acid 0.75 mg, hydroxocobalamine 75 µg in 1.5 ml Amp.

3. Ferrous-sucrose: 100 mg slow i.v. inj. over 5 min daily or on alternate days. Not for i.m. or s.c. inj;

MICROFER, UNIFERON, ICOR 50 mg/2.5 ml and 100 mg/5 ml inj.

4. Ferric-carboxymaltose: 100 mg slow i.v. inj. daily or upto 1000 mg diluted in 100 ml saline and infused i.v.

taking 15-30 min; infusion can be repeated after 1 week.

ENCICARB INJ 50 mg/ml in 2 ml and 10 ml vials.

Maturation factors

1. Cyanocobalamin/Hydroxocobalamin: Therapeutic dose: 30–1000 µg/day by i.m. or deep s.c. injection (not

i.v.) for 10 days followed by weekly and then monthly doses; Prophylactic dose 3–10 µg/day oral; available only

as combined formulations with other vitamins and iron:

NEUROBION FORTE (1000 µg/3 ml inj; 15 µg per tab), OPTINEURON (1000 µg/3 ml inj), NEUROXIN-12 (500

µg/10 ml inj), POLYBION (15 µg per cap), BECOSULES (5 µg/cap), AUTRIN (15 µg/cap).

2. Methylcobalamin: 0.5–1.5 mg/day oral;

BIOCOBAL, DIACOBAL, METHYLCOBAL 0.5 mg tab, MECOBA, BIGVIN 500 µg/ml inj.

3. Folic acid: Therapeutic dose 2–5 mg/day oral/i.m.; pro phylactic dose 0.5 mg/day;

FOLVITE, FOLITAB 5 mg tab.

Anticoagulants

Definition
Anticoagulants are medications that inhibit blood clotting (coagulation) and are used to prevent and treat thromboembolic disorders, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke.

Classification

Vitamin K Antagonists
- Warfarin (Coumadin, Jantoven)
- Acenocoumarol
Direct Oral Anticoagulants (DOACs)
- Direct Thrombin Inhibitors
  - Dabigatran (Pradaxa)
- Factor Xa Inhibitors
  - Rivaroxaban (Xarelto)
  - Apixaban (Eliquis)
  - Edoxaban (Savaysa)
Parenteral Anticoagulants
- Unfractionated Heparin
- Low Molecular Weight Heparins (LMWHs)
  - Enoxaparin (Lovenox)
  - Dalteparin (Fragmin)
Other Anticoagulants
- Fondaparinux (Arixtra)
- Bivalirudin (Angiomax)

Pharmacological Actions

Vitamin K Antagonists: Inhibit vitamin K-dependent clotting factors (II, VII, IX, X) leading to a reduced ability to form clots.
DOACs: Directly inhibit specific factors in the coagulation cascade:
- Dabigatran inhibits thrombin.
- Factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) inhibit factor Xa, which is crucial in the clotting process.
Heparins: Enhance the activity of antithrombin III, which inhibits thrombin and factor Xa, preventing clot formation.

Dosage

Warfarin: Dosing is individualized; typically started at 2-5 mg daily, monitored via INR.
Dabigatran: Standard dose is 150 mg twice daily.
Rivaroxaban: Doses vary based on indication; typically 20 mg once daily.
Enoxaparin: Commonly 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg once daily for DVT/PE.

Indications

Prevention and treatment of thromboembolic disorders, such as:
- DVT and PE
- Atrial fibrillation (to prevent stroke)
- Myocardial infarction
- Mechanical heart valves (e.g., warfarin)
- Certain types of surgeries (e.g., orthopedic procedures)

Contraindications

Active bleeding or high risk of bleeding (e.g., recent surgery, trauma, or bleeding disorders)
Severe liver or kidney disease (specific agents may have more restrictions)
Pregnancy (specific anticoagulants are contraindicated)
Hypersensitivity to the drug

Preparations

1. Heparin (unfractionated): 5000–10,000 U (children 50–100 U/kg) i.v. bolus dose followed by 750–1000 U/hr i.v.

infusion;

Low dose (s.c.) regimen: 5000 U s.c. every 8–12 hours;

HEPARIN SOD., BEPARINE, NUPARIN 1000 and 5000 U/ml in 5 ml vials for injection.

2. Low molecular weight (LMW) heparins:

Enoxaparin: CLEXANE 20 mg (0.2 ml) and 40 mg (0.4 ml) prefilled syringes; 20–40 mg OD, s.c. (start 2 hour

before surgery).

Reviparin: CLIVARINE 13.8 mg (eq. to 1432 anti Xa IU) in 0.25 ml prefilled syringe; 0.25 ml s.c. once daily for

5–10 days.

Nadroparin: FRAXIPARINE 3075 IU (0.3 ml) and 4100 IU (0.4 ml) inj., CARDIOPARIN 4000 anti Xa IU/0.4 ml,

6000 anti Xa IU/0.6 ml, 100,000 anti Xa IU/10 ml inj.

Dalteparin: 2500 IU s.c. OD for prophylaxis; 100 U/Kg 12 hourly or 200 U/Kg 24 hourly s.c. for treatment of

deep vein thrombosis. FRAGMIN 2500, 5000 IU prefilled syringes.

Parnaparin: 0.6 ml s.c. OD for unstable angina and prophylaxis of DVT; FLUXUM 3200 IU (0.3 ml), 6400 IU

(0.6 ml) inj.

Ardeparin: 2500–5000 IU s.c. OD; INDEPARIN 2500 IU, 5000 IU prefilled syringes.

3. Fondaparinux: 5–10 mg s.c. once daily; FONDAPARINUX, ARIXTRA 5 mg/0.4 ml, 7.5 mg/0.6 ml and

10 mg/0.8 ml prefilled single dose syringe.

4. Bishydroxycoumarin (Dicumarol): 200 mg for 2 days followed by 50–100 mg/day oral;

DICOUMAROL 50 mg tab.

5. Warfarin sod. (racemic): 5–10 mg followed by 2–10 mg/day;

UNIWARFIN 1, 2, 5 mg tabs, WARF-5 5 mg tab.

Antiplatelet Agents

Definition
Antiplatelet agents are medications that inhibit platelet aggregation and prevent the formation of blood clots, primarily used in cardiovascular diseases to reduce the risk of heart attacks and strokes.

Classification

Aspirin
- Acetylsalicylic acid
ADP Receptor Inhibitors (P2Y12 Inhibitors)
- Clopidogrel (Plavix)
- Prasugrel (Effient)
- Ticagrelor (Brilinta)
Glycoprotein IIb/IIIa Inhibitors
- Abciximab (ReoPro)
- Eptifibatide (Integrilin)
- Tirofiban (Aggrastat)
Phosphodiesterase Inhibitors
- Dipyridamole (Aggrenox when combined with aspirin)
- Cilostazol (Pletal)

Pharmacological Actions

Aspirin: Irreversibly inhibits cyclooxygenase-1 (COX-1), leading to decreased formation of thromboxane A2, a potent promoter of platelet aggregation.
ADP Receptor Inhibitors: Block the P2Y12 receptor on platelets, preventing activation and aggregation.
Glycoprotein IIb/IIIa Inhibitors: Inhibit the final common pathway of platelet aggregation by blocking the glycoprotein IIb/IIIa receptor on the surface of activated platelets.
Phosphodiesterase Inhibitors: Increase intracellular cAMP levels, which inhibits platelet activation and aggregation.

Dosage

Aspirin: Commonly 81-325 mg daily for cardiovascular protection.
Clopidogrel: Typically 75 mg daily after a loading dose of 300 mg or 600 mg.
Prasugrel: 60 mg loading dose, followed by 10 mg daily (5 mg in patients <60 kg).
Ticagrelor: 180 mg loading dose, then 90 mg twice daily.
Glycoprotein IIb/IIIa Inhibitors: Administered intravenously, dosage varies based on clinical situation.
Dipyridamole: 200 mg extended-release twice daily in combination with aspirin.
Cilostazol: 100 mg twice daily for intermittent claudication.

Indications

Prevention of myocardial infarction and stroke in patients with:
- Atherosclerotic disease
- History of coronary artery disease
- Peripheral arterial disease
Management of acute coronary syndromes (ACS)
Post-stent placement to prevent thrombosis

Contraindications

Active bleeding disorders (e.g., peptic ulcer disease, hemorrhagic stroke)
Severe liver or kidney dysfunction
Allergy to any of the agents
Recent surgery or trauma that poses a high risk of bleeding

Antiplatelet Drugs

1. Aspirin: 75–150 mg OD oral; ASA 50 mg tab., COLSPRIN, DISPRIN CV–100: 100 mg soluble tab, LOPRIN 75

mg tab, ASPICOT 80 mg tab, ECOSPRIN 75, 150 mg tab.

2. Dipyridamole: 150–300 mg/day; PERSANTIN, 25, 100 mg tabs, THROMBONIL 75, 100 mg tabs; DYNASPRIN:

dipyridamole 75 mg + aspirin 60 mg e.c. tab. CARDIWELL PLUS: dipyridamole 75 mg + aspirin 40 mg tab.

3. Ticlopidine: 250 mg BD with meals; TYKLID, TICLOVAS, TICLOP, 250 mg tab;

ASTIC ticlopidine 250 mg + aspirin 100 mg tab.

4. Clopidogrel: 75 mg OD, CLODREL, CLOPILET, DEPLATT 75 mg tab;

Clopidogrel 75 mg + aspirin 75 mg: CLODREL PLUS, CLOPITAB-A, THROMBOSPRIN, SYNPLATT tab.

5. Prasugrel: 10 mg OD: elderly and those below 60 kg body weight 5 mg OD; for urgent action 60 mg single

loading dose; PRASULET, PRASUSAFE, PRASUREL 5 mg, 10 mg tabs.

6. Abciximab: (Glycoprotein IIb receptor antagonist) 0.25 mg/kg i.v. 10–60 min before PTCA, followed by

10 µg/min for 12 hr; REOPRO 2 mg/ml inj.

7. Eptifibatide: Initially 180 µg/kg/i.v. followed by 2 µg/kg/min i.v. infusion for upto 72 hours;

CLOTIDE, UNIGRILIN, COROMAX 20 mg/10 ml and 75 mg/100 ml inj.

8. Tirofiban: Initially 0.4 µg/kg/min i.v. infusion for 30 min, followed by 0.1 µg/kg/min infusion for 48–108 hours.

AGGRAMED, AGGRITOR, AGGRIBLOC 5 mg/100 ml infusion.

Thrombolytic Drugs

Definition
Thrombolytic drugs are medications that dissolve blood clots (thrombi) by breaking down fibrin, the protein that makes up the bulk of the clot. They are used in emergencies to restore blood flow in conditions such as myocardial infarction, stroke, and pulmonary embolism.

Classification

Fibrinolytic Agents
- Tissue Plasminogen Activator (tPA)
  - Alteplase (Activase)
  - Reteplase (Retavase)
  - Tenecteplase (TNKase)
- Streptokinase
- Urokinase

Pharmacological Actions

Thrombolytics convert plasminogen to plasmin, which then digests fibrin, leading to the dissolution of the thrombus. This action helps restore normal blood flow to the affected area.

Dosage

Alteplase:
- Myocardial Infarction: 15 mg bolus, followed by 0.75 mg/kg over 30 minutes (max 50 mg), then 0.5 mg/kg over 60 minutes (max 35 mg).
- Ischemic Stroke: 0.9 mg/kg (max 90 mg), given as a 10% bolus over 1 minute, followed by the remainder over 60 minutes.
Reteplase: 10 units IV bolus, followed by another 10 units 30 minutes later.
Tenecteplase: Administered as a single IV bolus based on weight (e.g., 30 mg for patients <60 kg, up to 50 mg for patients ≥90 kg).
Streptokinase: 1.5 million units IV over 30-60 minutes for myocardial infarction.
Urokinase: Dosing varies based on the condition being treated; commonly, a 4400 units/kg bolus followed by an infusion.

Indications

Acute Myocardial Infarction: To restore blood flow to the heart muscle.
Ischemic Stroke: To dissolve clots blocking cerebral arteries.
Pulmonary Embolism: To treat significant clots obstructing blood flow in the lungs.
Peripheral Arterial Thrombosis: To restore blood flow in limbs.

Contraindications

Active bleeding (e.g., gastrointestinal bleeding, intracranial hemorrhage)
Recent surgery or trauma (especially within the past 2-4 weeks)
History of hemorrhagic stroke or other bleeding disorders
Severe hypertension (uncontrolled)
Known hypersensitivity to the thrombolytic agent

Fibrinolytics

1. Streptokinase: For myocardial infarction: 7.5–15 lac IU infused i.v. over 1 hr. For deep vein thrombosis and pulmonary embolism: 2.5 lac IU loading dose over 1/2–1 hr, followed by 1 lac IU/hr for 24 hr; STREPTASE, (freeze dried

powder in vials) 2.5 lac, 7.5 lac and 15 lac IU/vial, ESKINASE, CARDIOSTREP 7.5 lac, 15 lac IU/vial.

2. Urokinase: For myocardial infarction: 2.5 lac IU i.v. over 10 min followed by 5 lac IU over next 60 min (stop in

between if full recanalization occurs) or 6000 IU/min for upto 2 hr.

For venous thrombosis and pulmonary embolism: 4400 IU/kg over 10 min i.v. followed by 4400 IU/kg/hr for 12 hr;

UROKINASE, UROPASE, 2.5 lac, 5 lac, 7.5 lac, 10 lac IU per vial inj.

3. Alteplase (recombinant tissue plasminogen activator (rt-PA): For MI: 15 mg i.v. bolus injection

followed by 50 mg over 30 min, then 35 mg over the next 1 hr. For pulmonary embolism: 100 mg i.v. infused over 2 hr; ACTILYSE 50 mg vial with 50 ml solvent water.

4. Reteplase: 10 mg i.v. over 10 min, repeat after 30 min.

5. Tenecteplase: 0.5 mg/kg single i.v. bolus injection. ELAXIM 30 mg, 50 mg per vial inj.

Antifibrinolytics

1. Epsilon amino-caproic acid (EACA): Initial priming dose is 5 g oral/i.v., followed by 1 g hourly till

bleeding stops (max. 30 g in 24 hrs).

AMICAR, HEMOCID, HAMOSTAT 0.5 g tab., 1.25 g/5 ml syr., 5 g/20 ml inj.

2. Tranexamic acid: 10–15 mg/kg 2–3 times a day or 1–1.5 g TDS oral, 0.5–1 g TDS by slow i.v. infusion.

DUBATRAN, PAUSE, TRANAREST 500 mg tab, 500 mg/5 ml inj.

Bronchodilators

Definition
Bronchodilators are medications that relax the muscles surrounding the airways, leading to widened air passages and improved airflow in conditions such as asthma and chronic obstructive pulmonary disease (COPD).

Classification

Short-Acting Beta Agonists (SABAs)
- Albuterol (Salbutamol)
- Levalbuterol
Long-Acting Beta Agonists (LABAs)
- Salmeterol
- Formoterol
Anticholinergics
- Short-Acting Anticholinergics
  - Ipratropium bromide
- Long-Acting Anticholinergics
  - Tiotropium
  - Glycopyrrolate
Methylxanthines
- Theophylline
- Aminophylline
Combination Bronchodilators
- SABA/LABA combinations (e.g., albuterol/ipratropium)
- LABA/Long-Acting Anticholinergic combinations (e.g., formoterol/glycopyrrolate)

Pharmacological Actions

Beta Agonists: Activate beta-2 adrenergic receptors in the bronchial smooth muscle, leading to relaxation and bronchodilation.
Anticholinergics: Block muscarinic receptors, preventing bronchoconstriction and promoting airway dilation.
Methylxanthines: Inhibit phosphodiesterase, increasing cAMP levels, which relaxes bronchial smooth muscle and has anti-inflammatory effects.

Dosage

Albuterol (SABA):
- Inhalation: 90-180 mcg (1-2 puffs) every 4-6 hours as needed.
Salmeterol (LABA):
- Inhalation: 50 mcg twice daily.
Ipratropium (Short-Acting Anticholinergic):
- Inhalation: 250-500 mcg every 6-8 hours.
Tiotropium (Long-Acting Anticholinergic):
- Inhalation: 18 mcg once daily.
Theophylline:
- Oral: 300-600 mg daily, dosing based on serum levels.

Indications

Asthma: For acute relief and long-term control.
COPD: For symptom management and improvement of lung function.
Bronchospasm: Associated with various pulmonary conditions.

Contraindications

Beta Agonists: Known hypersensitivity to the medication.
Anticholinergics: Narrow-angle glaucoma, urinary retention, and certain prostate conditions.
Methylxanthines: Active peptic ulcer disease, seizures, and arrhythmias; use with caution in the elderly and those with liver disease.

Preparations

1. Salbutamol (Albuterol): 2–4 mg oral, 0.25–0.5 mg i.m./s.c., 100–200 µg by inhalation; ASTHALIN 2, 4 mg

tab., 8 mg SR tab., 2 mg/5 ml syrup, 100 µg metered dose inhaler; 5 mg/ml respirator soln., 200 µg rota caps;

CROYSAL 0.5 mg/ml inj, SALOL 2.5 mg/3 ml inj; VENTORLIN 2 mg/5 ml syr, 4 mg, 8 mg CR caps., DERIHALER

100 µg metered dose inhaler.

2. Terbutaline: 5 mg oral, 0.25 mg s.c., 250 µg by inhala tion; TERBUTALINE, BRICAREX 2.5, 5 mg tab., 3 mg/

5 ml syrup, 0.5 mg/ml inj; MISTHALER 250 µg/metered dose, 10 mg/ml nebulizing soln.; BRICANYL 0.5 mg/

ml inj, 2.5 mg, 5 mg tabs, 1.5 mg/5 ml syr.

3. Bambuterol: 10–20 mg OD in the evening;

BAMBUDIL 10 mg, 20 mg tabs, 5 mg/5 ml oral soln; BETADAY 10, 20 mg tabs.

4. Salmeterol: 50–100 µg by inhalation;

SALMETER, SEROBID 25 µg per metered dose inhaler; 2 puffs BD; severe cases 4 puffs BD; also SEROBID

ROTACAPS 50 µg; 1–2 caps BD by inhalation.

SEROFLO—100/250/500 ROTACAPS: Salmeterol 50 µg + fluticasone 100 µg/250 µg/500 µg per rotacap

SEROFLO—125/250, COMBITIDE—125/250, INHALERS: Salmeterol 25 µg + fluticasone 125 µg or 250 µg per puff.

5. Formoterol: 12–24 µg by inhalation twice daily; FORATEC 12 µg rotacaps.

6. Theophylline (anhydrous): 100–300 mg TDS (15 mg/kg/day), THEOLONG 100, 200 mg SR cap., DURALYNCR 400 mg continuous release cap, UNICONTIN 400 mg, 600 mg CR tabs, THEOBID 200, 300 mg tabs.

7. Aminophylline (Theophylline-ethylenediamine; 85% theophylline): water soluble, can be injected

i.v. but not i.m. or s.c., 250–500 mg oral or slow i.v. injection; children 7.5 mg/kg i.v.; AMINOPHYLLINE 100

mg tab, 250 mg/10 ml inj.

8. Hydroxyethyl theophylline (Etophylline, 80% theophyl line): water soluble; can be injected i.v. and

i.m. (but not s.c.), 250 mg oral/i.m./i.v.; DERIPHYLLIN 100 mg tab., 300 mg SR tab., 220 mg/2 ml inj.

Expectorants

Definition
Expectorants are medications that help facilitate the clearance of mucus from the airways, improving respiratory function by thinning and loosening mucus in the lungs.

Classification

Guaifenesin
- The most common expectorant used in various formulations (tablets, syrups).
Other Agents (less commonly used)
- Potassium iodide
- Bromhexine
- Ambroxol

Pharmacological Actions

Guaifenesin: Increases the hydration of mucus in the airways, reducing its viscosity and promoting the expectoration of mucus.
Bromhexine and Ambroxol: Act on mucus secretion and improve mucociliary clearance, leading to thinner mucus.

Dosage

Guaifenesin:
- Adults: Typically 200-400 mg every 4-6 hours as needed (maximum 2400 mg/day).
- Children: Dosing varies by age and formulation; consult specific guidelines.
Bromhexine:
- Adults: 8-16 mg three times daily.
Ambroxol:
- Adults: 30 mg three times daily; can be adjusted as needed.

Indications

Respiratory Conditions:
- Common cold
- Bronchitis
- Pneumonia
- Chronic obstructive pulmonary disease (COPD)
Dry Cough: To help convert a dry cough into a productive cough.

Contraindications

Guaifenesin: Generally safe, but should be used cautiously in patients with severe renal impairment.
Bromhexine and Ambroxol: Known hypersensitivity to these agents.
Potassium iodide: Contraindicated in individuals with iodine sensitivity or hyperthyroidism.

Preparations

1. Sod./Pot. citrate/acetate: 0.3–1.0 g TDS.

2. Guaiphenesin: 100–200 mg TDS.

3. Tolu balsam: 0.3–0.6 g TDS.

4. Vasaka syrup: 2–4 ml TDS.

5. Ammonium chloride: 50–200 mg TDS.

6. Bromhexine: 8 mg TDS, child 1–5 yr 4 mg BD, 5–10 yr 4 mg TDS; BROMHEXINE 8 mg tab, 4 mg/5 ml elixer.

7. Ambroxol: 15–30 mg TDS;

AMBRIL, AMBROLITE, AMBRODIL, MUCOLITE 30 mg tab, 30 mg/5 ml liq, 7.5 mg/ml drops.

8. Carbocisteine: 250–750 mg TDS; MUCODYNE 375 mg cap, 250 mg/5 ml syr.

9. Acetylcysteine: 200 mg/ml solution by nebulization or instillation through tracheostomy tube;

MUCOMIX 200 mg/ml inj in 1, 2, 5 ml amps.

10. Codeine: 15–30 mg TDS; children 2–6 years 7.5 mg, 6–12 years 15 mg; CODINE 15 mg tab, 15 mg/5 ml linctus.

11. Ethylmorphine: 10-30 mg TDS; DIONINDON 16 mg tab.

12. Pholcodine: 10–15 mg BD–TDS.

13. Noscapine: 15–30 mg, children 2–6 years 7.5 mg, 6–12 years 15 mg;

COSCOPIN 7 mg/5 ml syrup, COSCOTABS 25 mg tab.

14. Dextromethorphan: 10–20 mg TDS, child 2–6 yr 2.5–5 mg, 6–10 yrs 5–10 mg.

15. Chlophedianol: 20–40 mg BD–TDS;

DETIGON, TUSSIGON 20 mg/5 ml linctus with Ammon. chloride 50 mg and menthol 0.25 mg.

16. Prenoxdiazine: 100–200 mg TDS. PRENOXID 100, 200 mg tab.

Antitussive Agents

Definition
Antitussive agents are medications that suppress or reduce coughing. They are used to relieve coughing that is dry and unproductive, often associated with irritation in the airways.

Classification

Opioid Antitussives
- Codeine
- Hydrocodone
Non-Opioid Antitussives
- Dextromethorphan (found in many over-the-counter products)
- Benzonatate (Tessalon)
Combination Products
- Cough syrups containing antitussives combined with expectorants, decongestants, or antihistamines.

Pharmacological Actions

Opioid Antitussives: Act on the central nervous system (CNS) to inhibit the cough reflex in the medulla oblongata. They can also provide analgesic effects.
Non-Opioid Antitussives: Dextromethorphan acts by inhibiting the cough center in the brain without the sedative effects typical of opioids. Benzonatate numbs the throat and lungs, which decreases the cough reflex.

Dosage

Codeine: Typically 10-20 mg every 4-6 hours as needed (not exceeding 120 mg/day).
Hydrocodone: 5-10 mg every 4-6 hours as needed (with similar limits).
Dextromethorphan:
- Adults: 10-20 mg every 4 hours or 30 mg every 6-8 hours (max 120 mg/day).
- Children: Dosing varies by age; consult guidelines.
Benzonatate: 100 mg three times daily as needed (max 600 mg/day).

Indications

Dry Cough: Associated with respiratory infections, allergies, or other conditions.
Chronic Cough: Related to conditions like asthma or post-nasal drip.
Cough Associated with Irritation: Such as from smoke, dust, or pollutants.

Contraindications

Opioid Antitussives:
- Respiratory depression, severe asthma, or significant respiratory disease.
- Known hypersensitivity to opioids.
Dextromethorphan:
- Concurrent use with monoamine oxidase inhibitors (MAOIs).
- Known hypersensitivity.
Benzonatate: Known hypersensitivity; caution in patients with a history of respiratory issues, as it may cause bronchospasm.

Mucolytic Agents

Definition
Mucolytic agents are medications that help dissolve or break down mucus, making it thinner and easier to expel from the respiratory tract. They are commonly used in conditions characterized by excessive or thick mucus production.

Classification

N-Acetylcysteine (NAC)
- Commonly used as a mucolytic and also as an antidote for acetaminophen overdose.
Carbocisteine
- A derivative of cysteine, specifically designed to reduce mucus viscosity.
Ambroxol
- A metabolite of bromhexine, it also has expectorant properties.
Dornase alfa
- Recombinant human DNase used primarily in cystic fibrosis to reduce mucus viscosity.

Pharmacological Actions

N-Acetylcysteine: Breaks disulfide bonds in mucus proteins, reducing viscosity and promoting easier expectoration.
Carbocisteine: Modifies the structure of mucus, making it less thick and sticky, facilitating its clearance.
Ambroxol: Increases mucus secretion and enhances mucociliary clearance.
Dornase alfa: Degrades extracellular DNA in thick mucus, particularly beneficial in cystic fibrosis patients.

Dosage

N-Acetylcysteine:
- Oral: 600 mg once or twice daily.
- Inhalation: 3-5 mL of a 10% or 20% solution, typically 1-2 times daily.
Carbocisteine:
- 750 mg three times daily, reducing to 375 mg three times daily after improvement.
Ambroxol:
- 30 mg three times daily; may vary by formulation.
Dornase alfa:
- Inhalation: 2.5 mg once daily via nebulizer for cystic fibrosis.

Indications

Chronic Respiratory Conditions:
- Chronic obstructive pulmonary disease (COPD)
- Cystic fibrosis
- Bronchiectasis
- Chronic bronchitis
Acute Respiratory Conditions:
- Pneumonia with excessive mucus production.

Contraindications

N-Acetylcysteine:
- Hypersensitivity to the drug. Caution in patients with asthma.
Carbocisteine:
- Known hypersensitivity; caution in patients with active peptic ulcer disease.
Ambroxol:
- Known hypersensitivity; caution in severe liver or kidney disease.
Dornase alfa:
- Known hypersensitivity. Not recommended for patients with acute respiratory failure.

Anti-Ulcer Drugs

Definition
Anti-ulcer drugs are medications used to prevent or treat peptic ulcers and gastroesophageal reflux disease (GERD) by reducing gastric acid secretion, promoting healing, or providing a protective barrier.

Classification

Proton Pump Inhibitors (PPIs)
- Omeprazole (Prilosec)
- Esomeprazole (Nexium)
- Lansoprazole (Prevacid)
- Pantoprazole (Protonix)
- Rabeprazole (AcipHex)
H2-Receptor Antagonists
- Ranitidine (Zantac) (Note: some formulations have been withdrawn from markets)
- Famotidine (Pepcid)
- Cimetidine (Tagamet)
- Nizatidine (Axid)
Antacids
- Aluminum hydroxide
- Magnesium hydroxide
- Calcium carbonate
- Sodium bicarbonate
Mucosal Protective Agents
- Sucralfate (Carafate)
- Bismuth subsalicylate (Pepto-Bismol)
Prostaglandin Analogues
- Misoprostol (Cytotec)

Pharmacological Actions

Proton Pump Inhibitors (PPIs): Inhibit the hydrogen-potassium ATPase enzyme system in gastric parietal cells, leading to decreased gastric acid secretion.
H2-Receptor Antagonists: Block H2 receptors on gastric parietal cells, reducing acid secretion.
Antacids: Neutralize existing gastric acid, providing symptomatic relief.
Mucosal Protective Agents: Form a protective barrier over ulcers and stimulate mucus production.
Prostaglandin Analogues: Increase mucus and bicarbonate secretion while decreasing gastric acid production, enhancing mucosal defense.

Dosage

Omeprazole:
- 20-40 mg once daily.
Esomeprazole:
- 20-40 mg once daily.
Ranitidine:
- 150 mg twice daily or 300 mg at bedtime.
Famotidine:
- 20 mg twice daily or 40 mg at bedtime.
Antacids:
- Dosage varies; typically 1-2 tablets or 15-30 mL of liquid between meals and at bedtime.
Sucralfate:
- 1 g four times daily before meals and at bedtime.
Misoprostol:
- 200 mcg four times daily, taken with food.

Indications

Peptic Ulcer Disease: For the treatment and prevention of gastric and duodenal ulcers.
Gastroesophageal Reflux Disease (GERD): To relieve symptoms and promote healing of the esophagus.
Zollinger-Ellison Syndrome: Excessive gastric acid production.
Prevention of NSAID-Induced Ulcers: Especially in high-risk patients.
Symptomatic Relief: From heartburn and indigestion.

Contraindications

PPIs: Known hypersensitivity; caution in patients with liver disease (dose adjustment may be needed).
H2-Receptor Antagonists: Caution in renal impairment; cimetidine can interact with various drugs due to its effect on cytochrome P450 enzymes.
Antacids: Renal impairment (particularly with aluminum and magnesium-containing products); caution in patients on low-sodium diets (sodium bicarbonate).
Sucralfate: Caution in patients with chronic renal failure.
Misoprostol: Contraindicated in pregnancy (can cause uterine contractions).

Preparations

1. Cimetidine: 400 mg BD or 800 mg OD at bed time, 50 mg/hour i.v. infusion;

CIMETIDINE, 200 mg, 400 mg, 800 mg tabs, 200 mg/2 ml inj.

2. Ranitidine: For ulcer healing–150 mg BD or 300 mg at bed time; For prevention of ulcer recurrence–150 mg at bed

time; For Zollinger-Ellison syndrome–300 mg TDS or QID; Parenteral dose 50 mg i.m. or slow i.v. injection every 6–8

hours or 0.1–0.25 mg/kg/hr i.v. infusion; ULTAC, ZINETAC 150 mg, 300 mg tabs; HISTAC, RANTAC, RANITIN,

ACILOC 150 mg, 300 mg tabs, 50 mg/2 ml inj.

3. Famotidine: 40 mg at bed time or 20 mg BD (for healing); 20 mg at bed time for maintenance; upto 480 mg/

day in ZE syndrome; parenteral dose 20 mg i.v. 12 hourly, or 2 mg/hr i.v. infusion.

FAMTAC, FAMONITE, TOPCID 20 mg, 40 mg tabs; FAMOCID, FACID 20, 40 mg tabs, 20 mg/2 ml inj.

4. Roxatidine: 150 mg at bed time or 75 mg BD; maintenance 75 mg at bed time.

ROTANE, ZORPEX 75 mg, 150 mg SR tabs.

5. Omeprazole: 20–60 mg/day, ZE syndrome 60–120 mg/day in two divided doses; OMIZAC, NILSEC 20 mg

cap. OMEZ, OCID, OMEZOL 10, 20 mg caps, PROTOLOC 20, 40 mg caps containing enteric coated granules.

Capsules must not be opened or chewed; to be taken in the morning before meals.

Esomeprazole (s-omeprazole): 20–40 mg OD; NEXPRO, RACIPER, IZRA 20, 40 mg tab.

6. Lansoprazole: Ulcer healing dose: 15–30 mg OD; LANZOL, LANZAP, LEVANT, LANPRO 15, 30 mg caps.

7. Pantoprazole: 40 mg OD; PANTOCID, PANTODAC 20, 40 mg enteric coated tab; PANTIUM, PANTIN

40 mg tab, 40 mg inj for i.v. use.

S(-) Pantoprazole: 20 mg OD; PANPURE, ZOSECTA 20 mg tab.

8. Rabeprazole: 20 mg OD, ZE syndrome 60 mg/day;

RABLET, RAZO, RABLOC, RABICIP, HAPPI 10, 20 mg tab, 20 mg/ml vial for inj.

Anti-Emetics

Definition
Anti-emetics are medications used to prevent or treat nausea and vomiting caused by various factors, including motion sickness, chemotherapy, surgery, or gastrointestinal disorders.

Classification

5-HT3 Receptor Antagonists
- Ondansetron (Zofran)
- Granisetron (Kytril)
- Palonosetron (Aloxi)
Dopamine Antagonists
- Metoclopramide (Reglan)
- Prochlorperazine (Compazine)
- Droperidol
Antihistamines
- Dimenhydrinate (Dramamine)
- Meclizine (Antivert)
- Diphenhydramine (Benadryl)
Anticholinergics
- Scopolamine (Transderm Scop)
Cannabinoids
- Dronabinol (Marinol)
- Nabilone (Cesamet)
Neurokinin-1 (NK1) Receptor Antagonists
- Aprepitant (Emend)

Pharmacological Actions

5-HT3 Receptor Antagonists: Block serotonin receptors in the gastrointestinal tract and central nervous system, reducing nausea and vomiting.
Dopamine Antagonists: Inhibit dopamine receptors in the brain's chemoreceptor trigger zone (CTZ), reducing the urge to vomit.
Antihistamines: Block H1 histamine receptors, which can help with motion sickness and vestibular disturbances.
Anticholinergics: Block acetylcholine at muscarinic receptors, primarily affecting the vestibular system.
Cannabinoids: Modulate the nausea response through various central nervous system mechanisms.
NK1 Receptor Antagonists: Block substance P from binding to NK1 receptors, particularly effective in preventing nausea related to chemotherapy.

Dosage

Ondansetron:
- 4-8 mg IV or orally every 8 hours as needed (higher doses for chemotherapy).
Metoclopramide:
- 10-15 mg IV or orally 30 minutes before meals and at bedtime, as needed.
Dimenhydrinate:
- 50-100 mg every 4-6 hours as needed, max 400 mg/day.
Scopolamine:
- Transdermal patch (1.5 mg) applied behind the ear, changed every 72 hours.
Aprepitant:
- 125 mg orally on day 1, followed by 80 mg on days 2 and 3 for chemotherapy-induced nausea.

Indications

Postoperative Nausea and Vomiting: Prevention and treatment.
Chemotherapy-Induced Nausea and Vomiting: Prophylaxis and treatment for acute and delayed symptoms.
Motion Sickness: Prevention and treatment.
Gastroenteritis: To alleviate nausea and vomiting.
Gastroparesis: To improve gastric motility and reduce symptoms.

Contraindications

5-HT3 Receptor Antagonists: Known hypersensitivity; caution in patients with prolonged QT interval.
Dopamine Antagonists: Use with caution in patients with Parkinson’s disease or those on other CNS depressants.
Antihistamines: Caution in patients with glaucoma, urinary retention, or prostate enlargement.
Anticholinergics: Caution in patients with angle-closure glaucoma or urinary retention.
Cannabinoids: Caution in patients with a history of substance abuse or mental health disorders.

Preparations

1. Hyoscine: 0.2–0.4 mg oral/i.m./transdermal patch.

2. Dicyclomine: 10–20 mg oral.

3. Promethazine theoclate: 25–50 mg oral; AVOMINE 25 mg tab.

4. Diphenhydramine: 25–50 mg oral.

5. Dimenhydrinate: 25–50 mg oral.

6. Meclozine: 25–50 mg oral; PREGNIDOXIN: Meclozine 25 mg + caffeine 20 mg tab; DILIGAN: Meclozine 12.5

mg + nicotinic acid 50 mg.

7. Doxylamine: 10–20 mg at bed time (for morning sickness);

DOXINATE, GRAVIDOX, VOMNEX, NOSIC 10 mg tab (with pyridoxine 10 mg)

8. Cinnarizine: 25–50 mg oral.

9. Chlorpromazine: 10–25 mg oral/i.m.

10. Prochlorperazine: 5–10 mg BD/TDS oral, 12.5–25 mg by deep i.m. inj.;

STEMETIL 5 mg tab, 12.5 mg/ml inj in 1 ml amp, VOMTIL 5 mg tab.

11. Metoclopramide: 10 mg (children 0.25–0.5 mg/kg) TDS oral or i.m. For chemotherapy induced vomiting

0.3–2.0 mg/kg i.v./i.m; PERINORM, MAXERON, REGLAN, SIGMET, 10 mg tab; 5 mg/5 ml syr; 10 mg/2 ml inj.;

50 mg/10 ml inj.

12. Domperidone: 10–40 mg (Children 0.3–0.6 mg/kg) TDS;

DOMSTAL, DOMPERON, NORMETIC 10 mg tab, 1 mg/ml susp, MOTINORM 10 mg tab, 10 mg/ml drops.

13. Mosapride: 5 mg (elderly 2.5 mg) TDS; MOZA, MOZASEF, MOPRIDE 2.5 mg, 5 mg tabs; MOZA MPS: 5 mg

+ methylpolysiloxane 125 mg tab.

14. Itopride: 50 mg TDS; ITOFLUX, ITOKINE, ITOPRID, GANATON 50 mg tab.

Laxatives and Purgatives

Definition
Laxatives and purgatives are medications used to relieve constipation and facilitate bowel movements. Laxatives generally promote softer stools and easier passage, while purgatives induce more forceful bowel evacuation.

Classification

Bulk-Forming Laxatives
- Psyllium (Metamucil)
- Methylcellulose (Citrucel)
- Wheat Dextrin (Benefiber)
Stimulant Laxatives
- Bisacodyl (Dulcolax)
- Senna (Senokot)
- Cascara sagrada
Osmotic Laxatives
- Polyethylene Glycol (PEG) (Miralax)
- Lactulose
- Sorbitol
- Magnesium hydroxide (Milk of Magnesia)
Emollient Laxatives (Stool Softeners)
- Docusate sodium (Colace)
- Docusate calcium
Saline Laxatives
- Sodium phosphate (Fleet Phospho-Soda)
Purgatives
- Castor oil
- High doses of osmotic laxatives

Pharmacological Actions

Bulk-Forming Laxatives: Absorb water and swell in the intestines, increasing stool bulk and stimulating peristalsis.
Stimulant Laxatives: Directly stimulate the intestinal mucosa or the nerve plexus in the intestinal wall, promoting increased peristalsis.
Osmotic Laxatives: Draw water into the bowel lumen through osmosis, increasing stool water content and facilitating evacuation.
Emollient Laxatives: Moisten the stool by increasing water penetration, making it easier to pass.
Saline Laxatives: Increase osmotic pressure in the intestines, drawing water in and stimulating bowel activity.

Dosage

Psyllium: 1 tablespoon mixed with water, 1-3 times daily.
Bisacodyl: 5-15 mg orally or 10 mg rectally as needed.
Lactulose: 15-30 mL orally once or twice daily.
Polyethylene Glycol (PEG): 17 g mixed in 4-8 oz of liquid once daily.
Docusate sodium: 50-500 mg per day, divided into 1-4 doses.
Sodium phosphate: Follow package instructions for bowel cleansing, usually 1-2 doses.

Indications

Constipation: Chronic or occasional constipation relief.
Preparation for Medical Procedures: Such as colonoscopy or surgery.
Fecal Impaction: To relieve severe constipation.
Postoperative Recovery: To prevent straining after surgery.
Hemorrhoids: To ease bowel movements and reduce discomfort.

Contraindications

Bulk-Forming Laxatives: Intestinal obstruction or fecal impaction.
Stimulant Laxatives: Known gastrointestinal obstruction, acute abdomen, or severe dehydration.
Osmotic Laxatives: Severe renal impairment, heart failure, or electrolyte imbalance.
Emollient Laxatives: Known hypersensitivity.
Saline Laxatives: Patients with bowel obstruction, kidney disease, or heart failure.

Preparations

1. Psyllium hydrophilic mucilloid: 6–12 g to be taken just after mixing with water; ISOVAC 65 g/100 g granules.

2. Ispaghula (refined husk): 3–12 g freshly mixed with water or milk 2–3 times a day;

ISOGEL (27 g/30 g), NATURE CURE (49 g/100 g), FYBOGEL (3.5 g/5.4 g) powder FIBRIL (3.4 g/11 g) powder.

3. Methyl cellulose: 4–6 g/day mixed with water.

4. Docusates (Dioctyl sodium sulfosuccinate, DOSS): 100–400 mg/day;

CELLUBRIL 100 mg cap; LAXICON 100 mg tab, DOSLAX 150 mg cap. As enema 50–150 mg in 50–100 ml; LAXICON

125 mg in 50 ml enema.

5. Liquid paraffin: 15–30 ml/day as such or in emulsified form.

6. Phenolphthalein: 60–130 mg; LAXIL 130 mg tab. To be taken at bedtime (tab. not to be chewed).

7. Bisacodyl: 5–15 mg; DULCOLAX 5 mg tab; 10 mg (adult) 5 mg (child) suppository;

CONLAX 5 mg, 10 mg suppository, BIDLAX-5 5 mg tab.

8. Sodium picosulfate: 5-10 mg at bed time; CREMALAX, LAXICARE 10 mg tab, PICOFIT 5 mg/5 ml syr.

9. Senna (as Sennosides Cal. salt): 10–40 mg at bed time:

GLAXENNA 11.5 mg tab; PURSENNID 18 mg tab; SOFSENA 12 mg tab.

10. Mag. sulfate (Epsom salt): 5–15 g dissolved in 150–200 ml water, taken in the morning.

11. Mag. hydroxide (as 8% W/W suspension—milk of magnesia) 30 ml.

12. Sod. sulfate (Glauber’s salt): 10–15 g dissolved in 150–200 ml water, taken in the morning.

13. Sod. phosphate: 6–12 g dissolved in 150–200 ml water, taken in the morning.

14. Sod. pot. tartrate (Rochelle salt): 8–15 g dissolved in 150–200 ml water, taken in the morning.

Anti-Diarrheal Drugs

Definition
Anti-diarrheal drugs are medications used to alleviate diarrhea by reducing stool frequency and improving consistency. They can act by slowing intestinal motility, absorbing excess fluid, or altering gut flora.

Classification

Opioid Derivatives
- Loperamide (Imodium)
- Diphenoxylate/Atropine (Lomotil)
Absorbents
- Kaolin and Pectin (Kaopectate)
- Bismuth subsalicylate (Pepto-Bismol)
Probiotics
- Lactobacillus and other beneficial bacteria
Antisecretory Agents
- Octreotide (Sandostatin)

Pharmacological Actions

Opioid Derivatives: Bind to opioid receptors in the gut, decreasing peristalsis and prolonging transit time, which leads to more water absorption from the stool.
Absorbents: Bind to and absorb toxins and pathogens in the gastrointestinal tract, reducing stool fluidity.
Probiotics: Help restore the balance of normal intestinal flora, which can be disrupted during episodes of diarrhea.
Antisecretory Agents: Inhibit intestinal secretions and increase fluid absorption.

Dosage

Loperamide:
- 4 mg initially, followed by 2 mg after each loose stool (max 8 mg/day for OTC use; 16 mg/day for prescription).
Diphenoxylate/Atropine:
- 2.5 mg/0.025 mg three to four times daily (max 20 mg/day).
Bismuth subsalicylate:
- 524 mg every 30-60 minutes as needed (max 8 doses/24 hours).
Probiotics: Dosing varies by specific product; generally, 1-10 billion CFU per day.
Octreotide: Dosing is individualized based on the condition being treated; typically started at 50-100 mcg subcutaneously.

Indications

Acute Diarrhea: Including viral gastroenteritis.
Chronic Diarrhea: Associated with conditions such as irritable bowel syndrome (IBS).
Traveler’s Diarrhea: To reduce symptoms.
Diarrhea Due to Antibiotics: To help restore normal gut flora.

Contraindications

Loperamide: Known hypersensitivity, acute diarrhea caused by bacterial infections (e.g., C. difficile), or bloody diarrhea.
Diphenoxylate/Atropine: Known hypersensitivity, diarrhea caused by bacterial infections, or pseudomembranous colitis.
Bismuth subsalicylate: Known allergy to salicylates, active gastrointestinal bleeding, or use in children with viral infections (risk of Reye’s syndrome).
Probiotics: Caution in immunocompromised patients.
Octreotide: Known hypersensitivity; caution in patients with liver disease.

Preparations

1. Rifaximin: For traveller's diarrhoea 200 mg TDS for 3 days. For suppressing ammonia forming gut bacteria 550

mg TDS. RIFAGUT 200 mg, 550 mg tabs; TORFIX, RACFAX 200 mg tab.

2. Probiotics:

• ECONORM, STIBS: Saccharomyces boulardii 250 mg sachet.

• BIFILAC: Lactobacillus 50 million (M), Streptococcus faecalis 30M, Clostridium butyricum 2M, Bacillus mesentericus

1M per cap/sachet.

• BIFILIN: Lactobacillus sp. 1 billion (B), Bifidobacterium bifidum 1B, Streptococcus thermophillus 0.25B, Saccharomyces

boulardii 0.25B cap and sachet.

• ACTIGUT: Lactobacillus sp., Bifidobacterium sp. cap.

• ENTEROGERMINA: Bacillus claussi 2B spores/5 ml oral amp.

3. Sulfasalazine (Salicylazosulfapyridine): For inflammatory bowel disease—Remission inducing dose

3–4 g/day, maintenance dose 1.5–2 g/day oral; SALAZOPYRIN, SAZO-EN 0.5 g tab.

4. Mesalazine (Mesalamine): 1.2–2.4 g/day oral; 4 g by retention enema; MESACOL 0.4 g and 0.8 g tab, 0.5 g

suppository; ASACOL, TIDOCOL 0.4 g tab, ETISA 0.5 g sachet; MESACOL ENEMA 4 g/60 ml.

5. Balsalazide: 1.5 g BD-2.25 g TDS; COLOREX 750 mg cap and per 5 ml syr., INTAZIDE 0.75 g tab.

6. Racecadotril: 100 mg (children 1.5 mg/kg) TDS for a maximum of 7 days; CADOTRIL, RACIGYL 100 mg cap, 15 mg

sachet, REDOTIL 100 mg cap, ZEDOTT, ZOMATRIL 100 mg cap, 10 mg and 30 mg sachets and dispersible tabs.

7. Codeine: 60 mg TDS oral.

8. Diphenoxylate-atropine: LOMOTIL 2.5 mg diphenoxylate + 0.025 mg atropine per tab and 5 ml liquid; 2–4

tab followed by 1–2 tab 6 hourly.

9. Loperamide: 4 mg followed by 2 mg after each motion (max. 10 mg in a day); 2 mg BD for chronic diarrhoea.

IMODIUM, LOPESTAL, DIARLOP: 2 mg tab, cap.

Diuretics

Definition
Diuretics are medications that promote the excretion of water and electrolytes through the urine, primarily by inhibiting sodium reabsorption in the kidneys. They are used to manage conditions such as hypertension, heart failure, and edema.

Classification

Loop Diuretics
- Furosemide (Lasix)
- Bumetanide (Bumex)
- Torsemide (Demadex)
Thiazide Diuretics
- Hydrochlorothiazide (HCTZ)
- Chlorthalidone
- Indapamide
Potassium-Sparing Diuretics
- Spironolactone (Aldactone)
- Eplerenone (Inspra)
- Amiloride
- Triamterene
Osmotic Diuretics
- Mannitol

Pharmacological Actions

Loop Diuretics: Inhibit the Na-K-2Cl cotransporter in the ascending loop of Henle, leading to increased sodium, chloride, and water excretion.
Thiazide Diuretics: Inhibit sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, along with potassium and magnesium.
Potassium-Sparing Diuretics: Inhibit aldosterone in the collecting ducts, leading to increased sodium excretion while conserving potassium.
Osmotic Diuretics: Increase osmolarity in the renal tubules, drawing water into the urine and increasing urine output.

Dosage

Furosemide:
- 20-80 mg orally once or twice daily; may be increased based on response.
Hydrochlorothiazide:
- 12.5-50 mg once daily, depending on indication.
Spironolactone:
- 25-100 mg orally daily, depending on condition.
Mannitol:
- 0.25-2 g/kg intravenously, dosed based on the clinical situation.

Indications

Hypertension: To lower blood pressure.
Heart Failure: To reduce fluid overload and manage symptoms.
Edema: Associated with heart failure, liver cirrhosis, or nephrotic syndrome.
Chronic Kidney Disease: To manage fluid retention.
Acute Kidney Injury: In specific cases to promote urine output.
Cerebral Edema: Mannitol is used to reduce intracranial pressure.

Contraindications

Loop Diuretics: Known hypersensitivity; caution in patients with severe electrolyte imbalances or anuria.
Thiazide Diuretics: Known hypersensitivity; anuria; caution in patients with severe renal impairment.
Potassium-Sparing Diuretics: Hyperkalemia, severe renal impairment, or known hypersensitivity to the drug.
Osmotic Diuretics: Severe renal disease, pulmonary edema, or dehydration.

Preparations

Diuretics

1. Furosemide (Frusemide): Usually 20–80 mg once daily in the morning. In renal insufficiency, upto 200 mg

6 hourly given by i.m./i.v. route. In pulmonary edema 40–80 mg i.v.;

LASIX 40 mg tab., 20 mg/2 ml inj. LASIX HIGH DOSE 500 mg tab, 250 mg/25 ml inj; (solution degrades spontaneously on exposure to light), SALINEX 40 mg tab, FRUSENEX 40, 100 mg tab.

2. Bumetanide: 1–5 mg oral once daily in the morning, 2–4 mg i.v./i.m. (max 15 mg/day in renal failure);

BUMET 1 mg tab, 0.25 mg/ml inj.

3. Torasemide: 2.5–20 mg once daily in the morning;

DIURETOR 10, 20 mg tabs, DYTOR, TIDE 5, 10, 20, 100 mg tabs.

4. Hydrochlorothiazide: 12.5–100 mg OD in the morning; AQUAZIDE, THIAZIDE, HYDRIDE 12.5, 25, 50 mg

tabs, ESIDREX 50 mg tab.

5. Chlorthalidone: 50–100 mg OD in the morning;

HYTHALTON 50, 100 mg tab, HYDRAZIDE, THALIZIDE 12.5, 25 mg tabs.

6. Metolazone: 5–20 mg OD in the morning; XAROXOLYN 5, 10 mg tab, DIUREM, METORAL 2.5, 5, 10 mg tabs.

7. Xipamide: 20–40 mg OD in the morning; XIPAMID 20 mg tab.

8. Indapamide: 2.5–5 mg OD in the morning; LORVAS 2.5 mg tab.

9. Clopamide: 10–60 mg OD in the morning; BRINALDIX 20 mg tab.

10. Acetazolamide: 250 mg OD–BD; DIAMOX, SYNOMAX 250 mg tab. IOPAR-SR 250 mg SR cap.

11. Spironolactone: 25–50 mg BD–QID; ALDACTONE 25, 50, 100 mg tabs; ALDACTIDE: Spironolactone 25 mg

+ hydro flumethiazide 25 mg tab; LACILACTONE, SPIROMIDE, Spironolactone 50 mg + furosemide 20 mg tab.

TORLACTONE spironolactone 50 mg + torasemide 10 mg tab.

Anti-Diuretics

Definition
Anti-diuretics are medications that reduce urine production by promoting water reabsorption in the kidneys. They are primarily used to treat conditions associated with excessive urination, such as diabetes insipidus and some types of nocturnal enuresis.

Classification

Vasopressin Analogues
- Desmopressin (DDAVP)
- Vasopressin (Pitressin)
Other Agents
- Chlorpropamide: A sulfonylurea that can enhance the effects of vasopressin.
- Carbamazepine: An anticonvulsant that can also have anti-diuretic effects.

Pharmacological Actions

Vasopressin Analogues: Mimic the action of the antidiuretic hormone (ADH) vasopressin, leading to increased water reabsorption in the collecting ducts of the kidneys. This results in decreased urine volume and increased urine concentration.

Dosage

Desmopressin:
- Intranasal: 10-40 mcg once daily for diabetes insipidus.
- Oral: 0.1-0.4 mg once daily, with adjustments as needed.
Vasopressin:
- Injection: 1-2 units subcutaneously or intramuscularly every 3-4 hours as needed (specific dosing varies based on the indication).
Chlorpropamide:
- 100-250 mg orally once daily, typically used in conjunction with vasopressin.
Carbamazepine:
- 200-600 mg daily, divided into two or three doses, as an adjunct in diabetes insipidus.

Indications

Diabetes Insipidus: Central diabetes insipidus due to insufficient ADH production.
Nocturnal Enuresis: Particularly in children who wet the bed at night.
Hemophilia A and von Willebrand's Disease: Desmopressin can increase levels of factor VIII and von Willebrand factor.
Preoperative Management: To control urine output in specific surgical procedures.

Contraindications

Desmopressin and Vasopressin: Known hypersensitivity; caution in patients with severe renal impairment, heart failure, or hyponatremia (risk of water retention).
Chlorpropamide: Known hypersensitivity; caution in patients with renal or hepatic impairment.
Carbamazepine: Known hypersensitivity, and caution in patients with a history of bone marrow suppression or certain enzyme deficiencies.

Thyroid Hormones

Physiological Role
Thyroid hormones, primarily thyroxine (T4) and triiodothyronine (T3), are crucial for regulating metabolism, growth, and development. They influence various bodily functions, including:

Metabolism: Increase the basal metabolic rate, enhancing energy production and consumption.
Growth and Development: Essential for normal growth, particularly in children, and crucial for brain development.
Cardiovascular Function: Increase heart rate and cardiac output.
Thermoregulation: Help maintain body temperature by increasing heat production.
Protein, Carbohydrate, and Lipid Metabolism: Influence the metabolism of macronutrients.

Pathological Role
Dysfunction of the thyroid can lead to various conditions:

Hypothyroidism: Insufficient production of thyroid hormones can cause fatigue, weight gain, cold intolerance, depression, and goiter.
Hyperthyroidism: Excessive hormone production can lead to weight loss, heat intolerance, anxiety, tremors, and goiter.
Thyroiditis: Inflammation of the thyroid, which can be autoimmune (e.g., Hashimoto's disease) or infectious.
Thyroid Cancer: Abnormal growth of thyroid cells can lead to malignant tumors.

Clinical Uses of Thyroid Hormones

Hypothyroidism:
- Levothyroxine (T4): The standard treatment for primary and secondary hypothyroidism. Dosing is individualized based on TSH levels and clinical response.
- Liothyronine (T3): Used in cases where rapid onset of action is needed or in patients who do not convert T4 to T3 effectively.
Goiter:
- Thyroid hormones can help shrink a goiter caused by hypothyroidism.
Thyroid Cancer:
- After thyroidectomy, patients often receive levothyroxine to suppress TSH levels, which can stimulate cancer growth.
Myxedema Coma:
- A severe form of hypothyroidism requiring emergency treatment with intravenous T3 or T4.
Weight Loss and Metabolic Disorders:
- Thyroid hormones may be used off-label for weight management in some cases, though this is generally discouraged due to potential adverse effects.

Contraindications and Precautions

Hypersensitivity: Known allergy to thyroid hormones.
Thyrotoxicosis: Use in hyperthyroid patients without appropriate treatment can exacerbate their condition.
Adrenal Insufficiency: Cortisol levels should be assessed and treated before initiating thyroid hormone therapy in suspected cases.
Cardiovascular Disease: Caution in patients with heart disease or arrhythmias, as thyroid hormones can increase heart rate and workload.

Anti-Thyroid Drugs

Definition
Anti-thyroid drugs are medications used to reduce the production of thyroid hormones in conditions such as hyperthyroidism (excessive thyroid hormone production) and thyroid storm. They work by inhibiting the synthesis of thyroid hormones and can help manage symptoms and prevent complications.

Classification

Thioamides
- Methimazole (Tapazole)
- Propylthiouracil (PTU)
Iodine Solutions
- Potassium Iodide (Lugol's solution, SSKI)
- Radioactive Iodine (I-131)
Beta-Blockers (Adjunct therapy)
- Propranolol
- Atenolol

Pharmacological Actions

Thioamides:
- Methimazole: Inhibits the enzyme thyroid peroxidase, which is involved in the synthesis of thyroid hormones (T3 and T4) from iodide and tyrosine.
- Propylthiouracil (PTU): Also inhibits thyroid peroxidase but additionally inhibits the conversion of T4 to T3 in peripheral tissues.
Iodine Solutions:
- High doses of iodine temporarily inhibit thyroid hormone release and decrease the vascularity of the thyroid gland.
Beta-Blockers:
- While not directly anti-thyroid, they help manage symptoms of hyperthyroidism (e.g., tachycardia, anxiety) by blocking adrenergic receptors.

Dosage

Methimazole:
- Initial dose: 15-60 mg daily, adjusted based on thyroid function tests.
Propylthiouracil (PTU):
- Initial dose: 300 mg daily, divided into 3 doses; may be adjusted based on response.
Potassium Iodide:
- 1-2 drops of Lugol's solution or 30-60 mg of SSKI, usually administered three times daily for short-term use.
Radioactive Iodine (I-131):
- Dosing is individualized based on thyroid uptake and size of the gland; typically given as a single oral dose.
Propranolol:
- 40-80 mg orally, 2-4 times daily; dosage adjusted based on heart rate and symptom control.

Indications

Hyperthyroidism:
- Management of Graves' disease and toxic nodular goiter.
Preoperative Preparation:
- To achieve euthyroid state before thyroid surgery.
Thyroid Storm:
- Acute, severe exacerbation of hyperthyroidism requiring urgent management.
Adjunctive Therapy:
- Used alongside other treatments (like radioactive iodine) to control symptoms.

Contraindications

Thioamides:
- Known hypersensitivity; caution in patients with liver disease (particularly PTU) and in pregnancy (methimazole is preferred over PTU due to the risk of liver toxicity with PTU).
Iodine Solutions:
- Avoid in patients with iodine allergy or in conditions where thyroid hormone synthesis is already impaired (e.g., thyroiditis).
Beta-Blockers:
- Caution in patients with asthma, severe bradycardia, or heart block.

Preparations

L-Thyroxine sod: Adult hypothyroidism—start with 50 µg/day, increase every 2–3 weeks by 25–50 µg to the optimum dose of

100–200 µg/day adjusted by the clinical response and serum TSH level. Cretinism—6–8 µg/kg/day;

ELTROXIN, 25, 50, 100 μg tabs, ROXIN 100 μg tab, THYRONORM, 12.5, 25, 50, 62.5, 75, 88, 100, 112, 125, 137, 150 μg

tabs, THYROX 25, 50, 75, 100 μg tabs.

1. Propylthiouracil: 50–150 mg TDS followed by 25–50 mg BD–TDS for maintenance. PTU 50 mg tab.

2. Methimazole: 5–10 mg TDS initially, maintenance dose 5–15 mg daily in 1–2 divided doses.

3. Carbimazole: 5–15 mg TDS initially, maintenance dose 2.5–10 mg daily in 1–2 divided doses;

NEO MERCAZOLE, THYROZOLE, ANTITHYROX 5 mg tab.

4. Lugol’s solution (5% iodine in 10% Pot. iodide solution):

LUGOL’S SOLUTION, COLLOID IODINE 10%: 5–10 drops/day. COLLOSOL 8 mg iodine/5 ml liq.

5. Iodide (Sod./Pot.): 5–10 mg/day prophylactic for endemic goiter; 100–300 mg/day before partial

thyroidectomy in Graves' disease.

Parathormone (Parathyroid Hormone)

Definition
Parathormone, commonly known as parathyroid hormone (PTH), is a peptide hormone produced by the parathyroid glands. It plays a crucial role in regulating calcium and phosphate levels in the blood and bone metabolism.

Physiological Role

Calcium Regulation:
- PTH increases serum calcium levels by promoting the release of calcium from bones, enhancing renal reabsorption of calcium, and stimulating the activation of vitamin D in the kidneys.
Phosphate Regulation:
- PTH decreases phosphate reabsorption in the kidneys, leading to increased phosphate excretion in urine.
Bone Remodeling:
- PTH stimulates osteoclast activity, which increases bone resorption and releases calcium into the bloodstream.

Pathological Role

Hyperparathyroidism:
- Overproduction of PTH can lead to hypercalcemia (elevated calcium levels), resulting in symptoms like kidney stones, osteoporosis, and gastrointestinal disturbances.
Hypoparathyroidism:
- Insufficient PTH production leads to hypocalcemia (low calcium levels), causing symptoms such as muscle cramps, spasms (tetany), and neurological symptoms.

Clinical Uses of Parathormone

Hypoparathyroidism:
- Recombinant PTH (teriparatide) is used in the treatment of hypoparathyroidism to help increase calcium levels and improve bone density.
Osteoporosis:
- Teriparatide is used to treat osteoporosis in postmenopausal women and men at high risk of fractures. It stimulates bone formation and increases bone density.
Diagnostic Use:
- PTH levels can be measured to help diagnose conditions related to calcium metabolism disorders.

Dosage

Teriparatide:
- Typically administered as a daily subcutaneous injection. The standard dosage is 20 mcg per day for up to 2 years.

Contraindications

Hyperparathyroidism:
- Caution is advised in patients with primary hyperparathyroidism due to the risk of exacerbating hypercalcemia.
Bone Metastasis:
- Teriparatide is contraindicated in patients with a history of bone cancer or skeletal metastases.
Paget’s Disease:
- Not recommended for patients with active Paget's disease of bone.

Calcitonin

Definition
Calcitonin is a peptide hormone produced by the parafollicular cells (C cells) of the thyroid gland. It plays a crucial role in regulating calcium and phosphate metabolism in the body, primarily by lowering serum calcium levels.

Physiological Role

Calcium Regulation:
- Calcitonin lowers blood calcium levels by inhibiting osteoclast activity in the bones, which reduces bone resorption and the release of calcium into the bloodstream.
Kidney Function:
- It promotes the excretion of calcium and phosphate by the kidneys, further contributing to lower serum calcium levels.
Bone Health:
- By inhibiting bone resorption, calcitonin helps maintain bone density and strength.

Pathological Role

Hypercalcemia:
- Elevated levels of calcium in the blood may prompt increased calcitonin production to help restore balance. However, its effectiveness can be limited in severe cases.
Osteoporosis:
- In conditions like osteoporosis, calcitonin's ability to inhibit bone resorption may be beneficial, although it is generally less potent than other treatments.

Clinical Uses of Calcitonin

Osteoporosis:
- Calcitonin (often as a nasal spray or injection) is used to treat osteoporosis in postmenopausal women, helping to reduce the risk of fractures.
Hypercalcemia:
- It can be used to manage acute hypercalcemia, especially in cancer patients where elevated calcium levels are a concern.
Paget's Disease:
- Calcitonin may be used to help manage symptoms and reduce bone pain associated with Paget's disease.
Bone Pain:
- It has been used to alleviate pain associated with bone metastases.

Dosage

Calcitonin (Nasal Spray):
- Typically, one spray (200 IU) in one nostril daily, though this can vary based on individual needs.
Calcitonin Injection:
- Dosing can range from 50 to 100 IU, administered subcutaneously or intramuscularly.

Contraindications

Hypersensitivity:
- Known allergy to calcitonin or any of its components.
Caution in Kidney Dysfunction:
- Use with caution in patients with renal impairment, as calcitonin is cleared by the kidneys.
Pregnancy and Lactation:
- Its use during pregnancy and breastfeeding should be approached with caution, and it’s generally recommended to consult a healthcare provider.

Vitamin D

Definition
Vitamin D is a fat-soluble vitamin that plays a crucial role in calcium and phosphorus metabolism, bone health, and immune function. It exists in several forms, with the most important being vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol).

Physiological Role

Calcium and Phosphate Regulation:
- Vitamin D enhances the intestinal absorption of calcium and phosphate, helping to maintain appropriate serum levels and supporting bone mineralization.
Bone Health:
- It is essential for the growth and remodeling of bone tissue. Adequate vitamin D levels help prevent conditions like rickets in children and osteomalacia in adults.
Immune Function:
- Vitamin D modulates immune responses and has been linked to reduced risk of certain autoimmune diseases and infections.
Cell Growth and Differentiation:
- It plays a role in regulating cell proliferation and apoptosis, influencing various physiological processes.

Sources of Vitamin D

Sunlight:
- The body synthesizes vitamin D3 when the skin is exposed to UVB rays from sunlight.
Dietary Sources:
- Fatty fish (e.g., salmon, mackerel), fortified dairy products, egg yolks, and mushrooms.
Supplements:
- Vitamin D can be obtained through supplements in the forms of D2 or D3.

Pathological Role

Vitamin D Deficiency:
- Leads to conditions such as rickets in children and osteomalacia or osteoporosis in adults. Symptoms may include bone pain, muscle weakness, and increased risk of fractures.
Hypervitaminosis D:
- Excessive vitamin D can lead to hypercalcemia (elevated calcium levels), causing nausea, vomiting, weakness, and serious complications like kidney damage.

Clinical Uses

Vitamin D Deficiency:
- Supplements are prescribed to correct deficiency and prevent associated disorders.
Osteoporosis:
- Vitamin D is often included in the treatment regimen to improve bone health and reduce fracture risk.
Hypoparathyroidism:
- Used to help maintain serum calcium levels in patients with low parathyroid hormone levels.
Autoimmune Diseases:
- Research suggests a potential role in managing conditions like multiple sclerosis and rheumatoid arthritis, although more studies are needed.

Dosage

General Guidelines:
- Recommended dietary allowance (RDA) varies by age, sex, and life stage. For adults, it's typically around 600-800 IU/day.
Therapeutic Use:
- Doses for treating deficiency can range from 1,000 to 4,000 IU/day or higher, depending on severity and clinical guidelines.

Contraindications

Hypercalcemia:
- Caution in individuals with elevated serum calcium levels.
Certain Medical Conditions:
- Conditions such as granulomatous diseases (e.g., sarcoidosis) may lead to increased sensitivity to vitamin D.

Insulin

Definition
Insulin is a peptide hormone produced by the beta cells of the pancreas. It plays a critical role in glucose metabolism and regulation of blood sugar levels. Insulin facilitates the uptake of glucose by tissues, particularly muscle and fat, and helps maintain normal blood glucose levels.

Physiological Role

Glucose Metabolism:
- Insulin promotes the uptake of glucose into cells, decreasing blood glucose levels. It stimulates the conversion of glucose into glycogen for storage in the liver and muscles.
Lipid Metabolism:
- It facilitates the storage of fats in adipose tissue and inhibits the breakdown of fat for energy.
Protein Metabolism:
- Insulin promotes amino acid uptake by cells, enhancing protein synthesis and inhibiting protein breakdown.
Regulation of Blood Sugar:
- Insulin works in conjunction with glucagon (another hormone produced by the pancreas) to maintain homeostasis of blood sugar levels.

Pathological Role

Diabetes Mellitus:
- Insufficient insulin production (Type 1 diabetes) or insulin resistance (Type 2 diabetes) leads to elevated blood glucose levels, resulting in various complications such as neuropathy, nephropathy, retinopathy, and cardiovascular disease.
Hypoglycemia:
- Excessive insulin administration can cause dangerously low blood glucose levels, leading to symptoms like dizziness, confusion, sweating, and in severe cases, loss of consciousness.

Clinical Uses

Diabetes Management:
- Insulin therapy is essential for managing Type 1 diabetes and is often used in Type 2 diabetes when other medications are insufficient.
Hyperglycemia in Hospitalized Patients:
- Insulin is used to control blood sugar levels in critically ill patients.
Gestational Diabetes:
- Insulin may be prescribed during pregnancy if blood glucose levels cannot be controlled with diet alone.
Insulinomas:
- Insulin can be used therapeutically in cases of insulinomas (insulin-secreting tumors) to manage symptoms.

Types of Insulin

Rapid-acting Insulin:
- Examples: Insulin lispro, insulin aspart, insulin glulisine.
- Onset: 15 minutes; Peak: 1-2 hours; Duration: 3-4 hours.
Short-acting Insulin:
- Example: Regular insulin.
- Onset: 30 minutes; Peak: 2-3 hours; Duration: 3-6 hours.
Intermediate-acting Insulin:
- Example: NPH insulin.
- Onset: 1-2 hours; Peak: 4-12 hours; Duration: 12-18 hours.
Long-acting Insulin:
- Examples: Insulin glargine, insulin detemir.
- Onset: 1-2 hours; Peak: Minimal or no peak; Duration: Up to 24 hours or longer.
Ultra-long-acting Insulin:
- Example: Insulin degludec.
- Onset: 1 hour; Peak: Minimal; Duration: Over 24 hours.

Dosage

Individualized Dosing:
- Insulin dosage varies widely based on individual needs, including body weight, diet, activity level, and specific blood glucose targets. Regular monitoring of blood glucose levels is essential for dose adjustments.

Contraindications

Hypoglycemia:
- Insulin should not be administered to individuals with known hypoglycemia or without adequate food intake.
Hypersensitivity:
- Caution in patients with known hypersensitivity to insulin or its components.

Oral Hypoglycemic Agents

Definition
Oral hypoglycemic agents are medications used to lower blood glucose levels in individuals with type 2 diabetes mellitus. They are typically prescribed when lifestyle changes (diet and exercise) alone are insufficient to manage blood sugar levels.

Classification

Biguanides
- Example: Metformin
- Mechanism: Decreases hepatic glucose production and improves insulin sensitivity in peripheral tissues.
Sulfonylureas
- Examples: Glipizide, Glyburide, Glimepiride
- Mechanism: Stimulates insulin secretion from pancreatic beta cells.
Meglitinides
- Examples: Repaglinide, Nateglinide
- Mechanism: Stimulates rapid insulin secretion from the pancreas in response to meals.
Thiazolidinediones (TZDs)
- Examples: Pioglitazone, Rosiglitazone
- Mechanism: Increases insulin sensitivity in muscle and adipose tissue and decreases insulin resistance.
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
- Examples: Sitagliptin, Saxagliptin, Linagliptin
- Mechanism: Inhibits the enzyme DPP-4, leading to increased levels of incretin hormones, which stimulate insulin release and decrease glucagon secretion.
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
- Examples: Canagliflozin, Dapagliflozin, Empagliflozin
- Mechanism: Inhibits glucose reabsorption in the kidneys, leading to increased glucose excretion in urine.
Alpha-Glucosidase Inhibitors
- Examples: Acarbose, Miglitol
- Mechanism: Delays carbohydrate absorption in the intestines by inhibiting alpha-glucosidase enzymes.

Pharmacological Actions

Metformin: Reduces hepatic glucose output and improves insulin sensitivity.
Sulfonylureas and Meglitinides: Increase insulin secretion from the pancreas.
TZDs: Enhance insulin sensitivity and decrease insulin resistance.
DPP-4 Inhibitors: Prolong the action of incretin hormones.
SGLT2 Inhibitors: Promote renal excretion of glucose.
Alpha-Glucosidase Inhibitors: Slow carbohydrate digestion and absorption.

Dosage

Metformin: Typically starts at 500 mg once or twice daily, increasing as needed (maximum of 2,000-2,500 mg per day).
Sulfonylureas: Dosing varies by specific agent; generally starting doses range from 2.5 mg to 5 mg, adjusted based on glycemic control.
Meglitinides: Usually taken before meals, starting doses range from 0.5 mg to 1 mg.
TZDs: Commonly started at 15-30 mg for pioglitazone, with a maximum of 45 mg.
DPP-4 Inhibitors: Typically 100 mg once daily for sitagliptin, adjusted based on renal function.
SGLT2 Inhibitors: Starting doses usually range from 100 mg to 300 mg, depending on the specific agent.
Alpha-Glucosidase Inhibitors: Starting at 25 mg with meals, increased as tolerated (maximum 100 mg).

Indications

Type 2 Diabetes Mellitus: Oral hypoglycemic agents are primarily indicated for the management of blood glucose levels in individuals with type 2 diabetes.

Contraindications

Metformin: Contraindicated in severe renal impairment, metabolic acidosis, and certain acute conditions (e.g., sepsis, dehydration).
Sulfonylureas and Meglitinides: Caution in patients with sulfa allergies or severe liver disease.
TZDs: Contraindicated in patients with heart failure or significant edema.
DPP-4 Inhibitors: Caution in patients with a history of pancreatitis.
SGLT2 Inhibitors: Caution in patients with renal impairment or a history of urinary tract infections.
Alpha-Glucosidase Inhibitors: Contraindicated in patients with gastrointestinal disorders, such as inflammatory bowel disease.

Estrogen

Definition
Estrogen refers to a group of hormones that play essential roles in the development and regulation of the female reproductive system and secondary sexual characteristics. The primary forms of estrogen in the body are estradiol, estrone, and estriol.

Physiological Role

Reproductive Function:
- Estrogen is crucial for the menstrual cycle, promoting the growth and maintenance of the uterine lining (endometrium) in preparation for potential pregnancy.
Secondary Sexual Characteristics:
- It contributes to the development of breasts, pubic and axillary hair, and the distribution of body fat in females.
Bone Health:
- Estrogen helps maintain bone density by inhibiting bone resorption and promoting bone formation, thus reducing the risk of osteoporosis.
Cardiovascular Health:
- It has a protective effect on the cardiovascular system by improving lipid profiles and maintaining endothelial function.
Skin and Hair:
- Estrogen influences skin elasticity, moisture retention, and hair growth.

Pathological Role

Hormonal Imbalance:
- An imbalance in estrogen levels can lead to various conditions. Elevated levels may be associated with conditions like breast cancer, endometrial hyperplasia, and uterine fibroids. Low levels can result in symptoms like hot flashes, night sweats, mood swings, and vaginal dryness.
Menopause:
- Estrogen levels decline significantly during menopause, leading to various symptoms and an increased risk of osteoporosis and cardiovascular diseases.

Clinical Uses of Estrogen

Hormone Replacement Therapy (HRT):
- Estrogen is commonly used in HRT for managing menopausal symptoms, such as hot flashes and vaginal dryness.
Contraception:
- Estrogen is used in combined oral contraceptives to prevent ovulation and regulate menstrual cycles.
Menstrual Disorders:
- It can be used to treat menstrual irregularities, heavy menstrual bleeding, and conditions like polycystic ovary syndrome (PCOS).
Bone Health:
- Estrogen therapy may be prescribed to prevent osteoporosis in postmenopausal women.
Hormonal Therapies in Cancer:
- In some cases, estrogen is used in the treatment of hormone-sensitive cancers, though more commonly, anti-estrogens are used to inhibit its effects.

Dosage

Hormone Replacement Therapy:
- Dosage varies based on the formulation (oral, transdermal, etc.) and individual needs; commonly, 0.5 to 2 mg of estradiol is used.
Contraceptive Use:
- Dosage in combined oral contraceptives typically ranges from 20 to 50 mcg of ethinyl estradiol.

Contraindications

Estrogen-Dependent Cancers:
- Contraindicated in patients with a history of estrogen-sensitive cancers (e.g., certain breast cancers).
Thromboembolic Disorders:
- Caution in patients with a history of deep vein thrombosis (DVT) or pulmonary embolism.
Severe Liver Disease:
- Not recommended for individuals with liver dysfunction.
Undiagnosed Vaginal Bleeding:
- Should be investigated before starting estrogen therapy.

Progesterone

Definition
Progesterone is a steroid hormone produced primarily by the corpus luteum in the ovaries and the placenta during pregnancy. It plays a crucial role in the menstrual cycle, pregnancy, and embryogenesis.

Physiological Role

Menstrual Cycle Regulation:
- Progesterone prepares the endometrium for potential implantation of a fertilized egg and helps maintain the uterine lining.
Pregnancy Maintenance:
- Supports early pregnancy by inhibiting uterine contractions and promoting the growth of the placenta.
Breast Development:
- Prepares breast tissue for milk production during pregnancy.

Clinical Uses

Hormonal Replacement Therapy:
- Used in combination with estrogens in HRT to protect the endometrium from hyperplasia and cancer.
Menstrual Disorders:
- Treats conditions like amenorrhea and abnormal uterine bleeding.
Fertility Treatments:
- Helps support the luteal phase in assisted reproductive technologies.

Dosage

Progesterone: Varies based on indication; commonly, 100-200 mg daily for luteal support or up to 400 mg in some HRT regimens.

Contraindications

Estrogen-Sensitive Cancers:
- Should be avoided in patients with a history of breast or endometrial cancer.
Severe Liver Disease:
- Use with caution in individuals with liver dysfunction.

Oxytocin

Definition
Oxytocin is a peptide hormone produced by the hypothalamus and released by the posterior pituitary gland. It is often referred to as the "love hormone" due to its roles in social bonding and reproductive functions.

Physiological Role

Labor Induction:
- Stimulates uterine contractions during childbirth and aids in the expulsion of the placenta.
Milk Ejection:
- Promotes the let-down reflex during breastfeeding by causing contraction of the mammary glands.
Social Bonding:
- Influences emotional responses and bonding behaviors, including maternal bonding and romantic attachment.

Clinical Uses

Labor Induction:
- Administered intravenously to induce or augment labor.
Postpartum Hemorrhage:
- Used to reduce bleeding after delivery by promoting uterine contractions.
Breastfeeding Support:
- Can be used to assist with milk ejection in breastfeeding mothers.

Dosage

Oxytocin for Labor Induction: Typically starts at 0.5-2 mU/min, adjusted based on uterine response.

Contraindications

Fetal Distress:
- Should be avoided in cases of abnormal fetal heart rate patterns or significant fetal distress.
Uterine Hyperstimulation:
- Use cautiously in patients with a history of uterine surgeries or abnormalities.

Corticosteroids

Definition
Corticosteroids are a class of steroid hormones produced in the adrenal cortex. They are classified into glucocorticoids (e.g., cortisol) and mineralocorticoids (e.g., aldosterone), with glucocorticoids being primarily involved in metabolism and immune response regulation.

Physiological Role

Metabolic Regulation:
- Glucocorticoids influence glucose metabolism, fat distribution, and protein catabolism.
Immune Response:
- They modulate immune system activity, reducing inflammation and suppressing the immune response.
Stress Response:
- Corticosteroids play a role in the body's response to stress by enhancing energy availability.

Clinical Uses

Anti-Inflammatory:
- Treats conditions like asthma, rheumatoid arthritis, and inflammatory bowel disease.
Immunosuppression:
- Used in organ transplantation and autoimmune diseases to reduce the immune response.
Adrenal Insufficiency:
- Replacement therapy in conditions like Addison's disease.

Dosage

Glucocorticoids: Varies widely depending on the condition; for example, prednisone may be prescribed at doses of 5-60 mg/day, depending on the severity of the disease.

Contraindications

Systemic Fungal Infections:
- Should be avoided in individuals with active fungal infections.
Severe Hypertension or Heart Failure:
- Caution in patients with cardiovascular diseases due to potential fluid retention and hypertension.

Autocoids

Autocoids are a group of biologically active substances that act locally and are involved in various physiological and pathological processes. Key examples include histamine, serotonin (5-HT), and prostaglandins. Here’s a look at their physiological roles:

Histamine

Physiological Role:

Allergic Reactions:
- Histamine is released from mast cells and basophils during allergic reactions, causing vasodilation, increased vascular permeability, and bronchoconstriction, leading to symptoms like itching, swelling, and redness.
Gastric Acid Secretion:
- In the stomach, histamine stimulates parietal cells to secrete gastric acid, facilitating digestion.
Neurotransmission:
- Histamine functions as a neurotransmitter in the central nervous system, influencing wakefulness, appetite, and cognitive functions.
Immune Response:
- It plays a role in the inflammatory response, promoting the recruitment of immune cells to sites of injury or infection.

Serotonin (5-HT)

Physiological Role:

Mood Regulation:
- Serotonin is crucial in regulating mood, anxiety, and happiness. Low levels are associated with depression and anxiety disorders.
Gastrointestinal Function:
- In the gut, serotonin regulates bowel motility and is involved in peristalsis. It also modulates gut secretions and blood flow.
Vascular Tone:
- 5-HT has vasoconstrictive properties in certain blood vessels, playing a role in regulating blood pressure.
Platelet Function:
- Serotonin is released by platelets during blood clotting, contributing to vasoconstriction and the regulation of hemostasis.

Prostaglandins

Physiological Role:

Inflammation:
- Prostaglandins are produced at sites of tissue injury and inflammation, promoting vasodilation and increasing blood flow, which leads to redness and swelling.
Pain Sensation:
- They sensitize nerve endings to pain stimuli, playing a critical role in the perception of pain, especially in inflammatory conditions.
Gastric Protection:
- Prostaglandins help protect the gastric mucosa by stimulating mucus and bicarbonate secretion, maintaining the integrity of the stomach lining.
Reproductive Functions:
- They are involved in processes such as ovulation, uterine contraction during labor, and the regulation of menstrual cycles.
Regulation of Blood Flow:
- Prostaglandins can influence renal blood flow and glomerular filtration rate, playing a role in kidney function.

Antihistamines

Classification:

First-Generation Antihistamines:
- Examples: Diphenhydramine, Chlorpheniramine, Promethazine, Doxylamine
- Characteristics: Cross the blood-brain barrier, causing sedation and central nervous system effects.
Second-Generation Antihistamines:
- Examples: Cetirizine, Loratadine, Fexofenadine, Desloratadine
- Characteristics: Less likely to cross the blood-brain barrier, causing fewer sedative effects.

Clinical Uses:

Allergic Reactions:
- Used to relieve symptoms of allergic rhinitis (hay fever), urticaria (hives), and other allergic conditions.
Motion Sickness:
- First-generation antihistamines (e.g., Dimenhydrinate) are effective in preventing and treating motion sickness.
Insomnia:
- Some first-generation antihistamines (e.g., Diphenhydramine) are used as over-the-counter sleep aids.
Nausea and Vomiting:
- Certain antihistamines (e.g., Promethazine) are used to prevent and treat nausea and vomiting, particularly in chemotherapy or post-operative settings.

Adverse Effects:

First-Generation Antihistamines:
- Sedation, dizziness, impaired coordination, dry mouth, urinary retention, blurred vision (anticholinergic effects).
Second-Generation Antihistamines:
- Generally well-tolerated; may cause headache, dry mouth, and mild sedation in some individuals.

5-HT Antagonists (Serotonin Antagonists)

Classification:

5-HT3 Receptor Antagonists:
- Examples: Ondansetron, Granisetron, Palonosetron
- Mechanism: Block serotonin receptors in the central nervous system and the gastrointestinal tract.
5-HT2 Receptor Antagonists:
- Examples: Ketanserin, Ritanserin
- Mechanism: Block serotonin receptors involved in various CNS functions and cardiovascular regulation.

Clinical Uses:

Nausea and Vomiting:
- 5-HT3 antagonists are primarily used to prevent and treat nausea and vomiting associated with chemotherapy, radiation therapy, and post-operative settings.
Gastrointestinal Disorders:
- Some 5-HT antagonists can be used in the treatment of functional gastrointestinal disorders, such as irritable bowel syndrome.
Anxiety and Depression:
- Certain 5-HT2 antagonists have been explored for their potential role in managing anxiety and depression, although they are less commonly used for this purpose compared to SSRIs.

Adverse Effects:

5-HT3 Receptor Antagonists:
- Common side effects include headache, constipation, dizziness, and fatigue. Rarely, they can cause cardiac arrhythmias (e.g., QT interval prolongation).
5-HT2 Receptor Antagonists:
- Can cause sedation, hypotension, and other side effects related to serotonin modulation.

Chemotherapeutic Agents

Introduction
Chemotherapeutic agents are substances used to treat diseases, primarily infections, infestations, and neoplastic (cancer) conditions. These agents target rapidly dividing cells or specific pathogens, aiming to eliminate disease while minimizing damage to healthy tissues.

Basic Principles of Chemotherapy:

Selective Toxicity:
- The ideal chemotherapeutic agent selectively targets pathogens or cancer cells while sparing normal cells. This principle is crucial to reduce side effects.
Mechanism of Action:
- Chemotherapeutic agents can work by inhibiting cell wall synthesis, interfering with nucleic acid synthesis, or disrupting metabolic pathways in pathogens or tumor cells.
Pharmacokinetics:
- Understanding absorption, distribution, metabolism, and excretion (ADME) is vital for effective dosing and achieving therapeutic concentrations.
Combination Therapy:
- In many cases, combining drugs can enhance efficacy and reduce resistance. This is common in treating infections and certain cancers.
Monitoring and Resistance:
- Continuous monitoring for efficacy and side effects is necessary. Resistance mechanisms in pathogens and tumor cells can limit treatment success.

Penicillins

Classification: Penicillins are a group of β-lactam antibiotics. They can be classified based on their spectrum of activity and resistance to β-lactamase enzymes:

Natural Penicillins:
- Examples: Penicillin G (benzylpenicillin), Penicillin V
- Indication: Primarily effective against Gram-positive bacteria and some Gram-negative cocci.
Aminopenicillins:
- Examples: Amoxicillin, Ampicillin
- Indication: Broader spectrum, effective against certain Gram-negative bacteria.
Penicillinase-Resistant Penicillins:
- Examples: Methicillin, Nafcillin, Oxacillin
- Indication: Resistant to staphylococcal β-lactamase; used for treating infections caused by penicillinase-producing Staphylococcus aureus.
Extended-Spectrum Penicillins:
- Examples: Piperacillin, Ticarcillin
- Indication: Effective against a broader range of Gram-negative bacteria, often used in combination with β-lactamase inhibitors.

Dosage: Dosages vary based on the specific penicillin and the indication, but general guidelines include:

Penicillin G: 1-5 million units IV every 4-6 hours, adjusted based on infection severity.
Amoxicillin: 250-500 mg orally every 8 hours or 875 mg every 12 hours.
Piperacillin: 3.375 g IV every 6 hours, often combined with tazobactam.

Indications:

Natural Penicillins: Streptococcal infections, syphilis, meningitis (with appropriate coverage).
Aminopenicillins: Respiratory tract infections, otitis media, urinary tract infections.
Penicillinase-Resistant Penicillins: Infections caused by methicillin-sensitive Staphylococcus aureus (MSSA).
Extended-Spectrum Penicillins: Infections due to Pseudomonas aeruginosa and other resistant Gram-negative bacteria.

Contraindications:

Allergy: History of hypersensitivity to penicillins or cephalosporins.
Caution: In patients with a history of allergic reactions to other beta-lactam antibiotics.
Renal Impairment: Dosage adjustment may be necessary in patients with renal dysfunction.

Preparations

1. Sod. penicillin G (crystalline penicillin) injection: 0.5–5 MU i.m./i.v. 6–12 hourly. BENZYL PENICILLIN

0.5, 1.0 MU dry powder in vial to be dissolved in sterile water at the time of injection.

2. Procaine penicillin G inj: 0.5–1 MU i.m. 12–24 hourly as aqueous suspension; PROCAINE PENICILLIN-G

0.5, 1 MU dry powder in vial.

3. Fortified procaine penicillin G inj: contains 3 lac U procaine penicillin and 1 lac U sod. penicillin G,

FORTIFIED P.P. INJ 3+1 lac U vial.

4. Benzathine penicillin G: 0.6–2.4 MU i.m. every 2–4 weeks as aqueous suspension.

PENIDURE-LA (long acting), LONGACILLIN, PENCOM, 0.6, 1.2, 2.4 MU as dry powder in vial.

5. Phenoxymethyl penicillin (Penicillin V): 250–500 mg, infants 60 mg, children 125–250 mg; given 6

hourly, (250 mg = 4 lac U); CRYSTAPEN–V, KAYPEN, 125, 250 mg tab, 125 mg/5 ml dry syr—for reconstitution;

PENIVORAL 65, 130 mg tab.

6. Cloxacillin: 0.25–0.5 g orally every 6 hours; for severe infections 0.25–1 g may be injected i.m. or i.v.—higher

blood levels are produced; KLOX, BIOCLOX, 0.25, 0.5 g cap; 0.25, 0.5 g/vial inj. CLOPEN 0.25, 0.5 g cap.

7. Ampicillin: 0.5–2 g oral/i.m./i.v. depending on severity of infection, every 6 hours; children 50–100 mg/kg/

day; AMPILIN, ROSCILLIN, BIOCILIN 250, 500 mg cap; 125, 250 mg/5 ml dry syr; 100 mg/ml pediatric drops;

250, 500 mg and 1.0 g per vial inj.

8. Ampicillin + cloxacillin: AMPILOX, DUOCLOX 250 + 250 mg cap, 500+500 mg DS tab, 125+125 mg kid tab

and per 5 ml dry syr, 100 mg + 50 mg/ml pediatric syr, 250 mg + 250 mg per vial inj, 500 mg + 500 mg/vial DS

inj, 125 mg + 125 mg/vial pediatric inj., 50 mg + 75 mg/vial neonatal inj.

Cephalosporins

Introduction
Cephalosporins are a class of β-lactam antibiotics derived from the fungus Cephalosporium acremonium. They are used to treat a wide range of bacterial infections by disrupting bacterial cell wall synthesis.

Classification

Cephalosporins are categorized into generations based on their spectrum of activity and the development of resistance to β-lactamases:

First Generation:
- Examples: Cefazolin, Cephalexin
- Spectrum: Primarily effective against Gram-positive bacteria (e.g., Streptococcus and Staphylococcus) and some Gram-negative bacteria (e.g., E. coli, Klebsiella).
Second Generation:
- Examples: Cefuroxime, Cefoxitin, Cefaclor
- Spectrum: Broader Gram-negative coverage compared to first-generation, with some retained activity against Gram-positive bacteria.
Third Generation:
- Examples: Ceftriaxone, Ceftazidime, Cefotaxime
- Spectrum: Enhanced activity against Gram-negative bacteria; some agents (e.g., Ceftriaxone) have good CNS penetration, making them useful for treating meningitis.
Fourth Generation:
- Examples: Cefepime
- Spectrum: Broad-spectrum activity against both Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa.
Fifth Generation:
- Examples: Ceftaroline
- Spectrum: Effective against methicillin-resistant Staphylococcus aureus (MRSA) and has activity against a variety of Gram-negative bacteria.

Clinical Uses

First Generation: Surgical prophylaxis, skin and soft tissue infections, and urinary tract infections.
Second Generation: Respiratory tract infections, particularly those caused by Haemophilus influenzae, and intra-abdominal infections.
Third Generation: Meningitis, pneumonia, and serious infections due to resistant Gram-negative organisms.
Fourth Generation: Hospital-acquired infections and severe infections caused by multi-drug resistant Gram-negative bacteria.
Fifth Generation: Infections caused by MRSA and complicated skin infections.

Dosage

Dosages vary widely based on the specific cephalosporin and the indication. General guidelines include:

Cefazolin: 1-2 g IV every 8 hours.
Cefuroxime: 250-500 mg orally every 8 hours or 750 mg to 1.5 g IV every 8 hours.
Ceftriaxone: 1-2 g IV once daily; CNS infections may require higher doses.
Cefepime: 1-2 g IV every 8-12 hours, depending on the severity of the infection.

Contraindications

Allergy: History of hypersensitivity to cephalosporins or other β-lactam antibiotics.
Caution: In patients with a history of allergic reactions to penicillins, as cross-reactivity may occur.
Renal Impairment: Dosage adjustments may be necessary for patients with renal dysfunction.

Adverse Effects

Common:
- Diarrhea, nausea, vomiting, and rash.
Serious:
- Allergic reactions (anaphylaxis), Clostridium difficile-associated diarrhea, and renal toxicity (especially with higher doses or in renal impairment).

Preparations

1. Cefazolin: 0.5 g 8 hourly (mild cases), 1 g 6 hourly (severe cases), children 25–50 mg/kg/day i.m. or i.v;

for surgical prophylaxis 1.0 g half hour before surgery. ALCIZON, ORIZOLIN, REFLIN 0.25 g, 0.5 g, 1 g per vial inj.

2. Cephalexin: 0.25–1 g 6–8 hourly (children 25–100 mg/kg/day).

CEPHACILLIN 250, 500 mg cap; SPORIDEX, ALCEPHIN, CEPHAXIN 250, 500 mg cap, 125 mg/5 ml dry syr.,

100 mg/ml pediatric drops.

ALCEPHIN-LA: Cephalexin + probenecid (250 + 250 mg and 500 + 500 mg) tabs.

3. Cefadroxil: 0.5–1 g BD. DROXYL 0.5, 1 g tab, 250 mg/5 ml syr; CEFADROX 0.5 g cap, 125 mg/5 ml syr and

250 mg kid tab; KEFLOXIN 0.5 g cap, 0.25 g distab, 125 mg/5 ml susp.

4. Cefuroxime: 0.75 –1.5 g i.m or i.v. 8 hourly, children 30–100 mg/kg/day;

CEFOGEN, SUPACEF, FUROXIL 250 mg and 750 mg/vial inj.

5. Cefuroxime axetil: 250–500 mg BD oral, children half dose;

CEFTUM, SPIZEF 125, 250, 500 mg captab and 125 mg/5 ml susp.

6. Cefaclor: 0.25–1.0 g 8 hourly oral; KEFLOR, VERCEF, DISTACLOR 250 mg cap, 125 and 250 mg distab,

125 mg/5 ml dry syr, 50 mg/ml ped. drops.

7. Cefprozil: 500 mg OD-BD (20 mg/kg/day); ORPROZIL 250, 500 mg tabs.

8. Cefotaxime: 1–2 g i.m./i.v. 6–12 hourly (children 50–100 mg/kg/day);

OMNATAX, ORITAXIM, CLAFORAN 0.25, 0.5, 1.0 g per vial inj.

9. Ceftizoxime: 0.5–1 g i.m./i.v. 8 or 12 hourly; CEFIZOX, EPOCELIN 0.5 and 1 g per vial inj.

10. Ceftriaxone: Skin/soft tissue/urinary infections: 1–2 g i.v./i.m. per day;

Meningitis: 4 g followed by 2 g i.v. (children 75–100 mg/kg) once daily for 7–10 days.

Typhoid: 4 g i.v. daily × 2 days followed by 2 g/day (children 75 mg/kg) till 2 days after fever subsides.

Aminoglycosides

Introduction
Aminoglycosides are a class of antibiotics primarily effective against aerobic Gram-negative bacteria. They work by inhibiting bacterial protein synthesis, leading to bacterial cell death. Due to their potent activity, they are often used for serious infections, particularly in a hospital setting.

Classification

Common aminoglycosides include:

Gentamicin
Tobramycin
Amikacin
Neomycin (primarily used topically due to toxicity)
Streptomycin (used for tuberculosis and certain Gram-negative infections)

Mechanism of Action

Aminoglycosides bind to the 30S ribosomal subunit, interfering with protein synthesis. This can lead to:

Misreading of mRNA
Inhibition of translocation
Disruption of cell membrane integrity at high concentrations

Clinical Uses

Serious Gram-Negative Infections: Often used to treat infections caused by Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae.
Tuberculosis: Streptomycin is used in combination therapy for multidrug-resistant TB.
Endocarditis: Used in combination with other antibiotics (e.g., penicillins or vancomycin) for synergy in treating endocarditis.
Sepsis: Empirical treatment for sepsis, especially in critically ill patients.

Dosage

Dosages vary depending on the specific aminoglycoside, the infection being treated, and patient factors (like renal function). General guidelines include:

Gentamicin: 3-5 mg/kg/day IV in divided doses, or a once-daily regimen of 5-7 mg/kg.
Tobramycin: Similar dosing to gentamicin, typically 5-7 mg/kg/day.
Amikacin: 15 mg/kg/day in divided doses or a once-daily dose of 20-25 mg/kg.

Contraindications

Allergy: History of hypersensitivity to aminoglycosides or related compounds.
Pregnancy: Use with caution; may be associated with fetal harm (ototoxicity).
Severe Renal Impairment: Caution is required, as aminoglycosides can be nephrotoxic.

Adverse Effects

Nephrotoxicity:
- Damage to renal tubules can lead to acute kidney injury, particularly in patients with existing renal impairment or when used with other nephrotoxic agents.
Ototoxicity:
- Can cause hearing loss or balance issues, especially with prolonged use or high doses. Risk increases with prior ear problems or concurrent use of other ototoxic drugs.
Neuromuscular Blockade:
- May exacerbate muscle weakness in patients with neuromuscular disorders.
Hypersensitivity Reactions:
- Rash, fever, or anaphylactic reactions, although rare.

Fluoroquinolones

Introduction
Fluoroquinolones are a class of broad-spectrum antibiotics that are highly effective against a variety of Gram-negative and some Gram-positive bacteria. They are synthetic derivatives of quinolone antibiotics and work by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial DNA replication and repair.

Classification

Common fluoroquinolones include:

Ciprofloxacin:
- Effective against a broad range of Gram-negative bacteria, including Pseudomonas aeruginosa.
Levofloxacin:
- A respiratory fluoroquinolone, effective against both Gram-negative and Gram-positive bacteria, including Streptococcus pneumoniae.
Moxifloxacin:
- Effective against anaerobic bacteria and has a broader spectrum against Gram-positive organisms.
Ofloxacin:
- Similar spectrum to ciprofloxacin but less commonly used.
Norfloxacin:
- Primarily used for urinary tract infections.

Mechanism of Action

Fluoroquinolones inhibit bacterial enzymes DNA gyrase and topoisomerase IV, disrupting DNA replication and transcription, which ultimately leads to bacterial cell death.

Clinical Uses

Respiratory Infections:
- Moxifloxacin and levofloxacin are often used for community-acquired pneumonia and chronic bronchitis exacerbations.
Urinary Tract Infections (UTIs):
- Ciprofloxacin and norfloxacin are commonly prescribed for uncomplicated and complicated UTIs.
Gastrointestinal Infections:
- Effective against certain enteric pathogens, including Shigella and Salmonella.
Bone and Joint Infections:
- May be used in osteomyelitis and septic arthritis.
Anthrax:
- Ciprofloxacin is used as a prophylactic treatment following exposure to anthrax.

Dosage

Dosages vary based on the specific fluoroquinolone and the indication, but general guidelines include:

Ciprofloxacin: 250-750 mg orally every 12 hours; 400 mg IV every 8-12 hours.
Levofloxacin: 250-750 mg orally or IV once daily, depending on the severity of the infection.
Moxifloxacin: 400 mg orally or IV once daily.

Contraindications

Allergy: History of hypersensitivity to fluoroquinolones or other quinolone antibiotics.
Tendon Disorders: Increased risk of tendon rupture (especially the Achilles tendon) in patients with a history of tendon disorders or concurrent use of corticosteroids.
Pregnancy and Lactation: Use is generally avoided due to potential effects on fetal and infant cartilage development.

Adverse Effects

Gastrointestinal Disturbances:
- Nausea, diarrhea, and abdominal pain are common side effects.
Central Nervous System Effects:
- Headache, dizziness, and in rare cases, seizures or hallucinations.
Tendon Rupture:
- Increased risk of tendon injury, particularly in older adults and those on corticosteroids.
Cardiac Effects:
- QT interval prolongation, which can increase the risk of serious arrhythmias.
Photosensitivity:
- Increased sensitivity to sunlight, leading to a higher risk of sunburn.
Clostridium difficile Infection:
- Risk of antibiotic-associated diarrhea due to disruption of normal gut flora.

Macrolides

Introduction
Macrolides are a class of antibiotics characterized by their macrocyclic lactone ring structure. They are primarily effective against Gram-positive bacteria and some Gram-negative bacteria, as well as atypical pathogens. They work by inhibiting bacterial protein synthesis.

Classification

Common macrolides include:

Erythromycin:
- The first macrolide discovered, effective against various Gram-positive and some Gram-negative bacteria.
Azithromycin:
- Has a broader spectrum and better tissue penetration, commonly used for respiratory and sexually transmitted infections.
Clarithromycin:
- Similar to erythromycin but has improved pharmacokinetics and is effective against Helicobacter pylori.

Mechanism of Action

Macrolides bind to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the exit tunnel of the ribosome, preventing the elongation of the peptide chain.

Clinical Uses

Respiratory Infections:
- Used to treat community-acquired pneumonia, bronchitis, and sinusitis.
Skin Infections:
- Effective for soft tissue infections and acne.
Atypical Infections:
- Treatment of infections caused by atypical pathogens, such as Mycoplasma pneumoniae and Chlamydia pneumoniae.
Helicobacter pylori:
- Often used in combination therapy for peptic ulcer disease.
STIs:
- Azithromycin is commonly used to treat chlamydia and gonorrhea.

Dosage

Dosages vary based on the specific macrolide and the condition being treated:

Erythromycin: 250-500 mg orally every 6 hours; 1-2 g IV daily for severe infections.
Azithromycin: 500 mg orally on the first day, followed by 250 mg once daily for 4 more days.
Clarithromycin: 250-500 mg orally every 12 hours.

Contraindications

Allergy: History of hypersensitivity to macrolides.
Hepatic Impairment: Caution is advised due to metabolism through the liver.
Drug Interactions: Can interact with drugs that affect the cytochrome P450 system, leading to increased toxicity.

Adverse Effects

Gastrointestinal Disturbances:
- Nausea, vomiting, diarrhea, and abdominal pain.
Cardiac Effects:
- Can cause QT interval prolongation, leading to the risk of arrhythmias.
Liver Toxicity:
- Elevated liver enzymes and cholestatic hepatitis can occur, particularly with erythromycin.
Allergic Reactions:
- Rash, urticaria, and, in rare cases, anaphylaxis.

Tetracyclines

Introduction
Tetracyclines are a group of broad-spectrum antibiotics effective against a wide range of Gram-positive and Gram-negative bacteria, as well as some protozoa and atypical pathogens. They inhibit bacterial protein synthesis and are often used in various clinical settings.

Classification

Common tetracyclines include:

Tetracycline:
- The original drug in the class, used less frequently due to side effects.
Doxycycline:
- Widely used for respiratory tract infections, acne, and Lyme disease.
Minocycline:
- Effective for acne and respiratory infections, known for good tissue penetration.
Oxytetracycline:
- Used in veterinary medicine and some human applications.

Mechanism of Action

Tetracyclines bind to the 30S ribosomal subunit, inhibiting protein synthesis by preventing the attachment of aminoacyl-tRNA to the ribosome.

Clinical Uses

Infectious Diseases:
- Used to treat a variety of infections, including respiratory infections, urinary tract infections, and certain skin infections.
Atypical Infections:
- Effective against Mycoplasma pneumoniae and Chlamydia species.
Acne:
- Doxycycline and minocycline are commonly used to treat moderate to severe acne.
Malaria:
- Doxycycline is used as prophylaxis and treatment in certain cases.
Tick-Borne Diseases:
- Effective against Lyme disease and Rocky Mountain spotted fever.

Dosage

Dosages vary based on the specific tetracycline and the condition being treated:

Tetracycline: 250-500 mg orally every 6 hours.
Doxycycline: 100 mg orally or IV every 12 hours.
Minocycline: 200 mg orally or IV on the first day, then 100 mg daily.

Contraindications

Allergy: History of hypersensitivity to tetracyclines.
Pregnancy and Childhood: Contraindicated in pregnant women and children under 8 years due to risks of teeth discoloration and skeletal development issues.
Liver and Kidney Impairment: Caution is required due to potential accumulation.

Adverse Effects

Gastrointestinal Disturbances:
- Nausea, vomiting, and diarrhea.
Photosensitivity:
- Increased sensitivity to sunlight, leading to a higher risk of sunburn.
Teeth Discoloration:
- Permanent yellow-gray staining of teeth in children and during pregnancy.
Liver Toxicity:
- Potential for hepatotoxicity, particularly in patients with pre-existing liver disease.
Vestibular Reactions:
- Dizziness and vertigo, especially with minocycline.

Sulphonamides

Introduction
Sulphonamides, also known as sulfa drugs, are a group of synthetic antibiotics that inhibit bacterial growth by interfering with the synthesis of folic acid. They were among the first antibiotics developed and played a significant role in the treatment of bacterial infections.

Mechanism of Action

Sulphonamides act as competitive antagonists of para-aminobenzoic acid (PABA), a substrate necessary for the synthesis of folate in bacteria. By inhibiting the enzyme dihydropteroate synthase, they prevent the conversion of PABA to dihydropteroic acid, ultimately disrupting bacterial nucleic acid synthesis and leading to cell death.

Classification

Common sulphonamides include:

Sulfamethoxazole:
- Often used in combination with trimethoprim (as co-trimoxazole) for a synergistic effect.
Sulfadiazine:
- Used for various infections, including those caused by Streptococcus and certain protozoa.
Sulfisoxazole:
- Primarily used for urinary tract infections.
Silver Sulfadiazine:
- Used topically for preventing and treating infections in burn wounds.

Clinical Uses

Urinary Tract Infections (UTIs):
- Often used to treat uncomplicated UTIs.
Respiratory Tract Infections:
- May be used for certain types of bacterial pneumonia.
Gastrointestinal Infections:
- Effective against some enteric bacteria.
Pneumocystis jirovecii Pneumonia:
- Sulfamethoxazole in combination with trimethoprim is used for prophylaxis and treatment.
Burn Wound Infection:
- Silver sulfadiazine is commonly used for preventing infection in burn patients.

Dosage

Dosages can vary based on the specific sulphonamide and the condition being treated. General guidelines include:

Sulfamethoxazole: Typically 800 mg orally every 12 hours in combination with trimethoprim.
Sulfadiazine: 1-2 g orally every 6-8 hours, depending on the infection.
Silver Sulfadiazine: Applied topically once or twice daily to affected areas.

Contraindications

Allergy: History of hypersensitivity to sulfonamides.
Pregnancy: Use is generally avoided during the last trimester due to the risk of kernicterus in neonates.
G6PD Deficiency: Caution is necessary as sulphonamides can trigger hemolytic anemia in these patients.

Adverse Effects

Hypersensitivity Reactions:
- Rash, fever, and in severe cases, Stevens-Johnson syndrome.
Gastrointestinal Disturbances:
- Nausea, vomiting, and diarrhea.
Hematologic Effects:
- Can cause hemolytic anemia, leukopenia, and thrombocytopenia, particularly in susceptible individuals.
Renal Toxicity:
- Potential for crystalluria if not adequately hydrated; renal function should be monitored.
Photosensitivity:
- Increased risk of sunburn and skin reactions upon exposure to sunlight.

Anti-Tubercular Drugs

Introduction
Anti-tubercular drugs are essential in the treatment of tuberculosis (TB), a contagious infection caused by Mycobacterium tuberculosis. The treatment regimen typically involves a combination of multiple drugs to prevent the development of resistance and to ensure effective eradication of the bacteria.

Classification of Anti-Tubercular Drugs

Anti-tubercular drugs are classified into two main categories: first-line and second-line drugs.

First-Line Drugs

Isoniazid (INH)
- Mechanism: Inhibits the synthesis of mycolic acids, essential components of the bacterial cell wall.
- Indications: Used for active TB and as prophylaxis in high-risk individuals.
- Adverse Effects: Hepatotoxicity, peripheral neuropathy (prevented with pyridoxine), and hypersensitivity reactions.
Rifampicin (RIF)
- Mechanism: Inhibits bacterial RNA synthesis by binding to DNA-dependent RNA polymerase.
- Indications: Used for active TB and some atypical mycobacterial infections.
- Adverse Effects: Hepatotoxicity, discoloration of body fluids (orange-red), and potential drug interactions (induces CYP450 enzymes).
Pyrazinamide (PZA)
- Mechanism: Disrupts mycobacterial cell membrane metabolism and transport functions.
- Indications: Used in combination therapy for active TB.
- Adverse Effects: Hepatotoxicity, hyperuricemia, and gastrointestinal disturbances.
Ethambutol (EMB)
- Mechanism: Inhibits arabinogalactan synthesis, affecting the cell wall of mycobacteria.
- Indications: Used in combination therapy for active TB.
- Adverse Effects: Optic neuritis (visual disturbances), hyperuricemia, and allergic reactions.

Second-Line Drugs

Fluoroquinolones (e.g., Levofloxacin, Moxifloxacin)
- Indications: Used for multidrug-resistant TB (MDR-TB) and when first-line drugs are contraindicated.
- Adverse Effects: Gastrointestinal disturbances, tendon rupture, and CNS effects.
Aminoglycosides (e.g., Kanamycin, Amikacin)
- Indications: Used for MDR-TB; typically given via injection.
- Adverse Effects: Nephrotoxicity, ototoxicity, and injection site reactions.
Capreomycin
- Indications: Used for MDR-TB.
- Adverse Effects: Nephrotoxicity and ototoxicity.
Bedaquiline
- Indications: Approved for treatment of MDR-TB.
- Adverse Effects: QT interval prolongation, hepatotoxicity, and risk of arrhythmias.
Linezolid
- Indications: Effective against some MDR-TB strains.
- Adverse Effects: Myelosuppression, peripheral neuropathy, and serotonin syndrome.

Treatment Regimen

The standard treatment for drug-susceptible TB typically lasts 6 months and involves the combination of the first-line drugs. The initial phase usually includes isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months, followed by a continuation phase of isoniazid and rifampicin for an additional 4 months.

For MDR-TB, treatment can last 18-24 months or longer and may involve a combination of second-line drugs.

Monitoring and Follow-Up

Regular monitoring is essential to assess the effectiveness of treatment and to watch for side effects. Key aspects include:

Liver Function Tests: To monitor for hepatotoxicity, especially with isoniazid, rifampicin, and pyrazinamide.
Visual Acuity: For patients on ethambutol to detect optic neuritis.
Hematologic Monitoring: Especially for drugs like linezolid that can cause myelosuppression.

Antitubercular Drugs

1. Isoniazid (Isonicotinic acid hydrazide, INH): 300 mg (5 mg/kg) daily or 600–900 mg (10 mg/kg) thrice

weekly oral; ISONEX 100, 300 mg tabs, ISOKIN 100 mg tab, 100 mg per 5 ml liq.

2. Rifampin (Rifampicin): 600 mg (10 mg/kg) daily or thrice weekly oral one hour before or two hours after

meals; RCIN 150, 300, 450, 600 mg caps, 100 mg/5 ml susp. RIMACTANE, RIMPIN 150, 300, 450 mg caps, 100

mg/5 ml syr; RIFAMYCIN 450 mg cap, ZUCOX 300, 450, 600 mg tabs.

3. Pyrazinamide: 25 mg/kg daily or 35 mg/kg thrice weekly oral; PYZINA 0.5, 0.75, 1.0 g tabs, 0.3 g kid tab;

PZA-CIBA 0.5, 0.75 g tabs, 250 mg/5 ml syr; RIZAP 0.75, 1.0 g tabs.

4. Ethambutol: 15 mg/kg daily or 30 mg/kg thrice weekly oral; MYCOBUTOL, MYAMBUTOL, COMBUTOL 0.2,

0.4, 0.6, 0.8, 1.0 g tabs.

5. Streptomycin: 1000 mg (15 mg/kg) daily or thrice weekly i.m.; patients over 60 years age—reduce dose to

10 mg/kg or 500–750 mg/day i.m. AMBISTRYN-S 0.75 g and 1.0 g dry powder per vial for i.m. inj.

6. Paraaminosalicylic acid (PAS): 10–12 g (200 mg/kg) per day oral in divided doses; SODIUM-PAS 0.5 g

tab, 80 g/100 g granules.

7. Ethionamide: 0.5–0.75 g (10–15 mg/kg) per day oral; ETHIDE, ETHIOCID, MYOBID 250 mg tab.

8. Prothionamide: 0.5–0.75 g (10–15 mg/kg/day) oral; PROTHICID, PETHIDE 250 mg tab.

9. Cycloserine: 250 mg BD, increased if tolerated upto 750 mg per day oral; CYCLORINE, COXERIN, MYSER

250 mg cap.

10. Terizidone: 500–700 mg/day oral; TERICOX 250 mg cap.

11. Kanamycin: 0.75–1.0 g/day (10–15 mg/kg/day) i.m.; KANCIN, KANAMAC 0.5, 1 g inj.

Anti-Fungal Drugs

Introduction
Anti-fungal drugs are used to treat infections caused by fungi, which can affect various parts of the body, including the skin, nails, and internal organs. Fungal infections can range from superficial to systemic, and treatment depends on the type and severity of the infection.

Classification of Anti-Fungal Drugs

Anti-fungal agents are classified into several categories based on their mechanism of action and chemical structure.

1. Azoles

Examples:
- Fluconazole: Commonly used for Candida infections and cryptococcal meningitis.
- Itraconazole: Effective against a variety of fungal infections, including histoplasmosis and onychomycosis.
- Voriconazole: Primarily used for invasive aspergillosis and other serious fungal infections.
Mechanism of Action: Inhibit the synthesis of ergosterol, an essential component of the fungal cell membrane.
Adverse Effects: Gastrointestinal disturbances, liver toxicity, and drug interactions due to effects on cytochrome P450 enzymes.

2. Echinocandins

Examples:
- Caspofungin: Used for candidemia and invasive aspergillosis.
- Micafungin: Effective against Candida infections and used in stem cell transplant patients.
- Anidulafungin: Similar indications as other echinocandins.
Mechanism of Action: Inhibit the synthesis of β-(1,3)-D-glucan, a critical component of the fungal cell wall.
Adverse Effects: Generally well tolerated; may cause infusion reactions and liver enzyme elevation.

3. Polyene Antifungals

Examples:
- Amphotericin B: Used for severe systemic fungal infections, including cryptococcal meningitis and invasive aspergillosis.
- Nystatin: Primarily used topically for superficial Candida infections (e.g., oral thrush).
Mechanism of Action: Bind to ergosterol in the fungal cell membrane, forming pores that lead to cell lysis.
Adverse Effects: Infusion-related reactions, nephrotoxicity, and electrolyte imbalances (e.g., hypokalemia).

4. Allylamines

Examples:
- Terbinafine: Used for dermatophyte infections (e.g., athlete's foot, nail fungus).
- Naftifine: Topical treatment for skin infections.
Mechanism of Action: Inhibit squalene epoxidase, blocking ergosterol synthesis.
Adverse Effects: Liver function abnormalities, gastrointestinal upset, and skin reactions.

5. Thiazole and Other Antifungals

Examples:
- Griseofulvin: Used for dermatophyte infections of skin, hair, and nails.
- Flucytosine: Often used in combination with amphotericin B for cryptococcal meningitis.
Mechanism of Action: Griseofulvin inhibits fungal cell mitosis, while flucytosine interferes with DNA and RNA synthesis.
Adverse Effects: Griseofulvin can cause headache and gastrointestinal upset, while flucytosine can lead to bone marrow suppression and liver toxicity.

Clinical Uses

Superficial Infections: Treated with topical azoles, allylamines, or nystatin.
Systemic Infections: Amphotericin B, echinocandins, and systemic azoles are used based on the type of fungus and site of infection.
Prophylaxis: In immunocompromised patients (e.g., those undergoing chemotherapy or with HIV), antifungal prophylaxis is often employed.

Monitoring and Follow-Up

Monitoring is essential for patients on antifungal therapy, particularly for systemic treatments. Key aspects include:

Liver Function Tests: Especially for azoles and terbinafine due to potential hepatotoxicity.
Renal Function: Important for amphotericin B due to nephrotoxic potential.
Drug Interactions: Monitor for interactions, particularly with azoles that affect liver enzyme metabolism.

Preparations

1. Amphotericin B: 0.3–0.7 mg/kg daily by slow i.v. infusion over 4–8 hours (total dose 3–4 g); 0.5 mg intrathecal,

3% topically in ear, 50–100 mg QID oral; FUNGIZONE INTRAVENOUS, MYCOL 50 mg dry powder per vial for

i.v. infusion, FUNGIZONE OTIC 3% ear drops.

Liposomal amphotericin B: 3-5 mg/kg/day i.v. infusion; FUNGISOME 10 mg, 25 mg, 50 mg per vial inj,

AMPHOLIP 10 mg/2 ml, 50 mg/10 ml, 100 mg/20 ml inj.

2. Nystatin: 5 lac U 8 hourly oral, 1 lac U nightly for vaginal insertion, 10,000 U/ml for buccal application; 1 lac

U per g for application over skin and in the eye;

MYCOSTATIN 5 lac U tab, 1 lac U vaginal tab, 1 lac U/g oint, NYSTIN EYE 1 lac U/g ophthalmic oint.

3. Hamycin: 2–5 lac U/g for topical application, 4 lac U vaginal application;

HAMYCIN 5 lac U/g oint, 2 lac U/ml susp for topical use, 4 lac U vaginal ovules.

4. Caspofungin: 70 mg infused i.v. over 1 hour (loading dose), followed by 50 mg i.v. daily.

CANCIDAS 70 mg in 10 ml and 50 mg in 10 ml inj.

5. Griseofulvin: 125–250 mg QID oral taken with meals; GRISOVIN–FP, GRISORAL, WALAVIN-FP 250 mg tab.

6. Clotrimazole: 1% topical application twice daily, 100 mg intravaginal at bed time:

SURFAZ, CLODERM 1% lotion, cream, powder; 100 mg vaginal tab. CANDID 1% cream, mouth paint.

7. Econazole: 1% topical application 2–3 times daily, 150 mg intravaginal every night;

ECONAZOLE 1% oint, 150 mg vaginal tab; ECODERM 1% cream.

8. Miconazole: 2% topical application 2–3 times daily, 100 mg intravaginal nightly;

DAKTARIN 2% gel, 2% powder and solution; GYNODAKTARIN 2% vaginal gel; ZOLE 2% oint, lotion, dusting

powder and spray, 1% ear drops, 100 mg vaginal ovules.

9. Oxiconazole: 1% topical; OXIZON, ZODERM 1% + benzoic acid 0.25% cream and lotion

Anti-Viral Drugs

Introduction
Anti-viral drugs are medications used to treat viral infections by inhibiting the development or replication of viruses. Unlike antibiotics, which target bacteria, anti-viral drugs specifically target viral mechanisms, making them effective against a range of viral infections.

Classification of Anti-Viral Drugs

Anti-viral drugs can be classified based on the viruses they target and their mechanism of action.

1. Nucleoside/Nucleotide Analogues

Examples:
- Acyclovir: Used primarily for herpes simplex virus (HSV) infections and varicella-zoster virus (VZV).
- Valacyclovir: A prodrug of acyclovir with improved bioavailability, used for similar indications.
- Ganciclovir: Used for cytomegalovirus (CMV) infections, especially in immunocompromised patients.
- Tenofovir: Used for HIV and hepatitis B.
Mechanism of Action: These drugs mimic nucleotides, leading to premature termination of viral DNA synthesis when incorporated into the viral genome.
Adverse Effects: Can include nephrotoxicity (especially with ganciclovir), gastrointestinal disturbances, and neurological effects (e.g., tremors with acyclovir).

2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Examples:
- Efavirenz: Used in the treatment of HIV.
- Rilpivirine: Another NNRTI for HIV, often used in combination therapies.
Mechanism of Action: Bind to and inhibit reverse transcriptase, an enzyme critical for converting viral RNA into DNA.
Adverse Effects: Can include rash, liver enzyme elevation, and central nervous system effects (e.g., dizziness, vivid dreams with efavirenz).

3. Protease Inhibitors

Examples:
- Ritonavir: Initially used as an HIV protease inhibitor, but now often used at low doses to boost other protease inhibitors.
- Lopinavir/ritonavir (Kaletra): A combination used for HIV treatment.
- Darunavir: Another protease inhibitor for HIV.
Mechanism of Action: Inhibit the protease enzyme, preventing the cleavage of viral polyproteins into functional proteins, thereby blocking viral replication.
Adverse Effects: Can include gastrointestinal disturbances, lipid abnormalities, and increased risk of cardiovascular disease.

4. Integrase Inhibitors

Examples:
- Raltegravir: Used for HIV treatment.
- Dolutegravir: Highly effective with a high barrier to resistance.
Mechanism of Action: Inhibit integrase, the enzyme that integrates viral DNA into the host cell's genome.
Adverse Effects: Generally well tolerated; some may experience insomnia, headache, or gastrointestinal upset.

5. Fusion Inhibitors

Example:
- Enfuvirtide: Used in HIV treatment, especially in patients with drug-resistant strains.
Mechanism of Action: Prevents the fusion of the virus with the host cell membrane, blocking entry into the cell.
Adverse Effects: Injection site reactions, increased risk of pneumonia, and hypersensitivity reactions.

6. Neuraminidase Inhibitors

Examples:
- Oseltamivir (Tamiflu): Used for the treatment and prevention of influenza.
- Zanamivir: Another neuraminidase inhibitor, administered via inhalation for influenza.
Mechanism of Action: Inhibit neuraminidase, an enzyme that facilitates the release of new viral particles from infected cells, thus limiting viral spread.
Adverse Effects: Can include nausea, vomiting, and in some cases, respiratory issues with zanamivir.

7. Other Anti-Viral Agents

Interferons:
- Used for chronic hepatitis B and C, as well as some cancers. They enhance the immune response against viruses.
Ribavirin:
- Often used in combination with other antivirals for hepatitis C and certain viral hemorrhagic fevers.
Remdesivir:
- An investigational drug for the treatment of COVID-19, acting as a nucleotide analog.

Clinical Uses

HIV: Combination antiretroviral therapy (ART) using multiple classes of drugs to suppress viral replication.
Herpes Simplex and Varicella-Zoster Infections: Acyclovir and its derivatives are commonly used.
Influenza: Neuraminidase inhibitors are effective for treatment and prevention.
Hepatitis B and C: Various nucleoside analogues and interferons are used.

Monitoring and Follow-Up

Monitoring is essential during antiviral therapy, particularly for:

Liver Function Tests: Especially for patients on hepatitis treatments.
Renal Function: Important for drugs like acyclovir and ganciclovir.
Viral Load and CD4 Counts: In HIV patients to assess treatment efficacy.

Antiviral Drugs (Non-retroviral)

1. Idoxuridine: 0.1% topically in eye 1 hourly to 6 hourly, apply 0.1% eye ointment at night;

IDURIN, TOXIL 0.1% eye drops and oint.

2. Acyclovir: 200 mg 5 times a day oral (15 mg/kg/day), 5 –10 mg/kg 8 hourly by slow i.v. infusion, 5% topical

application 6 times a day; ZOVIRAX 200 mg tab, 250 mg/vial for i.v. inj; CYCLOVIR 200 mg tab, 5% skin cream;

HERPEX 200 mg tab, 3% eye oint, 5% skin cream; OCUVIR 200, 400, 800 mg tab, 3% eye oint, ACIVIR-DT 200,

400, 800 mg tab. ACIVIR EYE 3% oint.

3. Valacyclovir: For genital herpes simplex 0.5-1.0 g BD × 10 days, suppressive treatment 0.5 g OD × 6–12 months.

For orolabial herpes 2 g BD × 1 day

For herpes zoster 1 g TDS × 7 days.

VALCIVIR 0.5 g, 1.0 g tabs.

4. Famciclovir: Genital herpes (1st episode) 250 mg TDS × 5 days; recurrent cases 250 mg BD for upto 1 year.

Herpes zoster and orolabial herpes 500 mg TDS for 7–10 days. FAMTREX 250, 500 mg tabs.

5. Ganciclovir: For treatment and prophylaxis of CMV infections—5 mg/kg BD initially, followed by OD;

GANGUARD 250, 500 mg tabs.

6. Amantadine: 100 mg BD, elderly—half dose, children 5 mg/kg/day; AMANTREL, NEAMAN 100 mg tab.

7. Rimantadine: 100 mg BD, elderly 100 mg OD, child 5 mg/kg/day;

FLUMADINE 100 mg tab, 50 mg/5 ml syr.

8. Oseltamivir: therapeutic dose—75 mg BD × 5 days; prophy lactic dose—75 mg OD;

TAMIFLU, ANTIFLU 75 mg cap, 12 mg/ml susp, FLUVIR 75 mg cap.

Antiretroviral Drugs

15. Zidovudine (Azidothymidine, AZT): Adults 300 mg BD; Children 180 mg/m2

(max 200 mg) BD.

RETROVIR, ZIDOVIR 100 mg cap 300 mg tab, 50 mg/5 ml syr, ZIDOMAX, ZYDOWIN 100 mg cap, 300 mg tab

(to be taken with plenty of water).

16. Didanosine: 400 mg/day (for > 60 kg BW), 250 mg/day (< 50 kg BW); 1 hour before or 2 hours after meals;

DINEX EC, DD RETRO, VIROSINE DR 250, 400 mg tabs.

17. Stavudine: 30 mg BD; STAG, STAVIR, VIROSTAV 30, 40 mg caps.

18. Lamivudine: For chronic hepatitis B—100 mg OD;

For HIV infection—150 mg BD (along with other antiretroviral drugs); LAMIVIR 150 mg tab, 150 mg/5 ml soln;

LAMIVIR-HBV 100 mg tab; HEPTAVIR, LAMIDAC, LAMUVID 100, 150 mg tabs.

19. Abacavir: 300 mg BD or 600 mg OD (along with other antiretroviral drugs); ABAMUNE, ABAVIR 300 mg tab.

20. Nevirapine: 200 mg/day oral to be increased after 2 weeks to 200 mg BD; NEVIMUNE, NEVIVIR, NEVIPAN,

NEVIRETRO 200 mg.

Anti-Amoebic Agents

Introduction
Anti-amoebic agents are medications used to treat infections caused by amoebae, primarily Entamoeba histolytica, which causes amoebic dysentery and liver abscesses. These infections can lead to severe gastrointestinal and systemic complications, making effective treatment crucial.

Classification of Anti-Amoebic Agents

Anti-amoebic agents can be classified into several categories based on their mechanism of action and the type of amoebic infections they treat.

1. Luminal Amoebicides

These agents are effective against amoebae in the intestinal lumen and are often used for asymptomatic infections or as adjunctive therapy in symptomatic cases.

Examples:
- Iodoquinol: Used to treat asymptomatic intestinal amoebiasis.
- Paromomycin: An aminoglycoside antibiotic effective against E. histolytica in the intestine.
- Diloxanide Furoate: Effective for treating asymptomatic and mild cases of amoebiasis.
Mechanism of Action: These drugs act by disrupting amoebic metabolism or inhibiting protein synthesis.
Adverse Effects: Generally well tolerated, but may include gastrointestinal disturbances and allergic reactions.

2. Systemic Amoebicides

These agents are effective against both the intestinal and extraintestinal stages of amoebic infections.

Examples:
- Metronidazole: Widely used for treating amoebic dysentery and liver abscesses.
- Tinidazole: Similar to metronidazole, with a longer half-life, allowing for shorter treatment courses.
Mechanism of Action: These drugs work by disrupting DNA synthesis in anaerobic microorganisms and protozoa, leading to cell death.
Adverse Effects: Can include gastrointestinal upset, headache, dizziness, and potential neurotoxicity with prolonged use. Disulfiram-like reaction may occur with alcohol.

3. Combination Therapy

In some cases, a combination of luminal and systemic amoebicides may be used to achieve effective treatment of invasive infections.

Example: Metronidazole is often combined with a luminal agent like iodoquinol or paromomycin for comprehensive management of amoebic infections.

Clinical Uses

Intestinal Amoebiasis: Treated with luminal agents for asymptomatic cases and systemic agents for symptomatic dysentery.
Amoebic Liver Abscess: Generally treated with metronidazole or tinidazole, followed by a luminal agent to eradicate any remaining parasites in the intestine.

Monitoring and Follow-Up

Monitoring is important during treatment to assess:

Response to Therapy: Symptoms should improve within a few days of starting treatment.
Adverse Effects: Regular assessment for gastrointestinal side effects and potential neurotoxicity, especially with metronidazole.

Anthelmintics

Introduction
Anthelmintics are medications used to treat infections caused by helminths, which are parasitic worms. These infections can affect various organs and systems in the body and are often classified into three main groups: nematodes (roundworms), cestodes (tapeworms), and trematodes (flukes).

Classification of Anthelmintics

Anthelmintics can be categorized based on their mechanism of action and the type of helminth infections they target.

1. Benzimidazoles

Examples:
- Albendazole: Broad-spectrum anthelmintic effective against many nematodes and some cestodes.
- Mebendazole: Primarily used for intestinal nematodes.
- Fenbendazole: Used in veterinary medicine and effective against various helminths.
Mechanism of Action: Inhibit microtubule synthesis, disrupting cellular function and leading to the death of the parasite.
Adverse Effects: Generally well tolerated, but may cause gastrointestinal disturbances, headache, and liver enzyme elevations.

2. Praziquantel

Indication: Effective against trematodes and cestodes, particularly for schistosomiasis and various tapeworm infections.
Mechanism of Action: Increases the permeability of the cell membrane to calcium ions, leading to paralysis and death of the parasite.
Adverse Effects: May include dizziness, headache, nausea, and abdominal discomfort.

3. Ivermectin

Indication: Used for several nematode infections, including strongyloidiasis and onchocerciasis (river blindness), as well as for ectoparasites like scabies.
Mechanism of Action: Binds to glutamate-gated chloride channels, causing paralysis and death of the parasite.
Adverse Effects: Typically well tolerated; may cause mild dizziness, pruritus, and in some cases, an inflammatory response following death of the parasites.

4. Levamisole and Pyrantel Pamoate

Indications: Effective for treating various intestinal nematodes.
Mechanism of Action:
- Levamisole: Stimulates the immune response and causes paralysis of the parasite.
- Pyrantel Pamoate: Works by depolarizing the neuromuscular junction, causing paralysis.
Adverse Effects: Both are generally well tolerated but may cause nausea, vomiting, and abdominal pain.

5. Diethylcarbamazine (DEC)

Indication: Used for lymphatic filariasis and tropical pulmonary eosinophilia.
Mechanism of Action: Alters the immune response to the parasite and enhances phagocytosis.
Adverse Effects: Can include fever, headache, and gastrointestinal upset, especially during the initial treatment phase.

Clinical Uses

Nematode Infections: Treated with benzimidazoles (albendazole, mebendazole), ivermectin, or pyrantel pamoate.
Cestode Infections: Praziquantel is the primary treatment for tapeworm infections.
Trematode Infections: Praziquantel is also used for fluke infections such as schistosomiasis.

Monitoring and Follow-Up

Monitoring may include:

Response to Therapy: Symptom resolution and stool examination for the presence of eggs or parasites.
Adverse Effects: Monitoring for gastrointestinal side effects and potential liver function abnormalities, especially with prolonged use of benzimidazoles.

Anti-Malarial Agents

Introduction
Anti-malarial agents are medications used to prevent and treat malaria, a disease caused by parasites of the Plasmodium species, transmitted through the bites of infected Anopheles mosquitoes. Effective management of malaria is critical due to its global health impact, particularly in tropical and subtropical regions.

Classification of Anti-Malarial Agents

Anti-malarial drugs can be classified based on their mechanism of action and the stage of the malaria life cycle they target.

1. Aminoquinolines

Examples:
- Chloroquine: Used for the treatment of uncomplicated P. falciparum malaria and other Plasmodium species.
- Hydroxychloroquine: Used for both malaria and autoimmune conditions like lupus and rheumatoid arthritis.
Mechanism of Action: Interfere with the parasite's ability to detoxify heme, leading to the accumulation of toxic compounds.
Adverse Effects: Generally well tolerated, but can cause gastrointestinal upset, headache, and retinal toxicity with long-term use.

2. Artemisinin-Based Combination Therapies (ACTs)

Examples:
- Artemether-Lumefantrine (AL): Commonly used for uncomplicated P. falciparum malaria.
- Artesunate-Amodiaquine: Another combination used for treatment.
Mechanism of Action: Artemisinin compounds rapidly kill parasites in the blood, while the partner drug helps prevent resistance.
Adverse Effects: Generally well tolerated, but may cause nausea, vomiting, and mild hematologic effects.

3. Anti-folate Agents

Examples:
- Sulfadoxine-Pyrimethamine (SP): Used in intermittent preventive therapy and treatment of uncomplicated malaria.
- Proguanil: Often combined with atovaquone for malaria prophylaxis and treatment.
Mechanism of Action: Inhibit folate synthesis, which is crucial for parasite DNA replication.
Adverse Effects: Can cause skin reactions, gastrointestinal disturbances, and hematological effects (e.g., agranulocytosis).

4. Atovaquone-Proguanil

Indication: Used for both treatment and prevention of malaria.
Mechanism of Action: Atovaquone disrupts mitochondrial function, while proguanil inhibits folate synthesis.
Adverse Effects: Generally well tolerated; possible side effects include abdominal pain, headache, and diarrhea.

5. Quinoline Derivatives

Examples:
- Quinine: An older treatment for severe malaria, often used in combination with other drugs.
- Quinidine: Used in a hospital setting for severe P. falciparum malaria.
Mechanism of Action: Interfere with parasite metabolism and function, leading to cell death.
Adverse Effects: Can cause cinchonism (tinnitus, headache, nausea), hypoglycemia, and cardiac arrhythmias.

6. Primaquine

Indication: Used for radical cure of P. vivax and P. ovale to eliminate hypnozoites (dormant liver forms).
Mechanism of Action: Interferes with the metabolism of the parasite in the liver.
Adverse Effects: Can cause hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency; gastrointestinal upset may also occur.

Clinical Uses

Uncomplicated Malaria: Treated with ACTs, chloroquine (where appropriate), or other anti-malarial combinations.
Severe Malaria: Typically treated with intravenous quinine or artesunate.
Prophylaxis: Medications like atovaquone-proguanil or doxycycline are used for travelers to endemic areas.

Monitoring and Follow-Up

Monitoring during treatment may include:

Clinical Response: Assessing for resolution of symptoms.
Adverse Effects: Regular checks for potential side effects, especially with drugs like chloroquine and primaquine.
Laboratory Tests: Hematological monitoring for drugs that can cause blood dyscrasias.

Anti-Neoplastic Agents

Introduction
Anti-neoplastic agents, also known as chemotherapy agents, are used to treat cancer by inhibiting the growth and proliferation of neoplastic cells. These agents can target cancerous cells directly or modify the body’s immune response to fight cancer. They are categorized based on their mechanism of action, chemical structure, and the type of cancer they target.

Classification of Anti-Neoplastic Agents

Anti-neoplastic agents can be classified into several categories:

1. Alkylating Agents

Examples:
- Cyclophosphamide: Used for various cancers, including lymphomas and breast cancer.
- Carmustine: Effective for brain tumors and multiple myeloma.
Mechanism of Action: These agents work by adding alkyl groups to DNA, leading to DNA cross-linking and ultimately cell death.
Adverse Effects: Myelosuppression, nausea, vomiting, and risk of secondary malignancies.

2. Antimetabolites

Examples:
- Methotrexate: Used for leukemia, lymphomas, and solid tumors.
- 5-Fluorouracil (5-FU): Commonly used for colorectal cancer and other solid tumors.
Mechanism of Action: Mimic natural metabolites, interfering with DNA and RNA synthesis.
Adverse Effects: Myelosuppression, gastrointestinal toxicity, and mucositis.

3. Natural Products

Examples:
- Vincristine: Used for leukemias and lymphomas.
- Paclitaxel: Effective for ovarian, breast, and lung cancers.
Mechanism of Action:
- Vincristine: Inhibits microtubule formation, disrupting mitosis.
- Paclitaxel: Stabilizes microtubules, preventing their disassembly.
Adverse Effects: Neuropathy (vincristine), hypersensitivity reactions (paclitaxel), and myelosuppression.

4. Hormonal Agents

Examples:
- Tamoxifen: Used for estrogen receptor-positive breast cancer.
- Anastrozole: An aromatase inhibitor for postmenopausal breast cancer.
Mechanism of Action: Block hormone receptors or inhibit hormone production, slowing or stopping the growth of hormone-sensitive tumors.
Adverse Effects: Hot flashes, risk of thromboembolic events, and endometrial changes (tamoxifen).

5. Targeted Therapy

Examples:
- Imatinib: Used for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).
- Trastuzumab: Used for HER2-positive breast cancer.
Mechanism of Action: Specifically target molecular pathways involved in cancer cell growth and survival.
Adverse Effects: Varies by drug; may include skin rash, diarrhea, and cardiac toxicity (trastuzumab).

6. Immunotherapy

Examples:
- Pembrolizumab: A PD-1 inhibitor used for various cancers, including melanoma and lung cancer.
- CAR T-cell therapy: A personalized treatment for certain hematological cancers.
Mechanism of Action: Enhances the body’s immune response against cancer cells.
Adverse Effects: Immune-related adverse effects such as colitis, dermatitis, and pneumonitis.

Clinical Uses

Curative Treatment: Often used for certain leukemias, lymphomas, and localized solid tumors.
Adjuvant Therapy: Used after surgery to eliminate residual disease and reduce recurrence risk.
Palliative Care: To control symptoms and improve quality of life in advanced cancer.

Monitoring and Follow-Up

Monitoring during anti-neoplastic therapy includes:

Regular Blood Tests: To check for myelosuppression and organ function.
Response Assessment: Imaging and clinical evaluations to assess treatment effectiveness.
Management of Side Effects: Proactive measures to manage nausea, infections, and other toxicities.

Preparations

1. Mechlorethamine (Mustine HCl): 0.1 mg/kg i.v. daily × 4 days; courses may be repeated at suitable

intervals; MUSTINE 10 mg dry powder in vial.

2. Cyclophosphamide: 2–3 mg/kg/day oral; 10–15 mg/kg i.v. every 7–10 days, i.m. use also possible;

ENDOXAN, CYCLOXAN 50 mg tab; 200, 500, 1000 mg inj.

3. Ifosfamide: 10–15 mg/kg i.v.; HOLOXAN, IPAMIDE 1 g vial, HOLOXAN-UROMITEXAN 1 g vial + 3 amps

of mesna 200 mg inj.

4. Chlorambucil: 4–10 mg (0.1–0.2 mg/kg) oral daily for 3–6 weeks, then 2 mg daily for maintenance;

LEUKERAN 2, 5 mg tab.

5. Melphalan: 10 mg daily for 7 days or 6 mg/day for 2–3 weeks—4 weeks gap—2 to 4 mg daily for maintenance

orally. Also used for regional perfusion in malignant melanoma; ALKERAN 2, 5 mg tab, 50 mg per vial for inj.

6. Thio-TEPA: 0.3–0.4 mg/kg i.v. at 1–4 week intervals; THIOTEPA 15 mg per vial inj.

7. Busulfan: 2–6 mg/day (0.06 mg/kg/day) orally; MYLERAN, BUSUPHAN 2 mg tab.

8. Lomustine (CCNU): 100–130 mg/m2

BSA single oral dose every 6 weeks; LOMUSTINE 40, 100 mg cap.

9. Dacarbazine (DTIC): 3.5 mg/kg/day i.v. for 10 days, repeat after 4 weeks;

DACARIN 100, 200, 500 mg inj; DACARZINE 200 mg/vial inj.

10. Temozolamide: 100–250 mg/day; GLIOZ 20, 100, 250 mg caps.

11. Procarbazine: 100 mg/m2/day for 14 days in 28 day cycles;

INDICARB 20 mg cap, NEOZINE, P-CARZINE 50 mg cap.

12. Methotrexate: 15–30 mg/day for 5 days orally or 20–40 mg/m2

body surface area (BSA) i.m./i.v. twice weekly,

main tenance therapy 2.5–15 mg/day;

NEOTREXATE 2.5 mg tab, 50 mg/2 ml inj; BIOTREXATE 2.5 mg tab, 5, 15, 50 mg/vial inj.

13. Pemetrexed: 500 mg/m2 i.v. every 3 weeks; PEMEX 500 mg vial for i.v. inj.

Biologicals

Definition
Biological agents, or biologics, are products derived from living organisms used in the diagnosis, prevention, or treatment of diseases. Unlike traditional pharmaceuticals, which are chemically synthesized, biologics are often large, complex molecules or mixtures produced using biotechnology.

Types of Biological Agents

Biological agents can be classified into several categories based on their source and mechanism of action:

1. Monoclonal Antibodies

Definition: Laboratory-produced molecules engineered to bind to specific antigens on cells.
Examples:
- Rituximab: Used for non-Hodgkin lymphoma and certain autoimmune diseases.
- Trastuzumab (Herceptin): Targets HER2-positive breast cancer.
Indications: Cancer treatment, autoimmune diseases, and inflammatory conditions.

2. Vaccines

Definition: Biological preparations that provide acquired immunity to a particular infectious disease.
Examples:
- MMR Vaccine: Protects against measles, mumps, and rubella.
- Influenza Vaccine: Protects against seasonal flu strains.
Indications: Prevent infectious diseases and promote immune response.

3. Cytokines

Definition: Signaling proteins that mediate and regulate immunity, inflammation, and hematopoiesis.
Examples:
- Interferons: Used for hepatitis B and C, and multiple sclerosis.
- Interleukin-2 (IL-2): Used for kidney cancer and melanoma.
Indications: Cancer treatment, immune system disorders, and viral infections.

4. Growth Factors

Definition: Proteins that stimulate cell growth, proliferation, and differentiation.
Examples:
- Erythropoietin (EPO): Stimulates red blood cell production, used in anemia.
- Granulocyte Colony-Stimulating Factor (G-CSF): Stimulates white blood cell production, used in chemotherapy-induced neutropenia.
Indications: Treatment of anemia, neutropenia, and other hematological disorders.

5. Gene Therapies

Definition: Techniques that modify a person’s genes to treat or prevent disease.
Examples:
- Luxturna: A gene therapy for a rare form of inherited blindness.
- Zolgensma: Treats spinal muscular atrophy.
Indications: Genetic disorders and certain cancers.

6. Cell Therapies

Definition: Treatments that involve the administration of whole living cells to a patient.
Examples:
- CAR T-cell Therapy: Engineered T-cells that target cancer cells.
- Stem Cell Transplants: Used in various hematological malignancies.
Indications: Cancer, autoimmune diseases, and certain genetic disorders.

Declaration

The information provided in this document or notes is compiled from various internet sources and the textbook "Essentials of Medical Pharmacology" by K.D. Tripathi. While every effort has been made to ensure accuracy, the author does not take responsibility for any errors or omissions. Users are encouraged to refer to official textbooks and clinical guidelines for comprehensive and authoritative information.

Page updated

Google Sites

Report abuse